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ABSTRACT 
 
 
Plasma Membrane Calcium-ATPases (PMCA’s) extrude calcium from a variety of 
cell types and have recently been shown to regulate signalling events and function in 
the cardiovascular system.  PMCA (isoform 4) is expressed in platelets, however its 
functional role remains undefined.  
The aims of this project were to investigate the roles of PMCA in regulating calcium 
homeostasis and human platelet function during the various stages of platelet 
activation by evaluating the effects of a pharmacological inhibitor of PMCA, 
carboxyeosin, upon a range of in vitro and in vivo assays. Additional experiments 
were performed to determine the functional consequences of PMCA4 ablation using 
platelets from PMCA4 knock-out mice and the roles of PMCA were contrasted with 
other calcium transporters. Finally, the mechanism of action of PMCA in platelets 
was investigated by integrating molecular studies with the functional assays. 
The findings presented in this thesis suggest that PMCA plays an important role in 
regulating calcium both basally and during platelet activation. PMCA positively 
regulates platelet aggregation through the modulation of negative signalling 
pathways but negatively regulates the earlier and later stages of activation measured 
as adhesion and clot retraction respectively. PMCA also regulates platelet function 
in vivo. Experiments in PMCA4 knock-out mice implicated the PMCA4 isoform in 
the regulation of platelet function.  Comparison of PMCA, SERCA (sarco-
endoplasmic reticulum ATPase) and NCX (Na+/Ca2+-exchanger) pumps indicated 
that all three calcium transporters play pivotal but contrasting roles in platelet 
function and calcium homeostasis. 
In conclusion, PMCA is a key regulator of calcium homeostasis and 
differentially regulates the various stages of platelet activation. PMCA 
regulates intracellular signalling events in platelets although the mechanisms 
remain to be fully determined. PMCA is therefore a key modulator of 
haemostasis and thrombosis and may be a potential target in the treatment of 
conditions such as arterial thrombosis and stroke. 
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1.1. Platelets  
1.1.1. Platelets and haemostasis  
 
Platelets are small discoid, anuclear cells that circulate freely within the 
bloodstream. They play an important role in primary haemostasis i.e. the initial 
interaction of platelets when in contact with a damaged blood vessel and also in 
secondary haemostasis initiating factors with the coagulation cascade.  
Under normal conditions, platelets will circulate within blood vessels without 
directly coming into contact with the vasculature walls. However, when a blood 
vessel is severed, the interface between vessel and blood is altered promoting 
platelet adhesion between cell surface glycoprotein (GP) receptors and newly 
exposed extra cellular matrix (ECM) substances such as collagen. Platelets rapidly 
tether to these proteins, adhere to the exposed area, and spread to form a monolayer 
of cells. This, combined with the initial vasoconstriction of blood vessels, minimises 
both the flow of blood to the wound and prevents any further blood loss.  
The initial interaction of platelets to collagen promotes platelet shape change and 
activation through tyrosine kinase based signalling pathways , causing the release of 
biologically active substances, some of which are released from storage granules and 
some synthesised de novo. Soluble pro-thrombotic factors such as adenosine 
diphosphate (ADP) and thromboxane A2 (TXA2) act as a positive feedback as well 
as up-regulating cell surface receptors of nearby or approaching platelets flowing 
past the site of injury.  
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Platelet aggregation then follows, leading to the activation and a conformational 
change of the fibrinogen integrin αIIbβ3 and the formation of platelet aggregates 
through divalent cross linkage of platelets to one another. Stabilisation of the platelet 
aggregate is promoted through endogenous factors within the coagulation cascade 
which can become active when damaged tissues release thrombokinase (TF, tissue 
factor). This promotes the important catalytic conversion of Factor X to Xa and 
zymogen prothrombin to thrombin, an enzymatic component of the coagulation 
system and also a potent platelet agonist. Thrombin in turn cleaves circulating and 
platelet derived fibrinogen to yield fibrin. The deposition of fibrin to the site of 
injury is stabilised by Factor XIIIa (Falati et al. 2002), which provides a stable mesh 
encapsulating passing blood cells and compositing them into the assembling 
thrombus. The integrity of a vessel and blood flow is normalised as a result of 
connective tissue formation once the underlying vascular injury has healed 
sufficiently and final dissolution of the clot has occurred. 
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1.1.2. Platelet production 
 
It is now widely accepted that platelets are formed from megakaryocytes derived 
from megakaryoblasts found in bone marrow. This is achieved by a process of 
haematopoietic differentiation from haematopoietic stem cells under the regulation 
of thrombopoeitin (TPO) and its receptor c-Mpl (Italiano & Shivdasani 2003; 
Kaushansky 1995). TPO drives endomitosis in which the megakaryocytic DNA is 
replicated many times but cytokinesis does not occur (Patel et al. 2005) (S. R. Patel 
et al. 2005)(S. R. Patel et al. 2005)enabling the megakaryocyte to generate multiple 
copies of the proteins and receptors to be packaged into the platelet progeny. 
Megakaryocytes constitute less than 1% of all haematopoietic cells within the bone 
marrow (Patel et al. 2005), they can also be found to a much lesser extent in the lung 
(Sharma & Talbot 1986) and peripheral blood (Hume et al. 1964).   
Although the origin of blood platelets was recognised over a century ago (Brodie & 
Russell 1897), the mechanisms by which megakaryocytes release platelets into the 
circulation was elusive and it is only recently that more detailed theories have 
surfaced to clarify this. Most theories of platelet production focus on the hypothesis 
that pro-platelets bud from pseudopodial extensions of the megakaryocyte (Becker 
& De Bruyn 1976; Italiano & Shivdasani 2003). Italiano and colleagues described 
that platelets were released via the reorganisation of the megakaryocyte cytoplasm 
into an extensive pseudopodial network containing immature platelets. They 
observed this using video microscopy to monitor the structure of the megakaryocyte 
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cytoskeleton at specific stages of pro-platelet morphogenesis (Italiano et al. 1999), 
hypothesising that platelets are released only from the ends of pro-platelets and 
branching observed in these pseudopodia serves to increase platelet production. 
However, the mechanisms by which pro-platelets enter the blood remain unclear. It 
has been suggested that pro-platelet extensions push between endothelial cells and 
protrude into sinusoidal blood vessels where pro-platelets or platelets are shed from 
the tips (Hartwig & Italiano 2006). 
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1.1.3. Platelet ultrastructure 
 
Platelets measure between 1-3.5 μm in diameter and have a mean volume of around 
7.6 μm3.  The normal human circulating platelet count ranges from 150-400 x 109 
cells/L blood (Martin et al. 1982). In their inactive state, platelets remain disc shaped 
and circulate within the plasma for around 8-10 days (Stuart 1975), but their lack of 
nuclei, prevents them from regenerating themselves should they become damaged. 
Once aged, platelets are thought to be removed primarily via phagocytosis within the 
spleen (Hartley 2007). However, the exact physiological mechanisms controlling the 
removal and clearance of platelets are not fully understood. 
The outer phospholipid bilayer (plasma membrane, PM) is supported by a layer of 
microtubules and actin filaments (submembrane specialised filaments and 
microfilaments) which maintain the discoid shape of resting platelets and 
depolymerise when aggregation occurs (Fox 2001). Furthermore, contractile 
proteins can operate to initiate shape change and protrusion of pseudopodia at the 
onset of spreading (Werner & Morgenstern 1980).  
The membrane contains a number of proteins, integrins and G-protein coupled 
receptors (GPCR) which act as receptors for soluble agonists that are important for 
platelet functional responses. There are at least nine cell surface glycoproteins, some 
of which are important in facilitating the adhesion of platelets to damaged 
endothelium and also mediating cell signalling events that result in platelet 
aggregation (Bussel et al. 2000). 
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There are two types of channels expressed in platelets (Behnke 1967), a unique 
surface-connected open canalicular system (OCS), which comprises a series of 
membrane invaginations that extend from the plasma membrane into the platelet 
cytoplasm and serves as a transport system for substances entering or exiting the 
platelet (White & Escolar 1991), and a second network of channels found within 
platelets termed the dense tubular system (DTS), which is believed to be the 
remnants of the megakaryocytic endoplasmic reticulum (ER) and is widely 
distributed throughout the cytoplasmic region of the platelet (Cutler et al. 1978). The 
DTS is also a site for cyclooxygenase (COX) which is an enzyme involved in the 
conversion of membrane derived arachidonic acid (AA), important for TXA2 and 
prostaglandin synthesis. The DTS plays an important role in platelet responses by 
acting as a receptor-mediated Ca2+ store, which undergoes rapid morphological 
changes that are characteristic of Ca2+ release in response to platelet activation 
(Ebbeling et al. 1992). The DTS is also a store of ATPases which regulate the 
activity of adenylate cyclase (AC) which is important for the regulation of signalling 
downstream of GPCR’s (Teijeiro et al. 1999). Due to the anuclear nature of 
platelets, the majority of platelet protein content is determined by the parental 
megakaryocyte, although evidence of protein translation has been reported (Denis et 
al. 2005; Evangelista et al. 2006). 
Platelets contain three types of secretory granules within their cytoplasm, these are 
known as alpha (α), dense and lysosomal granules which form stores for adhesive 
proteins and other small molecule agonists. Alpha granules contain proteins 
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involved in platelet adhesion and aggregation which include fibrinogen, fibronectin, 
von Willebrand factor (vWF), fibrinolysis (e.g. α-antiplasmin, plasminogen), P-
selectin (Harrison & Cramer 1993; Holmsen 1994), various growth factors such as 
platelet derived growth factor (PDGF), epidermal growth factor (EGF) and a number 
of transmembrane receptor molecules including platelet endothelial cell adhesion 
molecule-1 (PECAM-1) and integrin αIIbβ3 (King & Reed 2002). The dense 
granules are a store for low molecular weight compounds involved in platelet 
activation such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), 
Ca2+, magnesium (Mg2+), serotonin ((5-HT), 5-hydroxytryptamine) and 
catecholamines. The contents of these granules are released into the peripheral blood 
(via the OCS) upon cell activation and act in either a paracrine fashion on other 
platelets or in an autocrine manner stimulating cell surface receptors of the secreting 
cell and endothelial cells (Gibbins 2004). The platelet cytoplasm also contains stored 
glycogen particles and mitochondria for energy generation purposes (see Figure 1.1. 
for a diagrammatical representation of a platelet structure). Lysosomal granules 
contain acidic hydrolytic enzymes, which upon secretion are thought to participate 
in the resolution of the haemostatic plug. Platelets also generate and release 
prostacyclin (a lipid ecosanoid), plasminogen activator and anti-coagulant 
substances heparin, heparin sulphate and nitric oxide (NO).  
However, the generation of NO in platelets has been recently challenged 
(Gambaryan et al. 2008; Tymvios et al. 2009). 
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Figure 1.1. Diagram representing the ultra-structural features of a human 
           platelet (equatorial plane) 
The peripheral zone compartments include the exterior coat, trilaminar unit membrane 
and sub-membrane area containing specialised filaments (e.g. actin). This forms the 
platelet wall and channels of the surface-connected (open) canalicular system (OCS). 
The external membranes comprise a circumferential band of microtubules and 
microfilaments which are important for the maintenance of the resting platelet shape 
and changes to this shape upon cellular activation. Two distinct membrane systems are 
found in platelets, the surface-connected OCS and the dense tubular system (DTS), both 
of which are important for the transport of substances into or out of the cytoplasm. The 
platelet cytoplasm contains many organelles which are important for platelet function, 
including the alpha and dense granules, lysosomes, mitochondria and stored glycogen 
particles (White 1979). 
 
 
 (Modified from White J G: Am. J. Clinical Pathology 71: 363, 1979) 
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1.1.4. Platelets and disease 
  
Several physiological mechanisms exist to prevent the inappropriate activation of 
platelets in the circulation; however these mechanisms are not infallible. Clot 
formation in the absence of vascular bleeding is known as thrombosis and is a 
common cause of mortality in developed society (Coronary Heart Disease Statistics 
2008/2009, British Heart Foundation). Thrombosis is routinely linked with other 
medical conditions such as atherosclerosis, coronary heart disease, stroke and also 
occasionally arises as a complication during pregnancy (Davis & Branch 2010).  
 
1.1.4.1. Atherosclerosis 
Atherosclerosis for example, selectively affects medium to large size arteries and 
can be attributed to many factors from genetic modification to environmental factors 
and lifestyle. The coronary localisation of atherosclerosis results in its major clinical 
manifestation, coronary artery disease (Libby 2000).  Atherosclerosis can propagate 
uniformly across the arterial tree, usually starting within the distal abdominal aorta, 
or can evolve in a mosaic fashion, with predilection for certain locations, such as 
coronary and extra-cranial vessels. Biological markers have evolved to assist with 
predicting an individual’s risk of developing the thromboembolic complications of 
atherosclerosis. The levels of C-reactive protein, low density lipoprotein (LDL), 
high density lipoprotein (HDL) and glycaemia have all been associated either 
directly or inversely with the likelihood of a coronary thromboembolic event. Toxins 
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and reactive oxygen species (ROS) generated by tobacco smoke, modified LDL 
particles, diabetes and resulting glycated products, homeocysteine and infectious 
organisms such as herpes viruses can cause endothelial injury and, in a susceptible 
host, can trigger the progression of atherosclerosis (Morel et al. 1983; Libby et al. 
1997; Eberhardt et al. 2000).  
 
1.1.4.2. Platelets Interactions 
Platelets represent an important link between inflammation and atherogenesis. They 
are able to interact with inflammatory cells including leukocytes and the 
endothelium where these interactions lead to leukocyte recruitment towards the 
vascular wall, initiating extra-vasation of circulating mononuclear cells and foam 
cell generation. During the adhesion process, platelets become activated and release 
an array of potent inflammatory and mitogenic substances into the local 
microenvironment, thereby altering chemotactic, adhesive, and proteolytic 
properties of endothelial cells. These platelet-induced alterations of the endothelial 
phenotype support chemotaxis, adhesion, and transmigration of monocytes to the 
site of inflammation. Released from dense granules, α-granules, lysosomes, the 
canalicular system, or the cytosol, platelets secrete or expose adhesion proteins (e.g., 
fibrinogen, fibronectin, vWF, thrombospondin, vitronectin, P-selectin, GPIIb/IIIa), 
growth factors (e.g., PDGF and TGF-β), chemokines (e.g., RANTES, platelet factor 
4 (CXC chemokine ligand 4), epithelial neutrophil-activating protein (CXC 
chemokine ligand 5), cytokine-like factors (e.g., IL-1β, CD40 ligand, β-
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thromboglobulin), and coagulation factors (e.g., factor V, factor XI, PAI-1 and 
plasminogen). These proteins act in a concerted and finely regulated manner to 
influence widely differing biological functions such as cell adhesion, cell 
aggregation, chemotaxis, cell survival and proliferation, coagulation, and 
proteolysis, all of which accelerate inflammatory processes and cell recruitment. For 
example, IL-1β has been identified as a major mediator of platelet-induced 
activation of endothelial cells (Hawrylowicz et al. 1991). The IL-1β activity 
expressed by platelets appears to be associated with the platelet surface, and co-
incubation of endothelial cells with thrombin-activated platelets induces IL-1β–
dependent secretion of IL-6 and IL-8 from nearby endothelial cells (Kaplanski et al. 
1994). Furthermore, incubation of cultured endothelial cells with thrombin-
stimulated platelets significantly enhances the secretion of endothelial monocyte 
chemo-attractant protein-1 (MCP-1) in an IL-1β–dependent manner (Gawaz et al. 
2000). MCP-1 belongs to the CC family of chemokines and is thought to play a key 
role in the regulation of monocyte recruitment to inflamed tissue and in 
atherosclerosis (Boring et al. 1998; Lu et al. 1998).  
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1.1.4.3. Platelets and Inflammation 
At sites of inflammation, recruitment of circulating leukocytes by platelets to the 
vascular wall requires multistep adhesive and signalling events that result in the 
infiltration of inflammatory cells into the blood vessel wall, including selectin-
mediated attachment and rolling, leukocyte activation, integrin-mediated firm 
adhesion, and diapedesis. Leukocytes tether to adherent platelets via PSGL-1–P-
selectin interactions and, subsequently, firmly adhere via binding of Mac-1 
(CD11b/CD18, αMβ2) to GPIbα and/or other receptors of the platelet membrane, 
including bridging proteins such as fibrinogen (bound to αIIbβ3) or high–molecular 
weight kininogen (bound to GPIbα). During this adhesive process, receptor 
engagement of PSGL-1 and Mac-1 together with platelet-derived inflammatory 
compounds induces inflammatory cascades in monocytes (Weyrich et al. 1996; 
Neumann et al. 1997). In addition, engagement of PSGL-1 by P-selectin also drives 
translationally regulated expression of proteins such as uPAR, a critical surface 
protease receptor and regulator of integrin-mediated leukocyte adhesion in vivo 
(May et al. 2002). Because atherothrombotic diseases are a major cause of morbidity 
and mortality in developed countries, understanding the role of platelets in vascular 
inflammation and atherosclerosis is an important challenge. Major achievements 
have been made in elucidating the molecular mechanisms of platelet interaction with 
endothelial cells of the arterial wall. Defining the specific requirements for platelets 
adhering to endothelium may lead to the development of novel therapeutic 
strategies. The era of genomics and proteomics has recently been introduced in 
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platelet research and will continue to offer major tools to help understand platelet 
pathology in the course of atherosclerosis. 
It has become clear that, besides their role in haemostasis and thrombosis, platelets 
regulate a variety of inflammatory responses. Because inflammation plays an 
important role in the progression of cardiovascular diseases, recent studies have 
focused on the connection between inflammation and epoxyeicosatrienoic acids 
(EET’s). EET’s have shown to exhibit anti-inflammatory properties in the 
vasculature, Kesser and colleagues demonstrated that pro-inflammatory mediators 
like cytokines and lipopolysaccharide decrease the formation of EET’s and 
endothelial epoxygenase enzyme expression (Kessler et al. 1999). Activated nuclear 
factor-κB (NF-κB) is a critical cell-signalling step for the induction of numerous 
inflammatory mediators in the cardiovascular system. NF-κB activity is essential for 
the up-regulation of genes encoding vascular cell adhesion molecule (VCAM), inter-
cellular adhesion molecule and E-selectin which contribute to the progression of 
cardiovascular diseases (Collins et al. 1995). EET’s or CYP2J2 over-expression was 
found to be anti-inflammatory and decreased tumor necrosis factor (TNF)-α induced 
endothelial VCAM-1 expression, and EET’s prevented leukocyte adhesion to the 
vascular wall (Node et al. 1999). Several studies demonstrated that inhibiting NF-κB 
activation is the primary signalling pathway by which epoxides exert their anti-
inflammatory effects (Falck et al. 2003). Additionally, endothelial cell shear stress 
can increase EET production and EET’s can subsequently bind and activate the 
peroxisome proliferator-activated receptor α (PPARα) to provide anti-inflammatory 
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effects on blood vessels (Liu et al. 2005). Studies have also demonstrated that 
epoxides have anti-aggregatory properties in platelets (Fitzpatrick et al. 1986; Krötz 
et al. 2004). Fitzpatrick and colleagues showed that 11,12-EET or 14,15-EET 
inhibits arachidonic acid stimulation of platelet aggregation. 11,12-EET, 8,9-EET 
and 14,15-EET cause membrane hyperpolarisation of human platelets through 
activation of BKCa (big potassium and calcium) channels that subsequently inhibits 
platelet adhesion to endothelial cells (Fitzpatrick et al. 1986). Vascular thrombosis is 
regulated in part by the tissue-type plasminogen activator (t-PA) and plasminogen 
activator inhibitor 1 (Collen 1980). Node and colleagues also demonstrated that 
11,12-EET increases the expression and activity of t-PA in human endothelial cells 
through activation of the G-protein, GαS and PKA. Therefore, EET’s decrease 
platelet aggregation through a membrane hyperpolarisation and enhanced expression 
of endothelial fibrolytic enzymes (Node et al. 2001). Overall these findings suggest 
that epoxygenase metabolites or EET agonists have the potential to decrease 
thrombolytic events associated with cardiovascular diseases. 
Taken together these experimental findings suggest that EET’s or EET agonists 
could be effective as anti-inflammatory agents.  
 
1.1.4.4.  Anti-platelet therapy 
Platelets also play a central role in myocardial infarction and stroke and targeting 
platelet signalling mechanisms and receptors as well as coagulation factors may well 
become an important therapeutic strategy for treatment of such acute ischemic 
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events (Michelson 2010; Stoll et al. 2008)  It must be noted however, that targeting 
platelets, particularly in ischemic stroke may provide limitations, as antithrombotic 
therapy may induce intracranial haemorrhage (Adams et al. 2008; Kleinschnitz et al. 
2007; Stoll et al. 2008). It is therefore is vital to investigate new therapeutic targets 
in platelets to regulate the fine balance between an anti-thrombotic effect in the 
vasculature without affecting haemostasis. 
In terms of anti-platelet therapy, acetylsalicylic acid (or aspirin) which was 
introduced into the commercial market in the late 1800’s is a synthetic compound, 
with anti-pyretic, analgesic, anti-inflammatory and anti-platelet properties and has 
since become one of the most versatile pharmaceutical agents known in the 
treatment of cardiovascular disease (identified by Friedrich Bayer 1825). The 
pharmacological effects of aspirin are mediated primarily through its interference 
with prostaglandin biosynthesis (Section 1.4.2.) by its covalent modification of COX 
through the irreversible acetylation of a specific serine moiety on the active site 
(Antman et al. 2005). This ultimately prevents the formation of platelet-generated 
TXA2 and subsequent inhibition of platelet aggregates (Mitchell et al. 2006). The 
long term use of aspirin is also accompanied by side effects. The inhibition of COX 
interferes with the production of homeostatic prostanoids, thereby potentially 
resulting in serious toxicities, including renal failure, gastric mucosal ulceration and 
impaired haemostasis (Batlouni 2010; Yamamoto et al. 2010; Bartfai & Conti 2010). 
Furthermore, aspirin’s platelet inhibitory effects predispose to both bleeding and 
major haemorrhage. 
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Other commercially available compounds are Prasugrel, Ticagrelor and Clopidogrel 
which act as ADP receptor antagonists. These compounds are structurally similar; 
however, Clopidogrel differs by possessing an additional carboxymethyl side group. 
Clopidogrel irreversibly inhibits binding of ADP to its receptor, thereby preventing 
ADP-induced activation of the αIIbβ3 receptor during platelet activation. It also 
prevents further release of granule stored ADP (Quinn & Fitzgerald 1999; Quinn et 
al. 2002). In general, Clopidogrel is known as the more tolerated and safer of these 
compounds, however, bone marrow toxicity, aplastic anaemia and haemolytic-
uremic syndrome (HUS) associated with Clopidogrel have been reported 
(Andersohn et al. 2004). This may be fatal and usually occurs within weeks to 
months following therapy initiation (McCarthy & Kockler 2003; Meyer et al. 2001; 
Trivier et al. 2001).  
 
1.1.4.4.1. Aspirin and Clopidorel resistance 
Aspirin and Clopidogrel have emerged as critical therapies in the treatment of 
cardiovascular disease. Despite their efficacy, patients on these medications continue 
to suffer complications. Millions of patients are currently on low-dose antiplatelet 
therapy but it is unknown how many of these patients are under-treated or on the 
wrong medication. Aspirin and clopidogrel resistance are emerging clinical entities 
with potentially severe consequences such as recurrent myocardial infarction, stroke, 
or death. The mechanism of resistance remains incompletely defined, but there are 
specific clinical, cellular, and genetic factors that influence therapeutic failure. These 
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factors range from physicians who fail to prescribe these medications despite 
appropriate indications to polymorphisms of platelet membrane glycoproteins. 
As mentioned previously aspirin works by irreversibly acetylating the COX-1 
enzyme, thus suppressing thromboxane A2. Thromboxane A2 serves as a potent 
agonist of platelet aggregation, and aspirin prevents thrombus formation via this 
mechanism. However, its antiplatelet effect is not uniform in all patients (Patrono et 
al. 2001) and its inhibition of platelet aggregation is subject to inter-individual and 
intra-individual variability (Homoncik et al. 2000). This unpredictable response to 
aspirin can be attributed to clinical, cellular, and genetic factors (Bhatt 2004). 
Clinical causes of aspirin resistance can range from patient non-compliance to 
physicians who display aspirin resistance, that is, physicians who fail to prescribe 
aspirin appropriately. Alternatively, patients may take aspirin but not absorb it, or 
may have interactions because of other medications. Ibuprofen, for example, can 
adhere to the COX-1 binding site of aspirin, and may via steric hindrance prevent 
aspirin from exerting its antiplatelet effect and limit its cardio-protective function 
(Catella-Lawson et al. 2001). The dose of aspirin may contribute to uninhibited 
platelet activity depending on the weight and age of patients (Maree et al. 2005). 
Cellular factors influencing aspirin efficacy include inadequate suppression of 
platelet COX-1. In addition, aspirin resistance has been attributed to COX-2 mRNA 
over-expression by platelets and endothelial cells, though this remains controversial 
(Weber et al. 1999; Zimmermann et al. 2003). Resolvins, a family of bioactive 
omega-3 fatty acid metabolites, mediate the inflammatory response and are 
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generated via COX-2 acetylation by aspirin (Serhan et al. 2002). A deficiency of 
these products could also influence therapeutic failure. 
Genetics also play a role in patient response to aspirin as polymorphisms of platelet 
membrane glycoproteins such as P1 (A1/A2) have been associated with an 
attenuated response to aspirin (Macchi et al. 2003). Polymorphisms of vWF or the 
collagen receptor gene have also been postulated to cause aspirin resistance 
(Pontiggia et al. 2002). Single nucleotide polymorphisms of the P2Y1 gene also can 
affect response to aspirin (Jefferson et al. 2005). Despite these findings, the impact 
of polymorphisms on aspirin response remains controversial (Bray 2000). 
Clopidogrel resistance may also be because of clinical, cellular, and genetic factors. 
It is converted in the liver by cytochrome P450 3A4 (CYP3A4) into its active 
metabolite. It inhibits platelet aggregation by irreversibly binding to the P2Y12 ADP 
receptor on the platelet surface. Similar to aspirin, clopidogrel therapy may fail 
owing to patient non-compliance or because physicians may not prescribe it. In 
addition, there may be variability in absorption (Taubert et al. 2004) with associated 
under-dosing in patients and possible drug–drug interactions (Lau et al. 2004). One 
study correlated the level of angina class with platelet inhibition by clopidogrel and 
found that patients with higher Braunwald angina class had lower inhibition of 
platelet aggregation (Soffer et al. 2003). Cellular mechanisms of clopidogrel 
resistance may be because of inter-individual differences in P2Y12 receptors and the 
number of receptors an individual possesses, varying the levels of ADP release, or 
platelet activation via alternative pathways.  
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It is therefore justified to state that the continuous search for anti-platelet compounds 
or targeting particular mediators in the treatment of platelet associated diseases is 
paramount, with the hope of one day establishing an effective treatment regime that 
balances drug efficacy with minimal toxicity. 
 
1.1.4.5. Platelets and Cancer Metastasis 
Platelets have long been associated with tumour metastasis and metastasis to distant 
organs is dependent on interactions between tumour cells and the host 
microenvironment within the circulation, lymphatic vessels and target tissues. This 
involves blood cells, components of the coagulation system, stromal cells and the 
extracellular matrix. Cells within the bloodstream that contribute to metastasis are 
endothelial cells, platelets, lymphocytes, macrophages, mast cells, fibroblasts and 
bone marrow-derived progenitor cells (Joyce & Pollard 2009). The link between 
platelets and cancer was first documented in the mid-nineteenth century by 
Trousseau, who diagnosed himself and his patients with excessive blood clotting, 
which was caused by occult carcinoma that led to the inflammation of blood vessels. 
He observed an association between thrombosis and cancer, and proposed that 
changes to the haemostatic system support the progression of the malignancy 
(Khorana 2003). These initial findings suggested that tumours that are capable of 
activating platelets and forming clots are likely to spread and have a poor outcome. 
It is now well recognised that in cancer patients, tumour growth is accompanied by 
the development of an increased tendency towards blood clotting (hypercoagulable 
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state), platelet abnormalities and an increased risk of thromboembolic disease 
(Khorana & Connolly 2009). Moreover, thromboembolism is an early diagnostic 
feature and a major cause of death (Sierko & Wojtukiewicz 2007). Platelet 
activation is amplified in many cancers and found within the tumour vasculature 
(Sierko & Wojtukiewicz 2004; Blann et al. 2001; Verheul et al. 2000). Platelet 
counts commonly vary during cancer progression and may predict the clinical 
outcome. Thrombocytosis (high platelet count) associates with poor prognosis in 
colon, breast, lung, gastric, renal, cervical, pancreatic, endometrial, brain and 
ovarian cancers (Sierko & Wojtukiewicz 2004; Erdemir et al. 2007; Costantini et al. 
1990; Ayhan et al. 2006; Taucher et al. 2003; Brown et al. 2005; Bensalah et al. 
2006; Brockmann et al. 2007). Thrombocytopenia (low platelet count) also occurs, 
but is mostly associated with chemotherapy that suppresses platelet production in 
the bone marrow. The changing requirements of disseminating tumour cells during 
metastasis provide challenging questions to address and understand the complexity 
of platelet involvement in different stages of cancer progression. Transgenic mouse 
models with defined aberrations in platelet and other host cell-type functions will 
help to further elucidate crucial molecular mechanisms. For example, one such 
model that has not been explored in the context of metastasis is a model of 
Glanzmann's thrombasthenia (Fang et al. 2005). This model recapitulates a human 
disease in which platelets lack or have aberrant expression of integrin αIIbβ3. 
Models like this offer the opportunity to explore the contribution of plateletreceptors 
and platelet functions that are key to understanding tumour metastasis in disease. 
CHAPTER ONE - Introduction 
 
 35 
 
1.2. Platelet receptors 
 
1.2.1. Cell adhesion receptors 
 
Vascular damage results in denudation of endothelial cells exposing the underlying 
ECM proteins of which collagen is considered to be the most thrombogenic. At least 
25 different varieties of human collagen are known to exist (Hashimoto et al. 2002), 
of these, types I, III, IV, V, VI, VIII, XII, XIII and XIV are present within the walls 
of human blood vessels (Barnes & Farndale 1999). Apart from collagen, the ECM 
also contains a large number of adhesive macromolecules, such as laminin, 
fibronectin and vWF (Ordinas et al. 1990). Under conditions of high shear, such as 
those found in small arteries and arterioles, the initial tethering of platelets to the 
ECM is meditated by the interaction between the platelet receptor glycoprotein 
(GP)Ib-V-IX and vWF bound to collagen. However, due to their fast off-rate, this 
interaction is insufficient to mediate stable adhesion but rather maintains the platelet 
in close contact with the ECM surface by continuous translocation in the direction of 
blood flow (Savage et al. 1999). It is the role of an immunoglobulin superfamily 
receptor GPVI to establish contact with the thrombogenic collagen proteins within 
the ECM. While GPVI binds to collagen with low affinity, it triggers intracellular 
signals that shift platelet integrins, namely integrin α2β1, to a high affinity state and 
induces the release of secondary mediators, ADP and TXA2.  
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1.2.2. Glycoprotein (GP)Ib-V-IX complex. 
 
This receptor belongs to the leucine-rich-repeat (LRR) family and its multimeric 
adhesive ligand vWF, is essential for platelet adhesion under high shear stress.  vWF 
has the ability to facilitate indirect interactions between the platelet surface GPIb-V-
IX complex and collagen fibres through its A3 domain present in the extracellular 
matrices (Alevriadou et al. 1993). This causes short lived tethering in which platelets 
slow down and roll along the surface of the damaged vascular tissue allowing more 
stable direct interactions with ECM (Moroi et al. 1997; Savage et al. 1998). GPIb-V-
IX is then able to bind the vessel wall-immobilised vWF through a second binding 
site found in the A1 domain of vWF (Andrews & Berndt 2004). In addition, GPIb-V-
IX is also a major receptor for not only vWF, but thrombospondin-1 (TSP), the 
leukocyte integrin αMβ2 and P-selectin expressed on activated endothelial cells and 
platelets. It also acts as a signalling receptor to propagate downstream events that 
activate integrins α2β1 and αIIbβ3. Furthermore, GPIb-V-IX can promote 
procoagulant activity on platelets by binding α-thrombin, Factors XI and XII and 
kininogen. 
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1.2.3. Glycoprotein-VI (GPVI) 
 
The GPVI receptor belongs to the immunoglobulin (Ig) superfamily and is one of 
the major Ig receptors for collagen (Clemetson et al. 1999). It is non-covalently 
associated with the Fc receptor γ-chain (FcRγ) (Gibbins et al. 1996; Gibbins et al. 
1997) which is critical for platelet signalling events. When the GPVI receptor binds 
to collagen, it stimulates receptor clustering with the FcR γ-chain acting as the 
signalling component of the complex (Clemetson et al. 1999; Gibbins et al. 1997). 
The cytoplasmic tail of FcR γ-chain contains an immunoreceptor tyrosine-based 
activation motif (ITAM) which becomes phosphorylated on its tyrosine residues 
upon GPVI clustering (Gibbins et al. 1997; Gibbins 2002) by the Src (sarcoma) 
family kinases - Fyn and Lyn (Briddon & Watson 1999; Quek et al. 2000; Inoue et 
al. 2002) leading to the activation of multiple signalling cascades and consequent 
platelet activation (Nieswandt & Watson 2003; Watson et al. 2001). The importance 
of this interaction in platelet responses to collagen has been demonstrated using 
mouse models lacking the FcRγ-chain, where tyrosine phosphorylation of spleen 
tyrosine kinase (Syk) and phospholipase Cγ2 (PLCγ2) is absent (Poole et al. 1997). 
(For schematic diagram of GPVI signalling see Figure 1.2.) 
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Figure 1.2. A schematic diagram of the GPVI signalling pathway 
Collagen binding to GPVI leads to clustering of the receptor and stimulates rapid 
phosphorylation of the tyrosine residues in the immunoreceptor tyrosine-based 
activatory motif (ITAM) of the associated FCRγ-chain by the Src-family kinases Lyn 
and Fyn. Syk then binds to the FcRγ-chain via its tandem Src-homology (SH2) domains 
and becomes phosphorylated. This in turn phosphorylates linker for the activation of T-
cells (LAT) which acts as a docking site for phosphatidylinositol 3-kinase (PI3K) and 
recruits phospholipase Cγ2 (PLCγ2) to the membrane. Downstream of this inositol 1,4,5 
trisphosphate (IP3) and diacyl-glycerol (DAG) are generated through the hydrolysis of 
phosphatidylinositol 4,5 bisphosphate (PIP2) which lead to the release of calcium from 
intracellular stores and protein kinase C (PKC) isoform activation respectively. 
Ultimately this impacts on the activation state of the integrins αIIbβ3 and α2β1. 
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1.2.4. Integrin α2β1 
 
The integrin α2β1 (also known as GPIa/IIa, VLA-2 on lymphocytes, or 
CD49b/CD29) was one of the first platelet collagen receptors to be identified, and 
serves mainly as an adhesion receptor  (Farndale et al. 2004) where it is able to bind 
collagen in an Mg2+ dependant fashion (Kunicki et al. 1988). Integrin α2β1 is 
present on the surface of a number of different cell types (Zutter & Santoro 1990) 
which unlike αIIbβ3 is expressed exclusively on megakaryocytes and platelets 
(Wagner et al. 1996). Upon stimulation, platelets undergo inside-out signalling 
which induces a conformational change in both α2β1 and αIIbβ3. This change 
converts α2β1 into an activated form with a high affinity for collagen (Jung & Moroi 
1998).  The proposal of α2β1 participating in outside-in signalling or not is a 
somewhat controversial issue. Hers and colleagues disputed that stimulation of α2β1 
does not induce tyrosine phosphorylation downstream of this receptor (Hers et al. 
2000) whereas other studies using selective ligands indicate that the phosphorylation 
of  tyrosine based signalling does occur (Inoue et al. 2003; Stevens et al. 2004).  The 
direct contribution of α2β1 to activate platelet signalling is poorly understood; 
nevertheless the essential role of this receptor in mediating initial responses to 
vascular damage is well established.  
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1.3. Soluble platelet agonists 
1.3.1. Introduction 
 
After the initial capture of platelets by adhesion receptors, outside-in signalling 
stimulates platelet activation and the release of a variety of soluble platelet agonists, 
which play an important role in the assembly of a thrombus, in particular, thrombin, 
ADP and TXA2. Other soluble platelet agonists include platelet activating factor 
(PAF) and 5-HT.  
The majority of these released agonists mediate their effects through binding to 
specific G-protein coupled receptors (GPCR’s). GPCR’s are a superfamily of cell 
membrane receptors composed of seven putative transmembrane (TM) domains, an 
extracellular N-terminus involved in ligand binding and an intracellular C-terminus 
which together, with the third intracellular loop, interact with a guanine nucleotide 
binding protein (G-protein) (Lerner et al. 1996; Verrall et al. 1997).  
G -proteins are heterotrimeric composing of an α, beta (β) and gamma (γ) -subunit. 
During their resting state the α-subunit has guanosine diphosphate (GDP) bound, 
which is exchanged for guanosine triphosphate (GTP) when the receptor is 
stimulated by an agonist. The subunits then change their conformation to form an 
active α-subunit and a βγ dimer.  Activation of the subunits is terminated by the 
hydrolysis of GTP to GDP leading to the restoration of the heterologous G-protein 
and re-association with the receptor.   Furthermore, some platelet receptors, such as 
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those for ADP, become desensitised by G-protein coupled receptor kinases 
(GPCRK) and are internalised following stimulation (Hardy et al. 2005).  
CHAPTER ONE - Introduction 
 
43 
 
1.3.2. Thrombin 
 
Thrombin is a multifunctional serine protease that is distinctly unique among 
coagulation proteins. It possesses both procoagulant and anticoagulant properties 
(Leung & Gibbs 1997). The precursor protein prothrombin is synthesised 
exclusively in the liver as an inactive zymogen. The conversion of prothrombin to 
thrombin requires the assembly of the prothrombinase complex Factor Xa found in 
the coagulation cascade which plays an important role in this biological 
amplification system.  
Thrombin generated by the coagulation cascade converts soluble fibrinogen into 
fibrin monomers, which polymerise to form a stable fibrin clot. It is also a potent 
platelet agonist which induces platelet signalling, secretion and aggregation through 
G-protein coupled protease activated receptor (PAR) isoforms (Kahn et al. 1998). 
Thrombin activates PAR’s by cleaving the N-terminal region of the receptor, which 
in turn acts as a tethered ligand. In the cleaved state, part of the receptor itself acts as 
the agonist leading to downstream signalling events within platelets. (For a 
schematic representation of PAR activation by thrombin, see Figure 1.3.) 
The first PAR’s to be identified was PAR1 (Vu et al. 1991), this was then followed 
by the identification of PAR2 (Nystedt et al. 1994), PAR3 (Ishihara et al. 1997) 
followed by PAR4 (Kahn et al. 1998; Xu et al. 1998). Human platelets express 
PAR1 (Gα12/13, Gαq and Gαi/z coupled) and PAR4 (coupled to Gαq and possibly the 
Gα12/13 pathways) on their surface (Kahn et al. 1998; Kahn et al. 1999).  
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PAR receptors form a heterodimer which enhances the signalling response to 
thrombin (Leger et al. 2006).  Signalling through the Gαq pathway downstream of 
PAR1 activation leads to increased phospholipase Cβ (PLCβ) generation and 
phosphatidylinositol 4,5-bisphosphate (PIP2) phosphorylation by PI3Kγ isoforms 
(Lian et al. 2005). PLCβ hydrolyses PIP2 to generate the second messengers inositol 
1,4,5-trisphosphate (IP3) and 1,2- diacylglycerol (DAG) (Lian et al. 2005; Rhee & 
Bae 1997). This mediates Ca2+ mobilisation from intracellular stores (Brass & 
Joseph 1985) which is important for integrin activation via inside-out signalling, 
essential for platelet activation. 
Murine platelets do not possess PAR1 receptors, instead they express PAR4 and the 
least understood of the protease receptors PAR3 (Leger et al. 2006). PAR3 enhances 
thrombin cleavage of the lower-affinity PAR4 receptor possibly by delivering 
thrombin to adjacent PAR4 (Nakanishi-Matsui et al. 2000).  
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Figure 1.3. Schematic representation of PAR activation by thrombin 
There are 4 known isoforms of protease-activated receptors (PARs), numbered from one 
to four, and platelets express 1 and 4. These receptors are members of the seven 
transmembrane G-protein-coupled receptor super-family. PAR’s contain a thrombin 
cleavage site at the N-terminal exodomain of the receptor which is cleaved by thrombin 
to reveal a new N-terminal region which contains a recognition sequence for the 
receptor. Binding to the newly exposed ‘tethered ligand’ activates the receptor (PAR*) 
and initiates signalling through the Gαq pathway. This leads to increased PLCβ 
generation and PIP2  phosphorylation by PI3Kγ isoforms. PLCβ hydrolyses PIP2 to 
generate the second messengers IP3 and DAG, this mediates Ca2+ mobilisation from 
intracellular stores which is important for integrin activation via inside-out signalling.
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1.3.3. ADP 
 
In the early 1960’s the low molecular weight molecule ADP was identified as a 
factor released from RBC that could influence the adhesiveness of human platelets 
(Gaarder et al. 1961) and induce platelet aggregation (Born 1962a). Savage and 
colleagues described ADP as a low, weak aggregating agonist that, as such, only 
induces platelet shape change and reversible aggregation (Savage et al. 2001). Apart 
from ADP found in RBC, platelets store ADP in their dense granules where it is 
released upon platelet stimulation (Gachet 2001a). ADP then binds in an 
autocrine/paracrine fashion to ADP receptors on the surface of the originating 
platelet as well as on those of approaching platelets. Initially, the molecular identity 
of these receptors remained elusive. However, in 2001 the complete identification of 
the platelet purinergic 2 (P2) range was reported (Gachet 2001b; Hollopeter et al. 
2001), eight years after the first reported cloning of a P2 receptor (Webb et al. 
1993). 
Three distinct purinergic receptors have been identified on platelets, two GPCR’s, 
P2Y1 and P2Y12 and a ligand gated ion channel P2X1, which preferentially binds 
ATP (Khakh 2001). The P2Y1 receptor is widely distributed in many tissues 
including the heart (Kumar et al. 2010), blood vessels (Kauffenstein et al. 2010), 
smooth muscle cells (Govindan et al. 2010) and neural tissues (Heinrich et al. 2008).  
The coupling of P2Y1 to Gαq triggers Ca2+ mobilisation from intracellular stores 
leading to shape change and weak transient aggregation. Despite this, P2Y1 remains 
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crucial to the initiation of ADP mediated activation and in the maintenance of 
collagen induced aggregation of platelets. The P2Y12 receptor, which is coupled to 
Gi2, was the last to be cloned (Hollopeter et al. 2001) and has very limited tissue 
distribution although not exclusive to platelets. P2Y12 plays a central role in the 
amplification of platelet responses stimulated by all platelet agonists including 
collagen, thrombin, TXA2, immune complexes, 5-HT and adrenaline (Hechler et al. 
2005; Conley & Delaney 2003; Gachet 2006) and is important in ongoing thrombus 
formation under high shear conditions (Moake et al. 1988; Remijn et al. 2002; 
Turner et al. 2001). (For a schematic representation of P2Y1 and P2Y12 activation by 
ADP, see Figure 1.4.) 
The third P2 receptor found on platelets is P2X1, a ligand-gated cation channel 
which permits the fast entry of Ca2+ induced by ATP. P2X1 receptors are rapidly 
desensitised impeding the study of their function in vitro. Although unable to 
stimulate platelet aggregation alone, P2X1 has been shown to participate in collagen 
and shear induced aggregation (Cattaneo et al. 2002; Oury et al. 2001). 
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Figure 1.4. Schematic representation of P2Y1 and P2Y12 activation by ADP 
P2Y receptors are a family of purinergic G protein-coupled receptors and platelets 
express isoforms 1 and 12. Binding of ADP to P2Y1 leads to mobilisation of 
intracellular calcium ions via activation of PLCβ, causing PIP2  phosphorylation by 
PI3Kγ isoforms. PLCβ hydrolyses PIP2 to generate the second messengers IP3 and DAG 
mediating platelet shape change. P2Y12 can also act on adenylate cyclase (AC). Active 
AC dephosphorylates ATP to form cyclic AMP. cAMP directly regulates ion channels 
in the DTS. Elevated cAMP maintains calcium sequestered in granules or within the 
DTS. P2Y12 can also regulate downstream signalling molecules such as Rab1b and 
Akt. Both receptors also functions as a receptor for extracellular ATP.  
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1.3.4. Thromboxane A2 (TXA2) 
 
Thromboxane (TXA2) is a short lived lipid mediator synthesised by activated 
platelets. It is released as a local signal, which amplifies activation and recruits other 
platelets to the site of clot formation (De Groot et al. 1999). TXA2 is derived from 
arachidonic acid liberated from membrane phospholipids by phospholipase A2 
(PLA2) as a result of increased cytosolic Ca2+ concentration following platelet 
activation. It is then rapidly metabolised by two distinctly different enzymatic 
pathways, the first leads to the production of prostaglandin H2 (PGH2) by COX, 
which is subsequently metabolised by thromboxane synthase (TXS) into TXA2. 
TXA2 is able to diffuse across the platelet plasma membrane where it can bind to 
and activate other platelets. TXA2 is unstable and is fairly rapidly converted to the 
more stable lipid, thromboxane B2 (TXB2). The other is the production of hydroxy-
eicosatetranoic acid (HETE) by lipoxygenase, which is then converted to 
leukotrienes whose effects on platelets are not yet understood (Lagarde et al. 2010). 
There are two isoforms of the thromboxane receptors (TP receptors) located on 
platelets, TPα and TPβ. They differ only in the composition of their C-terminus 
(Hirata et al. 1996). The association between TXA2 to these receptors initiates 
signalling through the Gαq pathway (Shenker et al. 1991) leading to the activation of 
PLC isoforms (Brass et al. 1987) which are important for Ca2+ mobilisation from 
intracellular stores and the upregulation of integrin activity (Hirata et al. 1991). TP 
receptors can also couple to the Gα12/13 pathway which mediates platelet shape 
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change through the activation of Rho kinase and myosin light chain phosphorylation 
(Klages et al. 1999). 
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1.3.5. Other soluble agonist 
 
Adrenaline and 5-HT are weak platelet agonists stored in dense granules and 
released upon platelet activation. Adrenaline has long been identified as a weak 
platelet agonist (Born et al. 1967) unable to stimulate platelet aggregation alone, but 
capable of potentiating the responses of other platelet agonists. Adrenaline mediates 
its effects on platelets through stimulation the α2-adrenergic receptor, a GPCR 
coupled to Gz, a member of the Gi family of G proteins. 5-HT, which is stored in 
platelet dense granules, is largely derived from the environment surrounding the 
platelet by two distinct transport systems, both of which are energy dependent. The 
first is by a plasma membrane 5-HT transporter (SERT) which binds extracellular 5-
HT and transports it across the platelet plasma membrane into the cytosol. The 
second transporter, referred to as vesicular monoamine transporter (VMAT), 
transports 5-HT across the vesicular membrane back into dense granules (Rudnick et 
al. 1997) where it is stored.  
Upon dense granule secretion, 5-HT is released enabling it to activate surface 5-
HT2A receptors, which are coupled to Gq G-proteins, stimulating signalling 
pathways. However, 5-HT is incapable of stimulating platelet aggregation in 
isolation but can synergise with low concentrations of other agonists to amplify their 
response. In addition, full aggregation can be achieved by combining adrenaline and 
5-HT, as this leads to stimulation of both Gi and Gq signalling pathways, which is 
thought to be a prerequisite for platelet aggregation (Jin & Kunapuli 1998).  
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In addition to its role in potentiating platelet activation, 5-HT stimulates receptors on 
endothelial cells, which in turn, signal to the underlying smooth muscle to contract 
resulting in vasoconstriction, a further physiological mechanism to limit blood loss 
in the event of vascular injury. 
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1.4. Negative regulatory signalling pathways 
 
1.4.1. Nitric Oxide  
 
Negative regulation of platelets is essential in preventing uncontrolled 
haemostasis/thrombosis. Nitric oxide (NO) and prostacyclin (PGI2) are key negative 
regulators of platelet function. NO is synthesised from L-arginine by a family of 
enzymes called NO synthases (NOS). There are three isoforms of NOS which are 
named after the tissues in which they were first identified. Endothelial (eNOS or 
NOSIII) and neuronal (nNOS or NOSI) are generally regulated by Ca2+/calmodulin 
(CaM) and phosphorylation, and inducible NOS (iNOS or NOSII), which as the 
name suggests, is not expressed constitutively in most tissues but induced upon 
stimulation (Bruckdorfer 2005).  
NO produced by endothelial cells and released into the circulation plays an 
important role in the negative regulation of platelets.  Vascular eNOS generates and 
releases NO that can diffuse across the platelet membrane passively where it is 
believed to bind and activate soluble guanylate cyclase (sGS) leading to the 
generation of cyclic guanosine monophosphate (cGMP) and downstream of this 
protein kinase G (PKG) (Radomski et al. 1987) leading to the inhibition of integrin 
activation, platelet adhesive responses and aggregation (Oberprieler et al. 2007a; 
Oberprieler et al. 2007b; Roberts et al. 2009; Roberts et al. 2008).  
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Other downstream effectors have been reported, such as the phosphorylation of 
vasodilator-stimulated phosphoprotein (VASP) at Ser157 by protein kinase C (PKC) 
which correlates with reduced activation of integrin aIIbβ3 and an inhibition of 
platelet aggregation (Horstrup et al. 1994). In addition, phosphorylation of VASP, 
which occurs downstream of cGMP, also reduces its ability to interact with actin, 
and therefore negatively regulates actin nucleation and bundling properties (Harbeck 
et al. 2000). At least one isoform of NOS has been demonstrated in platelets 
(Radomski et al. 1990) and the majority of reports suggest this to be eNOS 
(Randriamboavonjy & Fleming 2005), although there is also evidence that iNOS 
may also be expressed (Chen & Mehta 1996). NO produced by activated platelets 
inhibits platelet recruitment to aggregates (Freedman et al. 1997) and mice 
transfused with eNOS-/- platelets display decreased bleeding times when compared to 
wild-type mice (Freedman et al. 1999) thus highlighting the importance of platelet-
derived NO in the regulation of haemostasis. Interestingly, recent  evidence suggests 
that NO may in fact stimulate platelets (Li et al. 2003a), and exert a biphasic 
response whereby it produces an initial transient stimulatory response, promoting 
platelet aggregation, followed by an inhibitory response limiting the size of thrombi. 
This discovery however remains controversial as one research group has challenged 
whether eNOS is detectable in platelets (Gambaryan et al. 2008). The detailed study 
by Gambaryan and colleagues attempted to clarify some of the issues relating to 
platelet NOS. They suggested that neither iNOS nor eNOS are present in either  
mouse or human platelets, and secondly that cGMP can be synthesised in platelets 
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independently of NO (Gambaryan et al. 2008). Similarly, Tymvios and colleagues 
demonstrated a lack of eNOS in human and mouse platelets and found no functional 
consequence of eNOS ablation (Tymvios et al. 2009). The effects of eNOS on 
platelet function in vivo were also attributed to the vascular endothelium using a 
mouse model of platelet thromboembolism (Tymvios et al. 2008). 
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1.4.2. Prostacyclin (Prostaglandin I2)  
 
Prostacyclin (PGI2) is a derivative of the unsaturated fatty acid arachidonic acid, 
which was discovered in 1976 as a substance inhibiting platelet secretion, platelet 
aggregation and vasoconstriction (Moncada et al. 1976; Gryglewski et al. 1976). The 
biosynthesis of prostacyclin is part of the arachidonic acid metabolic pathway 
(similar to that for the generation of TXA2) and is secreted from the endothelium 
into the circulating blood (Moncada et al. 1977). After the release from the vessel 
wall, PGI2 mediates its inhibitory effects via the high-affinity PGI2 receptors (IP) on 
the platelet surface thus causing an increase AC activity and cyclic adenosine 
monophosphate (cAMP) accumulation (Best et al. 1977).  The accumulation of 
cAMP activates protein kinase A (PKA) which causes the phosphorylation and 
activation of a number of signalling molecules such a myosin light chain kinase 
(MLCK) (Hathaway & Adelstein 1979), the platelet inositol 1.4.5 triphosphate 
receptor (IP3R) (Cavallini et al. 1996) and VASP (Aszódi et al. 1999).  These 
signalling molecules are able to regulate actin polymerisation and maintain platelets 
in a resting state (Prehoda et al. 1999). 
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1.5.  Platelet Calcium 
 
1.5.1. Introduction 
 
Ca2+ homeostasis is tightly regulated in platelets to maintain low resting [Ca2+]i 
involving energy expenditure by transporting ions out of the cytosol into the 
extracellular milieu against a strong chemical gradient.  
Platelet Ca2+ signalling has been described as being controlled in space, time and 
amplitude (Berridge et al. 2003) and defines the importance of the link between the 
Ca2+ signal and functionality. Ca2+ is also an important secondary messenger in 
virtually all cells and regulates a range of fundamental cellular processes.  
In a resting cell, the concentration of cytoplasmic Ca2+ is less than 0.1 µM which is 
10,000 fold lower than outside the cell. The membrane potential is negative inside 
the cell which allows Ca2+ entry through open Ca2+ channels (across the plasma 
membrane) as a result of the large electrochemical gradient. 
In platelets, the elevation in intracellular calcium concentration [Ca2+]i contributes to 
various steps of cellular activation such as the reorganisation of the actin 
cytoskeleton necessary for shape change (Hathaway & Adelstein 1979) and 
degranulation or inside-out activation of the integrin αIIbβ3 which is central for 
platelet aggregation (Shattil & Brass 1987) For a diagrammatical representation of 
Ca2+ regulation see Figure 1.5.  The two major sources that drive the elevation of 
[Ca2+]i are the release of compartmentalised Ca2+ and the entry of extracellular Ca2+ 
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through the plasma membrane. The mechanisms of Ca2+ release from intracellular 
stores have been well established for many years, however the mechanistic 
processes underlying Ca2+ entry remained largely unknown until recently. 
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Figure 1.5. Mechanisms involving platelet Ca2+ homeostasis 
Various transport systems that are responsible for the regulation of cytosolic calcium 
levels. Intracellular stores are able to release calcium and increasing cytosolic levels. 
This is achieved via the inositol 1,4,5,trisphosphate receptor (IP3R), which in turn 
leads to a calcium influx through store operated calcium entry through membrane 
channels such as Orai1 upon stimulation with calcium sensitive molecules in the ER 
membrane such as stromal interaction molecule 1 (STIM1) via protein-protein 
interaction. The extrusion of intracellular calcium through the plasma membrane is 
tightly controlled by the plasma membrane calcium ATPase (PMCA) and the 
Na+/Ca2+ exchanger (NCX). Further sequestration into intracellular stores is 
achieved via the re-uptake by the sarco-endoplasmic reticulum calcium ATPase 
(SERCA). Calcium mobilisation is also initiated via outside in signalling through 
integrins and glycoproteins located on the plasma membrane such as GPVI, and also 
through G-protein coupled receptors such as those for thrombin, ADP and 
thromboxane. Other calcium-dependant receptors such as CLEC-2 are also involved 
in platelet calcium mobilisation though its association with PLCγ2. 
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1.5.2. Calcium store release 
 
As mentioned previously, a rise in [Ca2+]i is a major component of the signalling 
mechanisms regulating platelet function. Agonist induced stimulation of many 
platelet receptors leads to the activation of PLC isoforms, namely β, γ and δ, which 
hydrolyse PIP2 converting this to IP3 and DAG. This induces the release of Ca2+ 
from stores. IP3 generated by PLC, releases Ca2+ from the intracellular stores by 
direct action on the IP3R in the endoplasmic reticulum (ER), which themselves are 
Ca2+ permeable ion channels. The regulation of these receptors occurs through 
receptor phosphorylation, most likely through the actions of various protein kinases 
(Ferris et al. 1991). However, a number of studies have reported inhibition of 
receptor function after phosphorylation (Komalavilas & Lincoln 1994; Supattapone 
et al. 1988). IP3R have also been identified in the plasma membrane and a study 
performed by El-Daher and colleagues reported that this receptor may be involved in 
cation entry (El-Daher et al. 2000). 
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1.5.3. Calcium store entry 
 
Store operated Ca2+ entry (SOCE), a mechanism regulated by the filling state of the 
intracellular Ca2+ stores, is a major mechanism for Ca2+ influx in non excitable cells 
(Rosado et al. 2000) and the events that initiate SOCE, i.e. a decrease in the 
concentration of free Ca2+ in the stores  have long been characterised (Putney et al. 
1986). In the last five years, research concerning the nature of the channels that 
conduct SOCE has been a matter of debate, for example, the co-expression of the 
release-activated Ca2+ channel protein 1 (Orai1) with the intracellular Ca2+ sensor, 
stromal interaction molecule 1 (STIM1) has been reported to enhance SOCE 
(Mercer et al. 2006). Physiological agonists such as ADP and thrombin stimulate 
both the release of Ca2+ from intracellular stores and the entry of Ca2+ across the 
plasma membrane. The occupation of surface receptors results in the activation of 
PLC and the formation of the Ca2+ releasing messenger, IP3, which acts on receptors 
on the ER. Release of this finite Ca2+ store is insufficient for full platelet activation, 
which in addition, requires Ca2+ entry from the external medium. One of the major 
mechanisms generating Ca2+ entry in platelets is the depletion of Ca2+ stores.  
The mechanism underlying the activation of SOCE is, however, poorly understood.  
Two hypotheses have been put forward to explain how depletion of Ca2+ stores 
might be signalled to the PM to activate Ca2+ entry. One proposal was a direct 
interaction between proteins in the ER and PM (conformational coupling) and 
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another proposed a role for a potential diffusible messenger (Berridge 1995; 
Heemskerk et al. 1994; Parekh & Penner 1997; Sage 1997).  
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1.5.4. Calcium signalling and disease 
 
A sustained increase of cell Ca2+ to micromolar concentrations can impact 
dramatically to the signalling function of Ca2+. When injurious conditions increase 
the permeability of the plasma membrane allowing abnormal Ca2+ influx, 
mitochondria try to sustain with the cytosolic Ca2+ overload and may serve to 
prevent cell death should the noxious agent be removed rapidly. In some 
circumstances, however, a cell may undergo apoptosis due to the activation of Ca2+- 
dependent hydrolytic enzymes such as proteases. More subtle forms of pathology 
linked to Ca2+ signalling have also been recognised, e.g., the degeneration of the 
retina caused by gene defects of neuronal Ca2+. Calpain has also been involved in 
human pathology. The disruption of the gene for muscle isoform p94 (calpain III) 
causes limb limb gurdle muscular dystrophy type 2A (Richard et al.1995), whereas 
genetic variation in the gene for another isoform lacking the C-terminal Ca2+-
binding domain (calpian 10) favours the onset of type 2 diabetes (Horikawa et al. 
2000). 
Muscle disturbances resulting in prolonged Ca2+ overload have been linked to 
SERCA pump and ryanodine receptor defects. Malignant hyperthermia is a genetic 
disease in which inhalation anaesthetics induce skeletal muscle rigidity and extreme 
hyperthermia (among other symptoms). A leak in the Ca2+- releasing ryanodine 
receptor of the sarcoplasmic reticulum explains these symptoms. Defects in the 
genes for the four isoforms of plasma membrane calcium ATPases (PMCA’s) have 
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also been described. PMCA2 and 3 are mostly restricted to neuronal cells, e.g., 
PMCA2 is very abundant in the outer hair cells of the organ of Corti. Work on 
knock-out mice and in mice with a phenotype characterised by hearing defects that 
could be models for hereditary hearing loss in human (Takahashi et al.1999) has 
revealed essential roles PMCA2.  
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1.6. Calcium Receptors 
 
1.6.1. Membrane calcium ATPases 
 
Among the structures involved in Ca2+ signalling are the Ca2+ ATPases which are 
able to deplete free Ca2+ ions from the cytosol. Three families of such proteins are 
defined depending on the membranes they are inserted in. First, are the plasma 
membrane Ca2+ ATPases (PMCA’s) which are responsible for transporting Ca2+ ions 
outside the cell (Carafoli & Brini 2000; Strehler & Zacharias 2001). Second, the 
sarco/endoplasmic reticulum  Ca2+  ATPases (SERCA’s) which are inserted in the 
ER plasma membrane and are responsible for transporting  Ca2+  ions into the 
intracellular ER  Ca2+  reservoir (Wuytack et al. 2002; Strehler & Treiman 2004; 
Lipskaia & Lompré 2004) and finally the secretory pathway Ca2+ ATPases 
(SPCA’s) which have only emerged in recent years and are found (for example), 
within the golgi apparatus around the nucleus of mammalian spermatozoa (Harper et 
al. 2005). 
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1.6.2. Membrane calcium ATPases: Structure 
 
Both PMCA’s and SERCA’s are members of the P-type ATPases that transport Ca2+ 
ions against a deep concentration gradient at the expense of ATP.  
They share similar structure symmetry and are oriented in the membranes with 
extramembranous cytosolic loops. They consist of a single polypeptide chain folded 
into four main domains, a transmembrane domain (M) composed of 10 
transmembrane (TM) helices, and three cytosolic domains (N, P and A). The 
actuator (A) and phosphorylation (P) domains are connected to the M domain 
whereas the third nucleotide-binding domain (N) is connected to the P domain. The 
major difference that discriminates PMCA from SERCA structurally is the addition 
of a C-terminal tail in PMCA. This tail contains a calmodulin (CaM) binding site 
and acts as an auto-inhibitory segment which is thought to prevent catalytic 
turnover, keeping PMCA in an inactive state. More recently, the C-terminal end of 
PMCA has been shown to contain a PDZ binding domain, containing proteins as 
well as a specific site for caspase-3, one of the main proteases of the apoptotic 
cascade (Zabe & Dean 2001; Pászty et al. 2007). A representation of the structure of 
PMCA is shown in Figure.1.6.  
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Figure 1.6. Schematic representation of the Plasma Membrane Ca2+ ATPase  
   (including regulation sites) 
PMCA is organised with 10 transmembrane (TM) domains with approx. 80% of the 
pump mass protruding into the cytosol with an N-terminal sequence of approximately 
90 residues, two main central domains and a long C-terminal tail downstream of the 10th 
TM domain. The first central domain protrudes between TM domains 2 and 3; it 
contains a basic stretch of amino acids which is the main site of interaction with 
activatory acidic phospholipids. It also contains a site for the auto-inhibitory C-terminal 
calmodulin-binding domain. The second (and largest) cytosolic unit connects TM 
domains 4 and 5, and contains the active site for ATP It also contains binding sites for 
α1-synotrophin and calcineurin. Towards the N-terminal end contains a proposed 
inhibitory site for the 14-3-3 (sigma) protein identified on PMCA (isoforms 4). The 
cytosolic C-terminal tail contains the most important regulatory sites of the pump, 
including the calmodulin-binding domain and consensus sites for protein kinases A and 
C and a newly identified PDZ biding domain. The calmodulin-binding domain, owing 
to its basic character, also binds acidic phospholipids and thus could also mediate the 
response of the pump to them.  
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1.6.3. Membrane calcium ATPases: Conformational states 
 
Both PMCA and SERCA can exist in two conformational states, E1 and E2. E1 
binds to ATP and Ca2+ in the cytosol to form a high energy aspartylphosphate 
intermediate. The protein then undergoes a conformational change into the E2 state 
while translocating Ca2+ to the extracellular surface. Due to their low affinity for the 
E2 state, Ca2+ is released into the exoplasm and both revert back into the E1 state as 
a result of hydrolysation of the acetylphosphate. A report published by Salvador and 
colleagues suggested that PMCA could have a stoichiometry of 1:1  meaning one 
Ca2+ molecule is translocated for the hydrolysis of each ATP. This contrasts with 
SERCA, which has a stoichiometry of 2 Ca2+ molecules per ATP (Salvador et al. 
1998).Thus PMCA has a Hill coefficient of 1 for Ca2+ while SERCA has 2 (Grover 
& Samson 1986).  
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1.6.4. PMCA in the cardiovascular system 
 
PMCA’s are emerging as important regulators of the cardiovascular system 
(Cartwright et al. 2005). For example, studies using transgenic mice showed that 
isoform 4b regulates β-adrenergic cardiac contractile responses via the interaction 
and modulation of nNOS activity in cardiomyocytes (Oceandy, Cartwright et al. 
2007). Each isoform is said to be expressed in a tissue specific manner (Hammes et 
al. 1994). Recently, transgenic approaches have led to the elucidation of roles which 
are specific to PMCA4 in the heart and vasculature. For example, PMCA4 has large 
intracellular loops and a PDZ-binding domain which allow it to interact with 
intracellular signalling molecules such as nNOS (Schuh et al. 2001),  syntrophin 
(Williams et al. 2006), calcineurin (Buch et al. 2005; Holton et al. 2007) and Ras 
association domain-containing protein 1 (RASSF1) (Armesilla et al. 2004). These 
interactions regulate a number of processes in the cardiovascular system. PMCA4 
has also been shown to regulate paracrine secretion (Toescu & Petersen 1995), 
sperm motility (Schuh et al. 2004), apoptosis (Orrenius et al. 2003) and cell 
differentiation (Hammes et al. 1994). The fact that PMCA4 acts via signalling 
molecules specific to a particular cell type or a specific intracellular location, such as 
caveolae (Pang et al. 2005) explains its diverse functions. 
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1.6.5. PMCA in platelets 
 
There are four genes that encode for PMCA (PMCA1-4) (human genome database 
nomenclature (ATP2B1-ATP2B4)) and additional isoforms generated via alternative 
RNA splicing of the primary gene transcripts gives rise to over 30 possible isoforms 
(Brandt & Neve 1992; Strehler & Zacharias 2001). PMCA1 and 4 are expressed 
ubiquitously; whereas PMCA 2 and 3 are mainly found in excitable cell types i.e. 
the brain, heart and kidney. Platelets express PMCA1 and PMCA4 (Martin et al. 
2000). Very few isomer specific functional studies have been conducted to date; 
however, PMCA’s generally have been shown to form the main mechanism for Ca2+ 
removal across the platelet plasma membrane (Rosado & Sage 2000). 
PMCA’s are reportedly inactive during platelet activation (to promote a rapid 
increase in [Ca2+]i) and become active during the disaggregation phase (Wan et al. 
2003). Furthermore, PMCA4 interacts with the cytoskeleton and is translocated to 
filopodia during activation suggesting roles specific to this locality (Zabe & Dean 
2001). The physiological relevance of this interaction has been demonstrated by 
observing impaired clot retraction when association of PMCA4 with β-actin is 
blocked (Dean & Whiteheart 2004). One study by Zabe and colleagues 
demonstrated that the inhibition of PMCA4-β-actin interaction does not affect 
platelet aggregation. However, this observation may be due to functionally relevant 
interactions occurring later in the activation process (Zabe & Dean 2001). Over 
expression of constitutively active PMCA4 in platelets has also been shown to 
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enhance platelet aggregation and this was hypothesised to occur due to the localised 
removal from Ca2+ from unidentified signalling molecules (Schuh et al. 2001). 
PMCA’s therefore play an important role in platelet Ca2+ transport and there is ever 
more evidence of location-specific and time-specific functional roles of PMCA4 that 
could be useful in identifying a potential therapeutic target in the treatment of 
thrombotic associated cardiovascular diseases. The role of PMCA in regulating 
platelet Ca2+ homeostasis and function however, remains incompletely understood.  
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1.6.6. SERCA in platelets 
 
The SERCA family is issued from three genes named SERCA 1-3 (human genome 
database nomenclature (ATP2A1-ATP2A3)), that correspond to 3’-end alternatively 
spliced RNA’s and the corresponding protein isoforms (Bobe et al. 1994; Wuytack 
et al. 1994).  Early studies using molecular techniques such as cloning, reverse 
transcription-polymerase chain reaction (RT-PCR) and immunoblotting identified 
that human platelets express the SRECA2a isoforms (Enouf et al. 1992). Following 
this, two other isoforms were identified in platelets, each possessing molecular 
weights of 100 and 97kD. These were SERCA2b and SERCA3a (Papp et al. 1991; 
Papp et al. 1992; Papp et al. 1993). Few studies have addressed the physiological 
relevance of this pump in the removal of Ca2+ in either resting or activated platelets, 
however, some studies have suggested that following platelet stimulation, the 
activation of SERCA precedes that of the PMCA pump and that during the resting 
state of platelets, the extrusion of Ca2+ through PMCA is the principle mechanism of 
Ca2+regulation (Rosado & Sage 2000; Redondo et al. 2005). SERCA’s are 
responsible for the sequestration of Ca2+into the ER reservoir and only a minor 
fraction (about 1%) of the total platelet Ca2+ is retained within the ER itself (Brass 
1984; Cavallini & Alexandre 1994). When the concentration of  intracellular Ca2+ 
increases, this initiates the Ca2+-release mediator IP3  to release Ca2+ from the ER 
stores, and it is this depletion of Ca2+ into the cytosol, that activates the opening of 
Ca2+ influx channels in the plasma membrane (Putney 1990; Meldolesi et al. 1991).
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1.6.7. Sodium-Calcium Exchanger (NCX) in platelets 
 
The process of Na+/Ca2+ exchanger (NCX) was first described in the late 1960’s 
through measurements of Na+-dependent Ca2+ fluxes in various tissues (Blaustein & 
Lederer 1999). The NCX is a protein belonging to a secondary group of transporters, 
many of which utilise the energy stored in the transmembrane (TM) Na+ gradient for 
uphill transport of other substrates, in this case Ca2+. NCX’s are generally thought to 
operate via the so-called alternating access model in which a single set of substrate 
or ion binding sites change their accessibility from the extracellular environment to 
the cytosol and vice versa. Unlike ion channels, each ion translocation event of the 
NCX is thought to be accompanied by a major conformational change, and these 
proteins are therefore thought to exist in at least two, and possibly more, distinct 
conformational states (Altimimi & Schnetkamp 2007). 
Another important physiological consequence of the alternating access model is that 
NCX proteins are expected to be bidirectional. They can mediate both Ca2+ 
extrusion as well as Ca2+ import, dependent on the transmembrane Na+ gradient and 
to a lesser degree on membrane potential (Schnetkamp 1989). Specifically, events 
that remove or significantly lower extracellular Na+ or increase intracellular Na+ are 
expected to shift the transport mode from Ca2+ extrusion (forward exchange) to Ca2+ 
influx (reverse exchange) which could rapidly lead to Ca2+ overload in cells.  
The NCX expresses a low affinity but high capacity for Ca2+, transporting up to five 
thousand Ca2+ ions per second (Carafoli et al. 2001).  
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Therefore, it requires large concentrations of Ca2+ to be effective, but is useful for 
ridding the cell of large amounts of Ca2+ in a short time. This suggests that the NCX 
also plays an important role in regaining the cell's normal Ca2+ concentrations after 
an excitotoxic insult (Kiedrowski et al. 1994). This contrasts to PMCA, which has a 
much higher affinity and lower capacity for Ca2+ and is capable of effectively 
binding to Ca2+ even when its concentrations are quite low. The activities of NCX 
and PMCA therefore complement each other. 
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1.7. PMCA inhibitors 
 
1.7.1. Carboxyeosin (CE) 
 
Carboxyeosin (CE) is a derivative of the fluorescein isothiocyanates (FITC) 
commonly used for covalently labelling proteins and within cellular biology to label 
and track cells in fluorescence microscopy (for example, flow cytometry) 
(Vanderkooi et al. 1987). The use of fluorescein derivatives to inhibit plasma 
membrane Ca2+ pumps was first described by Gatto and Millanic in 1993. They 
demonstrated that CE irreversibly inhibits PMCA’s in red blood cells (Gatto & 
Milanick 1993) and later went onto demonstrate that Eosin (which is the active 
constituent of CE) inhibited PMCA’s in cardiac myocytes without affecting the 
NCX (Gatto et al. 1995). A number of studies have shown CE to have significant 
PMCA-inhibitory effects; for example, Moccia and colleagues demonstrated that by 
inhibiting the PMCA pump with CE, and NCX with benzamil and by removing 
extracellular Na+, the decay phase of an agonist-evoked Ca2+ transient in rat 
microvascular endothelial cells and  the removal of Ca2+ is achieved by both the 
PMCA pump and NCX (Moccia et al. 2002). Recently, CE has been used to inhibit 
PMCA in other cell types. For example, treatment of live sea urchin sperm with CE 
resulted in elevations of intracellular Ca2+ and loss of flagellar motility (Liang et al. 
2004) and within mice, the application of CE reduces sperm motility due to 
inhibition of PMCA4 (Schuh et al. 2004). 
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1.7.2. Caloxins 
 
Caloxins are specific extracellular peptide inhibitors of PMCA, and were first 
described by Chaudhary and colleagues in 2001 who showed that through screening 
a random peptide phage display library, they were able to select the first 
extracellular peptide to inhibit PMCA. They identified that Caloxin-2A1 binds to the 
second extracellular domain sequence of the PMCA pump. This domain links 
transmembrane domains 3 and 4 and mutagenesis of key residues in domain 4 has 
been shown to be inhibitory (Guerini et al. 1996).  They also investigated the effects 
of Caloxin-2A1 on endothelium-dependent relaxation of rat aorta where they 
observed Caloxin-2A1 produced relaxation by activating eNOS (Chaudhary et al. 
2001). Caloxin 2A1 was also the first peptide to be identified that inhibited PMCA 
by binding to the synthetic sequence of exdom domain 2. Since this development, 
groups have gone onto look at PMCA inhibition using Caloxins in mesenchymal 
stem cells (Kawano et al. 2003), aortic endothelium, smooth muscle cells (Pande et 
al. 2006) and in primary cultures of cerebellar granule cells (Vale-González et al. 
2006). 
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1.8. SERCA and NCX inhibitors 
 
1.8.1.  Thapsigargin and 2, 5-di-(tert-butyl)-1,4-benzohydroquinone (BHQ)  
 
Thapsigargin and BHQ are widely used as they are membrane permeable and can 
block ER Ca2+ pumps in intact cells (Kass et al. 1989; Thastrup et al. 1990; Moore et 
al. 1987). Both have been shown to exert their inhibitory action by stabilisation of 
the E2 conformational state of the ATPase and this is followed by an influx of 
Ca2+from the extracellular medium (Jackson et al. 1988; Thastrup et al. 1990; 
Wictome, et al. 1992a; Wictome, et al. 1992b). Whereas BHQ and Thapsigargin 
both act to elevate intracellular Ca2+ levels, Thapsigargin has been shown to induce 
rapid Ca2+ store depletion in platelets. In addition, both compounds have differing 
functional effects. Thapsigargin has been shown to induce aggregation through 
tyrosine phosphorylation of the PMCA (Rosado & Sage 2000) whereas BHQ does 
not (Brune & Ullrich 1991) This could be due to the presence of two platelets Ca2+ 
stores with high and low Ca2+ leakage rates being previously described  (Cavallini et 
al. 1995; Doni et al. 1994). It has been demonstrated that different SERCA isoforms 
in platelets are differentially sensitive to either BHQ or Thapsigargin, one that is 
sensitive to high thapsigargin concentrations and another by low concentrations of 
thapsigargin but is not affected by BHQ (Cavallini et al. 1995). Both of these 
compounds are therefore useful in studies examining the impacts of increasing 
cytosolic Ca2+ concentrations within various cell types. 
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1.8.2. Bepridil (1-N-benzylanilino-2-pyrodinino-3-isobutoxypropane) 
 
Bepridil is a class IV NCX antagonist and used in the treatment of angina pectoris 
and supraventricular and ventricular fibrillation (Sugi 2006). It decreases Ca2+ influx 
through potential-dependent and receptor-operated sarcolemmic channels and acts 
intracellularly as a CaM antagonist and Ca2+ sensitiser (A. Gill et al. 1992).  
In cardiac muscle, it enhances the sensitivity of troponin C to Ca2+, stimulates 
myofibrillar ATP activity, removes CaM’s inhibitory effect on sarcoplasmic 
reticulum Ca2+ release, and inhibits NCX actions that tend to offset the effects of 
Ca2+ influx blockade on cardiac contractile force (Gill et al. 1992; Murakami et al. 
2010; Nawada et al. 1995; Watanabe et al. 2006).  
The use of Bepridil in platelet studies has been described by Shiraga and colleagues. 
They reported that by using Bepridil, which is a relatively specific inhibitor of the 
NCX, inhibition of platelet aggregation induced by various physiological agonists 
could be achieved (Shiraga et al. 1996). 
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1.9. PMCA4-/- Mice  
 
Transgenic animals are used as experimental models in biomedical research. As 
PMCA is thought to play an important role in platelet Ca2+ transport, the use of 
genetically modified mice that lack the PMCA4 gene could be a useful tool in 
determining isomer specific roles. The first studies were carried out by Schuh and 
colleagues who showed that homozygous male mice with a targeted gene deletion of 
PMCA4, which is highly enriched in the sperm tail, are infertile due to severely 
impaired sperm motility. Embryonic stem cells underwent homologous 
recombination and were injected into C57Bl/6 blastocysts. These were transferred 
into pseudo-pregnant foster mice to generate chimeras and later mated with C57Bl/6 
females to test for germ line transmission of the targeted PMCA4 allele. PMCA4-
deficient mice were finally obtained by appropriate inbreeding of heterozygous 
offspring and subsequent genotyping (Schuh et al. 2004). 
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1.9.1 Research objectives 
Platelets play a central role in haemostasis and thrombosis and the regulation of Ca2+ 
within platelets is key to their function. PMCA’s are currently emerging as having an 
important role within the cardiovascular system, however their role in platelets remains 
to be defined. Therefore, the main objectives of this study were to investigate the role 
of PMCA in platelet function and Ca2+ homeostasis. This was achieved using a 
pharmacological inhibitor of PMCA, carboxyeosin. Following this, isomer specific 
roles were investigated using PMCA4 knock-out mice and the molecular signalling 
pathways of PMCA were also explored. Lastly, the consequence of inhibition in 
comparison to other Ca2+ regulators in platelets, SERCA and the NCX was also 
investigated. 
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2.1.  Materials 
 
Table 2.1.  List of compounds and purchasing companies  
Compound Purchased From 
• [3H]-5-HT 
Perkin Elmer 
(Cambridgeshire, 
UK) 
• 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxal 
in-1-one (ODQ) 
Tocris Bioscience (Bristol, 
UK) 
• 1x RIPA solution 
• Acetic acid solution 
• Acid Citrate-Dextrose Solution (ACD) 
• Bovine Serum Albumin Powder 
• Citric Acid 
• D-Glucose 
• EDTA 
• Ethanol solution 
• Ethidium Bromide Solution 
• Fibrinogen (Bovine) 
• 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid, N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid (HEPES) 
• Imipramine 
• Isopropanol solution 
• KCl 
• Methanol solution 
• MgCl2 
• Milk powder 
• Na2H.PO4 12H2O 
• NaCl 
• NaHCO3 
• NaOH 
• PGI2 
• SDS 
• Sodium Nitroprusside 
• Thrombin (Bovine) 
• Tris 
• Trisodium Citrate 
• Triton-X 100 
• Tween-20 
• Urethane 
Sigma (Poole, UK) 
CHAPTER TWO – Materials & Methods 
 
83 
 
• 2,5-di-(tert-butyl)-1,4-benzohydroquinone Calbiochem (Darmstadt, Germany) 
• AbGene Reddy-Mix  
• Enhanced chemiluminescence detection system 
(ECLTM) 
• Tris (2-Carboxyethyl) phosphine Hydrochloride 
(TECP.HCl) 
Thermo Scientific 
(Northumberland, UK) 
• Agarose powder 
• Hyperladder II  Bioline (London, UK) 
• Bio-Rad protein assay kit 
• Polyvinylidene difluoride (PVDF) membrane 
Bio-Rad (Hertfordshire, 
UK) 
• CEDA-SE 95-(and-6)-Carbon diacetate 
succinimidyl ester 
• Proteinase K 
• PMCA Antibody 
• PMCA (Neomycin) Antibody 
Invitrogen (Paisley, UK) 
• Collagen (Collagen fibres predominantly type I 
from equine tendons) 
Nycomed (Munich, 
Germany) 
• Ethly Chloride Spray (Local anaesthetic) - animal 
use only 
Miller Medical Supplies 
(Newport, UK) 
• Horseradish peroxidase-conjugated (HRP) 
• Secondary antibodies (anti-rabbit IgG, anti-mouse 
IgG) 
Dako (Glostrup, Denmark)
• Hyperfilm ECL 
• 111Indium Oxine 
• Molecular Weight Rainbow Marker (full range) 
GE Healthcare 
(Buckinghamshire, UK) 
• Phosp - VASP 239 and Total VASP antibody Cell Signalling (Hertfordshire, UK 
• PMCA4 Antibody SWANT (Bellinzona, Switzerland) 
• Protease Inhibitor cocktail I and II Roche (Hertfordshire, UK)
• Quick-Load 100bp DNA ladder 
• p-Nitrophenol Phosphate  
Biolabs (Hertfordshire, 
UK) 
• Scintillation  Fluid National Diagnostics (Hessle, UK) 
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Table 2.2. List of equipment and animals used detailing purchasing companies  
Equipment Purchased From 
• Single point extended area ratio 
(SPEAR) detector 
eV Products (Saxonburg, PA) 
• Sysmex F-820 Haematology 
Analyser 
Sysmex (Milton Keynes, UK) 
• Spectrum Techniques Software Mumed Systems (London, UK) 
• Chronolog Multi Channel 
Aggregometer 
Chronolog chorporation (Havertown, 
PA, USA) 
• Luminescence Spectrometer LS50B Perkin Elmer (Cambridgeshire, UK) 
• Quartz SUPRASIL Macro/Semi-
micro cell cuvette  
Perkin Elmer Instruments 
(Cambridgeshire, UK) 
• Liquid Scintillation Counter 1414 WALLUC Instruments (Minnesota, 
USA) 
• Semi-dry transfer blotter  
• Bio-Rad 18-630 microplate reader 
Bio-Rad (Hertfordshire, UK) 
Animals Purchased From 
PMCA4 C57/SV-129 mice (Male and 
Female) Approximately 12 weeks old 
(20-30 grams) 
Initial gift from Manchester University, 
breed at Imperial College London under 
a heterozygous breeding program 
 
Table 2.3. Buffer compositions 
Modified Tyrodes HEPES Buffer (mTHB) 
Compound Final concentration 
D-Glucose 10 mM 
HEPES 20 mM 
KCl 2.9 mM 
MgCl2 10 mM 
Na2H.PO4 12H2O 0.34 mM 
NaCl 134 mM 
NaHCO3 12 mM 
Dissolved in dH20 and pH to 7.4 - kept for one week only at 4 °C 
Ca2+ and Mg2+ Free Modified Tyrodes HEPES Buffer (CMFB) 
Compound Final concentration 
D-Glucose 10 mM 
KCl 2.9 mM 
Na2H.PO4 12H2O 0.34 mM 
NaCl 134 mM 
NaHCO3 12 mM 
Dissolved in dH2O – kept for one week only at 4 °C 
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Table 2.4.  Sequences of the oligonucleotide pair sequences used for genotyping 
   mouse  tail tips using PCR 
Primer Name      Sequence 
PMCA Forward     5’-GGTCTATCTGGGAACCCTGC-3’   
PMCA Reverse     3’-GAGAATGGCTTACTAGCTCT-5’  
PMCA Knock Out (Neomycin) Forward  5’-GAACAAGATGGATTGCACGC-3’ 
PMCA Knock Out (Neomycin) Reverse  3’-ACAACGTCGAGCACAGCTGC-5’ 
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2.2. EXPERIMENTAL METHODS 
 
2.2.1 Cell preparation techniques 
 
2.2.1.1. Preparation of human washed platelets 
 
Human blood was drawn from consenting, healthy drug-free volunteers at least 1 
hour prior to experiments as described previously by (Yanaga et al. 1995). 50 ml of 
blood was drawn from either a cephalic, basillic or medial vein using a 60 ml pull 
back syringe connected to a 21 gauge butterfly cannula into 1:9 volume 3.8% (w/v) 
trisodium citrate. 
Platelet rich plasma (PRP) was separated from erythrocytes and leukocytes by 
centrifugation at 100 g for 20 minutes at room temperature. Platelets were then 
isolated from the plasma by centrifugation at 1400 g for 10 minutes in the presence 
of 125 µg/ml PGI2 to reduce the risk of activation. 
Platelet poor plasma (PPP) was discarded and the pellet was recovered and re-
suspended in physiological modified Tyrodes-HEPES buffer (mTHB). A repeated 
wash was performed in mTHB containing PGI2 (125 μg/ml). Platelet numbers were 
determined using a Sysmex F-820 Haematology Analyser (Milton Keynes, UK) and 
adjusted to a density of 250 x 103 cells/ml unless stated otherwise. Platelets were 
then left to rest at 27 °C for 30 minutes. This study was approved by the Brompton, 
Harefield and National Heart and Lung Institute Research Ethics Committee (REC 
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approval number 07/H0708/72) and informed consent was obtained from all 
participants. 
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2.2.1.2. Mouse platelet preparation 
 
Blood from either male or female PMCA4 C57/SV-129 mice, approximately 12 
weeks old (20-30g) was obtained on the day of the experiment (under terminal 
anaesthesia Urethane 25% (w/v)) via cardiac puncture and followed by termination 
using a method approved in Schedule 1 of the Animals (Scientific Procedures) Act 
1986. Blood was drawn into a syringe containing 150 µl ACD. PRP was obtained by 
centrifugation at 300 g for 3 minutes at room temperature and transferred into new 
microcentrifuge tubes. 400 μl of CMFB and ACD solution (3:1v/v) containing PGI2 
(1 mg/ml) was then added to the remaining red blood cells (RBC) and the previous 
centrifugation step repeated. The diluted PRP was removed and added to the 
previous PRP. The removal of contaminating RBC was achieved by a further 
centrifugation step at 200 g for 2 minutes. PRP was transferred to fresh tubes and 
platelets isolated by centrifugation at 1500 g for 7 minutes. Platelets were finally re-
suspended in 200 µl CMFB prior to platelet numbers being determined using a 
Sysmex F-820 Haematology Analyser. Platelets were adjusted to 4 x 106  cells/ml 
unless otherwise stated and left to rest for 30 minutes at 27 °C to allow recovery 
prior to experiments. 
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2.2.2. Genotyping 
 
2.2.2.1. DNA extraction from mouse tail 
 
Male or female mice were restrained using an appropriate mouse restraining tube 
and tails sprayed with Ethyl Chloride local anaesthetic spray.  Up to 3 mm of mouse 
tail tip was removed using a sterile scalpel blade, and placed in a sterile 
microcentrifuge tube. Tail tips were left overnight in 700 µl digestion buffer (50 mM 
Tris, 100 mM EDTA, 0.5% SDS) along with 35 µl proteinase K (10 mg/ml) at 56 
°C). Tail samples were then centrifuged at 13000 g for 10 minutes at 4 °C and 
supernatants transferred into new sterile microcentrifuge tubes containing 700 µl 
isopropanol. Tubes were gently inverted to mix and left for 30 minutes on ice. DNA 
was pelleted by centrifugation at 13,000 g for 5 minutes and the supernatant 
discarded. The remaining pellet was washed in 70% ethanol, the supernatant 
removed and the pellet left to air dry for 20 minutes on ice. Pellets were re-
suspended in 50-500 µl Tris-EDTA buffer (TE, 10 mM Tris pH 7.5, 1 mM EDTA 
pH 8.0) and incubated at 65 °C for 1 hour with occasional agitation to gently 
dissolve the pellet. 
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2.2.2.2. Polymerase chain reaction (PCR) 
 
PCR (Mullis & Faloona 1987) was used to amplify DNA from digested mouse tail 
tip samples (Section 2.2.2.1.). A reaction mix containing the following was prepared 
for a 25 µl reaction (brackets refer to stock concentrations): 
• 12 µl AbGene Reddy-Mix (350 µM each dNTP, 2.25 mM MgCl2, Taq, DNA 
polymerase 1.25 U) 
• 1 µl each primer per sample (10 µM) 
• 1 µl DNA (1.5 ng/ml)  
• and made up to 25 µl using ddH20 
 
DNA samples were denatured at 94 °C for 23 minutes, prior to 40 cycles of 
denaturing at 94 °C for 10 seconds, annealing at 56 °C for 30 seconds and extension 
at 68 °C for 1 minute. The samples then underwent a final extension step at 68 °C 
for 7 minutes and were held at 4 °C. DNA was visualised on a 1% agarose gel (w/v) 
in Tris, acetic acid and EDTA buffer (TAE, Tris-base 96.8 g, acetic acid 22.84 ml, 
EDTA) (40 ml (of 0.5 M) in 1L) containing 10 µl Ethidium bromide (10 mg/ml) by 
short wave UV light using a UV transilluminator. DNA bands at 344bp represented 
PMCA (wild-type, +/+), whereas bands at 245bp represented Neomycin resistant 
PMCA (knock out, -/-). Bands at both positions represented PMCA (heterozygous, 
+/-) mice. 
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2.2.3. Molecular techniques 
 
2.2.3.1. Protein Quantification 
 
Protein concentration was measured using a Bio-Rad RC-DC (reducing agent and 
detergent compatible protein assay which was adapted from (Bradford 1976). 
Lysates of an unknown concentration (5 μl) or BSA standards (5 μl of 2, 1.5, 1, 0.5, 
0.25, 0.125 and 0.0625 mg/ml) were added in triplicate to a 96 well microtiter plate. 
Ready-made developing reagents were added to each well. The plate was then left in 
the dark at room temperature for 15 minutes to allow the colour to develop after 
which, the absorbance of each sample was measured using a Bio-Rad 18-630 
microplate reader at 595 nm. 
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2.2.3.2. Protein isolation and western blotting 
 
Tissue samples were homogenised (placed into liquid nitrogen and crushed using a 
pestle and mortar) and incubated with a detergent lysis buffer (platelets, were 
directly treated with the detergent buffer), (1.65 ml 1x RIPA buffer (containing 150 
mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 
mM Tris, pH 8.0), 350 µl 1x protease inhibitor cocktail, 2 µl phosphatase inhibitor 
cocktail I, 2 µl phosphatase inhibitor cocktail II and 2 µl Tris (2-Carboxyethyl) 
phosphine Hydrochloride (TECP.HCl)) and left for 30 minutes on ice. Cell lysates 
were then centrifuged at 13,000 g to pellet debris and cytoskeletal components and 
supernatants were removed into fresh microcentrifuge tubes and placed on ice. 
Proteins were later quantified using a Bio-Rad protein assay kit (Section 2.2.3.1.), 
electrophoresed on 8-12% SDS-polyacrylamide gels and electrophoretically 
transferred for 1 hour at 120 volts in a semi-dry blotter (Bio-Rad, UK) onto 
polyvinylidene difluoride (PVDF) membranes for subsequent probing. Blots were 
incubated overnight at 4 °C with either 5% (v/v) BSA or milk (depending on 
antibody used) in 1xPBST (phosphate buffered saline tween-20) to block residual 
protein binding sites. Membranes were then incubated with primary monoclonal 
antibodies diluted 1:1000 in 1xPBST for 1 hour at room temperature and washed six 
times for 5 minutes each with 1xPBST. To detect the primary antibody, blots were 
incubated with horseradish peroxidise-conjugated anti-mouse, rabbit or goat IgG 
(depending on primary antibody) diluted 1:10000 in 1xPBST for 1 hour at room 
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temperature. These were further washed six times for 5 minutes with 1xPBST and 
exposed to enhanced chemiluminescence reagents between 30 seconds to 4 minutes. 
Blots were then exposed to pre-flashed photographic film. 
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2.2.4. Functional assays 
 
2.2.4.1. Aggregation using washed platelets 
 
Washed platelets (Section 2.2.1.1.), (450 µl) were made up to a density of 250 x 103 
cell/ml and pre-warmed to 37 °C for 90 seconds prior to stimulation with an agonist 
(50 µl) in a siliconised glass cuvette in an optical platelet aggregometer, under 
stirring conditions (~1200rpm). Platelet aggregation was measured for up to 3 
minutes as described by Born 1962, using light transmission through a sample. 
Changes in optical density corresponding to shape change and aggregation following 
agonist administration were recorded using a chart recorder (Chrono-log 
Corporation, Havertown, PA, USA) (Born 1962b). Platelet agonists were 
administered in volumes of 50 µl per sample. 
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2.2.4.2. Adhesion using washed platelets 
 
Platelet adhesion was measured using a modified protocol from Bellavite and 
colleagues (Bellavite et al. 1994) in which platelet alkaline phosphatase is used as an 
indicator of the proportion of platelets adhering to an adhesive substrate coated onto 
the wells of a 96 well plate. Multiple wells of a sterile 96 well plate were coated 
with 50 μl of 50 µg/ml fibrinogen or collagen (in mTHB) or mTHB control and 
were incubated overnight at 4 °C. Platelets were isolated (Section 2.2.1.1.), counted 
on the day of experiment and made up to 1 x 108 cells/ml and left to rest until later 
use.  
Excess fibrinogen or collagen, incubated the night before, was removed by washing 
the wells twice with 200 μl mTHB and non specific adhesion was blocked with  50 
µl (0.5% w/v)  BSA for 1 hour at 37 °C. The wells were then washed twice with 200 
μl mTHB and 50 μl platelets with/out any additional drugs were added and allowed 
to bind for 1 hour at 37 °C. Non-adherent platelets were removed by washing each 
well twice with 200 μl mTHB. Wells containing adherent platelets were incubated 
with 150 µl per well of acid phosphatase substrate solution (0.1 M citrate buffer, pH 
5.4, containing 5 mM p-nitrophenol phosphate and 0.1% Triton X-100) and after 1 
hour of incubation at room temperature, the reaction was stopped and the colour 
developed by the addition of 100 µl  NaOH (2 M). The plate was immediately read 
on a Bio-Rad 18-630 microplate reader in the λ1-λ2 mode at wavelengths of 405-
600 nm. The percentage of adherent platelets was calculated from a standard curve 
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obtained with known numbers of platelets normalised as a percentage of control. All 
experiments were performed in triplicate. 
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2.2.4.3. Clot Retraction 
 
The measurement of clot retraction was adapted from Landesberg and colleagues 
2005, (Landesberg et al. 2005). Human blood was drawn into 3.8% (w/v) trisodium 
citrate and platelet rich plasma obtained by centrifugation at 100 g for 20 minutes. 
Platelet rich plasma was counted and adjusted to 250 x 103 cells/ml by the addition 
of platelet poor plasma (obtained by centrifugation of PRP at 1400 g for 10 minutes) 
and made up to 1 ml with/out the additional drugs into sterile test tubes. 5 μl of the 
donor’s erythrocytes were added to enable visualisation. Thrombin (2.5 U/ml) was 
then added and a sealed glass Pasteur pipette was fixed in place to promote the 
generation of fibrin. Tubes were left at room temperature for 2 hours. Photographs 
of the clots formed were taken and the clot weighed and measured. 
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2.2.4.4.  [Ca2+]i measurements using washed human platelets 
 
Measurements of Ca2+ were adapted from Rosado and colleagues 2000, (Rosado & 
Sage 2000). Platelets were isolated (Section 2.2.1.1.) and adjusted to 250 x 103 
cells/ml and loaded with Fura-2 by incubation with Fura-2-acetoxymethyl ester 
(Fura-2AM, 5 μM) after the first wash stage. Fura-2 was left to penetrate cells for 40 
minutes (in the dark) at 37 °C before continuing with the second wash. Pre-warmed 
platelets were stimulated with a chosen agonist (50 µl) in a Quartz SUPRASIL 
Macro/Semi-micro cell cuvette in a Perkin Elmer Luminescence Spectrometer 
LS50B with constant stirring at 1200 rpm at 37 °C. Excitation wavelengths were 
adjusted to 340 and 380 nm and emission at 509 nm. Changes in [Ca2+]i were 
measured using the Fura-2 340/380 fluorescence ratio (which is directly correlated 
to [Ca2+]i) as it automatically cancelled out confounding variables, such as variable 
dye concentration and cell thickness. Data was stored on time drive files using FL-
WinLab software (Perkin Elmer).   
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2.2.4.5. Dense granule secretion 
 
5-HT release from platelets was determined as a measure of dense granule secretion 
modified from Poole and colleagues (Poole et al. 1997). Human PRP was obtained 
as previously described in section 2.2.1.1. Platelets were then loaded with 1 µCi/ml 
[3H] 5-HT and left to rest for 1 hour at 37 °C. Platelets were then isolated from PRP 
as described previously (Section 2.2.1.1.) and adjusted to a density of 250 x 103 
cells/ml with the addition of 1 µM imipramine to inhibit any reuptake to 5-HT into 
storage granules. After platelets were rested for 30 minutes, platelet aggregometry 
was performed in either resting or stimulated platelets at 37 °C under stirring 
conditions as described in section 2.2.4.1. Stimulations were terminated after 90 
seconds with an equal volume of ice-cold 6% glutaraldhyde (v/v) and the samples 
immediately transferred to fresh microcentrifuge tubes on ice. Samples were 
centrifuged at 16, 000 g for 5 minutes to remove the platelets. Levels of [3H] 5-HT 
released into the supernatant was then measured by transferring 800 µl of the 
supernatant from each sample to scintillation vials containing 4 ml scintillation fluid 
and subjecting the samples to scintillation spectrometry using a WALLUC® 
scintillation analyser. [3H] 5-HT release was expressed as a percentage of total 
platelet content minus release in the presence of vehicle alone. 
CHAPTER TWO – Materials & Methods 
 
100 
 
2.2.5. In vivo measurements of thromboembolism 
 
2.2.5.1. 111Indium Oxine labelling of platelets 
 
Mouse platelets were collected as described previously (Section 2.2.1.2.). 
The surface of the platelet pellet was then washed carefully three times with 200 µl 
CMFB. Platelets were gently re-suspended in 1.5 ml of CMFB and incubated for 10 
minutes at room temperature wit 1.8 MBq 111Indium Oxine (111In). During this step, 
the radioactivity of the solution was measured by a γ-radiation spectrometer. A 
further centrifugation step (670 g for 7 minutes) was performed and the supernatant 
removed and the final radiolabelled platelet pellet re-suspended in CMFB (200 µl 
per mouse used). The radioactivity of platelets was again measured to calculate the 
percentage of labelling. 
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2.2.5.2. Radiolabelled platelet monitoring  
 
111In labelled platelets were injected intravenously through the femoral vein after 
minor surgery to expose the vein (Fig. 2.2B). Circulating platelets were monitored in 
the pulmonary circulation using a using a single point extended area ratio (SPEAR) 
detector (eV Products, Saxonburg, PA) probe located over the thorax (Fig. 2.2C). 
Counts were continuously recorded using a UCS-20 spectrometer connected to a 
laptop (Fig. 2.2D). Specialised software supplied by Mumed Systems (London, UK) 
was used to measure changes in counts over time. 
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(A)      (B) 
  
 
(C)      (D) 
  
 
Figure 2.2. Measurement of thromboembolic platelet responses in the mouse  
Figure A shows platelet collection via cardiac puncture from anaesthetised donor mice. 
(B) The femoral vein exposed prior to injection of 111Indium Oxine radiolabelled 
washed platelets. (C) Placement of probes over the thoracic region and abdomen and 
(D) Equipment used to monitor radiolabelled platelets.  
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2.2.5.3. Administration of compounds 
 
111In labelled platelets were allowed to equilibrate within the circulation for 30 
minutes prior to injection with experimental compounds or relevant control. Platelet 
aggregation was induced by intravenous injection (i.v) of collagen (50 µg/kg). The 
concentration of collagen was selected based on published data from our group 
(Tymvios et al. 2008). All compounds were administered intravenously in a 50µl 
volume, through the femoral vein and extra care was taken so as to ensure the vein 
did not collapse. A characterised “whitening” of the vein was apparent when the 
agent had been introduced successfully. The full time course of the platelet 
aggregation response was measured and recorded as changes in radioactive counts 
representing platelet aggregation and disaggregation in the pulmonary vasculature 
(Tymvios et al. 2008). 
Data was presented as percentage changes from stable baseline values recorded prior 
to administration of platelet agonists.  
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2.3. STATISTICS 
 
Data was analysed and all bar graphs were drawn using the GraphPad Prism 
software package (GraphPad, U.S.A). All results were given as the mean ± the 
standard error of mean (SEM). A one way ANOVA (Kruskal-Wallis) was used to 
determine significance followed by a multiple comparison test (Dunn’s correction) 
to identify significance between groups. 
Where indicated, paired t-Tests were performed on the results using Microsoft Excel 
after confirming normality. P values <0.05 were considered as significant. 
Details of statistical analysis for each data set are provided in the legends of 
accompanying figures. 
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3.1. INTRODUCTION 
 
PMCA’s extrude Ca2+ from a variety of cell types and have recently been shown to 
regulate signalling events and function in the cardiovascular system (Oceandy et al. 
2007; Oceandy, Cartwright et al. 2007; Choi & Eisner 1999). However, the 
functional and signalling roles of PMCA in platelets remain undefined. 
In this chapter, the effects of a pharmacological PMCA inhibitor, Carboxyeosin 
(CE) on platelet function were examined using various functional assays and its 
effects on Ca2+ homeostasis determined. The validity of CE as a selective inhibitor 
of PMCA was also investigated.  
CE has been used to inhibit PMCA in a variety of different cell types, including 
cardiomyocytes (Choi & Eisner 1999), embryonic stem cells (Yanagida et al. 2004) 
and in sperm (Schuh et al. 2004). It exerts its effects by crossing the plasma 
membrane where it is cleaved by intracellular esterases to yield eosin. Eosin further 
interacts with amine groups in proteins and inhibits PMCA independently of the 
ATPase site (Gatto & Milanick 1993; Gatto et al. 1995). 
The role of PMCA was investigated, not only through the use of CE, but also using 
PMCA4 knock-out mice to determine isomer specific roles. In addition, the 
signalling pathways mediating the effects of PMCA were investigated.  
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3.1.1. Aims of the study 
 
• To determine effective concentrations of CE that would impair Ca2+ 
extrusion through PMCA in platelets. 
• Validate CE as a selective pharmacological inhibitor of PMCA. 
• Ascertain the role of PMCA in regulating Ca2+ homeostasis in platelets. 
• Examine the consequences of PMCA inhibition by investigating the early 
and later stages of platelet activation using various functional assays. 
• Investigate the functional role of PMCA4 in platelets using PMCA4 knock-
out (-/-) mice. 
• Explore the molecular signalling mechanisms associated with PMCA in 
platelets. 
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3.2. RESULTS 
 
3.2.1. PMCA regulates Ca2+ in resting and stimulated platelets 
 
PMCA is thought to be the main route of Ca2+ extrusion within platelets (Rosado & 
Sage 2000), and changes in  intracellular calcium concentration [Ca2+]i are crucial 
for platelet activation. Furthermore, it has been previously shown in other cell types, 
for example within ventricular myocytes, that PMCA can be selectively inhibited 
using the pharmacological inhibitor Carboxyeosin (CE). However, no studies have 
used CE to inhibit PMCA in platelets. Preliminary studies were therefore required to 
determine effective concentrations of CE that could inhibit PMCA in platelets to 
allow future experiments to be conducted using a suitable concentration range.  
Following this, CE was used to identify whether PMCA could regulate Ca2+ 
homeostasis by observing Ca2+ measurements in either resting platelets or upon 
stimulation. 
Washed human platelets were loaded firstly with the Ca2+ sensitive loading dye 
Fura-2 for 40 minutes in the dark (Section 2.2.4.4.) and later with concentrations of 
CE (10-40 μM) or DMSO control (0.4%) for 30 minutes prior to stimulation. Ca2+ 
responses were recorded in the presence of EGTA (100 µM) and platelet were 
stimulated using thapsigargin (1 µM) plus ionomycin (50 nM).   
Stimulation of platelets with thapsigargin (1 µM) plus ionomycin (50 nM) induced a 
rapid and transient increase in fluorescence indicating Ca2+ release from intracellular 
stores and an increase in [Ca2+]i.  
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Once Ca2+ had been released from intracellular stores, extrusion of Ca2+ from the 
cytosol, which has been shown to be mediated through PMCA under these 
conditions (Rosado & Sage 2000),  was seen as a decay of the Ca2+ transient towards 
a stable baseline (Fig. 3.1A control blue line). 
The addition of CE to platelets resulted in Ca2+ extrusion being inhibited 
concentration dependently compared to the DMSO control, and this was observed as 
a slower return to baseline following stimulation (Fig. 3.1A). The mean percentage 
increase in [Ca2+]i remaining 3 minutes after stimulation was calculated for each 
concentration of CE and was increased concentration dependently compared to the 
DMSO control (normalised to 100%) (Fig. 3.1B): (10 µM) 124±2.3%, (20 µM) 
128±2.7%, (30 µM) 145±4.9% (p<0.01) and (40 µM) 144±4.2% (p<0.01). 
There was no evidence of an effect of CE on Ca2+ store loading since Ca2+ release 
(measured as peak minus basal) was unaffected by this treatment (Fig. 3.1C) 
Calculation were normalised to the DMSO control (100%): (10µM) 94±0.4%, 
(20µM) 97±0.2%, (30µM) 100±0.05% and (40µM) 95±0.3%.  
CE also concentration dependently increased [Ca2+]i in resting platelets compared to 
the DMSO control (normalised to 100%): (10 µM) 106±0.7%, (20 µM) 118±1.8%, 
(30 µM) 130±3.2% (p<0.05) and (40 µM) 141±4.3% (p<0.01) (Fig.3.1D), indicating 
a role for PMCA in maintaining basal [Ca2+]i.  
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Figure 3.1. The effects of carboxyeosin on thapsigargin plus ionomycin induced         
       Ca2+ release 
Washed human platelets were loaded with Fura-2 and incubated with CE (10-40 µM). 
Fura-2 ratio emission at 340/380 nm was measured in response to thapsigargin (1 µM) 
and ionomycin (50 nM) in the presence of EGTA (100 µM). Graph (A) shows a typical 
time course of response expressed as a Fura-2 340/380 nm emission ratio against time. 
Figure (B) shows the % of [Ca2+]i remaining at 3 minutes post stimulation. Figure (C) 
shows the % peak [Ca2+]i minus the basal [Ca2+]i post stimulation and figure (D) shows 
the % of [Ca2+]i in resting platelets pre-stimulation. Data represents mean percentage 
±S.E.M relative to DMSO (0.4%). Where statistical comparisons were made a one-way 
ANOVA followed by a multiple comparison test was used to compare mean values, 
*P<0.05, **P<0.01, n=9. 
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3.2.2. Validation of carboxyeosin as a PMCA inhibitor 
 
Although there appeared to be a significant change in the extrusion of platelet Ca2+ 
in the presence of CE, the specificity of CE needed to be verified. As described 
previously, CE is taken up into cells where it is cleaved to form eosin, which is 
fluorescently active. Therefore, since measurements to determine Ca2+ flux in 
platelets within previous experiments were conducted in the presence of Fura-2 (see 
Fig. 3.1.) which possesses a  fluorescence emission ratio close to eosin (eosin: 
538nm, Fura-2: 510 nm), experiments were conducted to see if eosin alone could 
concentration dependently increase Fura-2 emission independently of Ca2+. This 
would eliminate any confounding fluorescence issues that may have affected 
previous results observed with CE in the presence of Fura-2 in prepared platelet 
suspensions. A series of experiments was therefore conducted in distilled water 
(dH20), using a broad range of eosin concentrations and measured using a LS50B 
fluorescence spectrometer in the presence of Fura-2 (0.05 µM) and CaCl2 (0.01 
µM). Eosin (0.1-50 µM) caused an apparent suppression of 340/380 nm emission 
that was neither significant nor concentration dependent compared to the control 
(+0.01 µM CaCl2 0.9±2.7): (0.1 µM) 0.4±3.0, (0.5 µM) 0.6±1.9, (1 µM) 0.5±2.3, (5 
µM) 0.6±1.8, (10 µM) 0.4±2.8, (20 µM) 0.5±2.2, (30 µM) 0.4±3.2, (40 µM) 0.5± 
2.5 and (50 µM) 0.5±2.3 (Fig. 3.2A). In previous Ca2+ experiments (Fig. 3.1.), 
excess CE was not removed from platelets prior to analysis, so additional 
experiments showed that CE alone in dH20  (0.1 –50μM) did not affect Fura-2 
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340/380 nm emission in the presence of CaCl2 (+0.01 µM CaCl2 0.94±1.7): (0.1 
µM) 0.99±0.5, (0.5 µM) 1.0±0.8, (1 µM) 1.1±0.8, (5 µM) 1.1±1.7, (10 µM) 1.0±0.7, 
(20 µM) 1.0±1.0, (30 µM) 1.2±1.8, (40 µM) 0.9± 0.06 and (50 µM) 1.0±0.5 (Fig. 
3.2B) In addition, DMSO did not cause any interference with fluorescence when 
placed in dH20 (DMSO: 0.5% (0.002±0.01)). These experiments demonstrated that 
although the observed increases in Fura-2 emission in resting platelets containing 
eosin may have been suppressed (i.e. underestimated) and quantitative studies could 
not be performed, the finding of a concentration dependent increase in Fura-2 
emission with CE validates that PMCA regulates basal [Ca2+]i.
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Figure 3.2. The effects of eosin and carboxyeosin on Fura-2 emission spectra 
Measurements of Fura-2 340/380nm emission ratio in suspensions of dH20 containing 
Fura-2 (0.05 µM) and CaCl2 (0.01 µM) in the presence of either (A) eosin (0.1 – 50 
µM) or (B) carboxyeosin (0.1 – 50 µM) were recorded using a LS50B fluorescence 
spectrometer. Mean stable 340/380 ratio was measured over a 3 minute period. Blank 
readings were taken in dH2O (dH20(C)) and with DMSO (0.5 %) ((C)+DMSO). Data 
represents mean percentage ±S.E.M relative to control. Where statistical comparisons 
were made a one-way ANOVA followed by a multiple comparison test was used to 
compare mean values. No significant changes were observed, n=5. 
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3.2.3. Selectivity of carboxyeosin in platelets 
 
To further investigate the selectivity of CE for PMCA, platelets were incubated with 
the non-selective cationic channel antagonist Lanthanum Chloride (LaCl3). LaCl3 
has been used in several studies to interfere with Ca2+ channels in human and animal 
cells such as platelets and smooth muscle cells (Ng et al. 2009; London et al. 2006; 
Yu Shi et al. 2009). Washed human platelets were loaded with Fura-2 (5 µM) and 
later with either CE (40 μM), LaCl3 (1 mM), both compounds, and the relevant 
DMSO control (0.4%) for 30 minutes. Ca2+ responses were recorded in the presence 
of EGTA (100µM) and platelets stimulated with thapsigargin (1 µM) plus 
ionomycin (50 nM). Stimulation induced a rapid and transient increase in 
fluorescence indicating Ca2+ release from intracellular stores and an increase in 
[Ca2+]i (Fig. 3.3A). Extrusion of Ca2+ from the cytosol was seen as a decay of the 
Ca2+ transient towards a stable baseline (Fig. 3.3A DMSO control green line). The 
addition of CE (40 µM), LaCl3 (1 mM) or both resulted in the inhibition of Ca2+ 
extrusion observed as a sustained elevation of Ca2+ at three minutes compared to the 
DMSO control: (normalised to 100%) CE (40 µM) 180±3.3% (p<0.001), LaCl3 (1 
mM) 181±3.1% (p<0.001) and CE (40 µM)+LaCl3 (1 mM) 193±3.6% (p<0.001) 
(Fig. 3.3B). Similar increases were observed in basal [Ca2+]i with CE (40 µM) and 
LaCl3 (1 mM) compared to the DMSO control (100%): CE (40 µM) 155±5.9% 
(p<0.001), LaCl3 (1 mM) 152±5.5% (p<0.001) (Fig. 3.3C) confirming a comparable 
increase in [Ca2+]i following inhibition of Ca2+ extrusion through two entirely 
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independent mechanisms and in the absence of potentially confounding fluorescence 
issues. This data also shows that the effect of CE on Ca2+ homeostasis did not occur 
in platelets pre-treated with LaCl3, indicating that the effect of CE on Ca2+  
homoeostasis was exerted at the plasma membrane rather than at a location 
independent of PMCA.  
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Figure 3.3. The effects of Ca2+ extrusion blockade on platelet Ca2+ homeostasis  
Washed human platelets were loaded with Fura-2 and incubated with CE (40 µM), 
LaCl3 (1 mM) or both compounds. Fura-2 ratio emission was measured at 340/380 nm 
in response to thapsigargin (1 µM) and ionomycin (50 nM) in the presence of EGTA 
(100 µM). Graph (A) shows a typical time course of response expressed as 340/380 nm 
emission ratio against time. Figure (B) shows the % of [Ca2+]i remaining at 3 minutes 
post stimulation. Figure (C) shows the % of [Ca2+]i in resting platelets pre-stimulation.  
Data represents mean percentage ±S.E.M relative to DMSO (0.4%). Where statistical 
comparisons were made a one-way ANOVA followed by a multiple comparison test 
was used to compare mean values, * P<0.05 ***P<0.001, n=4 
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3.2.4. PMCA regulates platelet aggregation in isolated human platelets 
 
To investigate whether CE elicits a functional effect on washed platelets, cells were 
pre-incubated with concentrations of CE previously shown to selectively inhibit Ca2+ 
extrusion through PMCA and aggregation measured upon stimulation by two potent 
agonists, collagen or thrombin. 
Washed human platelets were incubated with CE (10-50 μM) or control DMSO 
(0.5%) and stimulated with either collagen (5 μg/ml) or thrombin (0.1 U/ml) which 
induced platelet aggregation shown as a fall in optical density (Fig. 3.4A and B). 
Maximal aggregation was achieved at around 3 minutes.  In the presence of CE (10-
50µM) platelets exhibited a concentration dependent inhibition of aggregation 
following stimulation (Fig. 3.4C and D). The mean percentage decrease in platelet 
aggregation was calculated for each concentration of CE stimulated with collagen (5 
µg/ml) which was significant between 30-50 µM: (10 µM) 80±1.5%, (20 µM) 
56±3.2%, (30 µM) 40±4.4% (p<0.05), (40 µM) 32±5.1% (p<0.01), and (50 µM) 
22±5.8% (p<0.01) compared to the DMSO control (normalised to 100%)  and 
thrombin (0.1U/ml) which was significant at 40 and 50µM: (10 µM) 94±0.4%, (20 
µM) 70±2.3%, (30 µM) 59±3.1%, (40 µM) 37±4.8% (p<0.01) and  (50 µM) 
31±5.3% (p<0.001) compared to the DMSO control (normalised to 100%). The 
effect of CE on isolated human platelets demonstrates the functional consequences 
of CE mediated inhibition of Ca2+ extrusion via PMCA. 
CHAPTER THREE – PMCA 
(A)      (B) 
          
 
(C)      (D) 
Collagen (5 μg/ml)
DMSO 10 20 30 40 50
0
25
50
75
100
**
**
*
Carboxyeosin (μM)
%
 A
gg
re
ga
tio
n 
(3
 m
in
ut
es
)
 
Thrombin (0.1 U/ml)
DMSO 10 20 30 40 50
0
25
50
75
100
***
**
Carboxyeosin (μM)
%
 A
gg
re
ga
tio
n 
(3
 m
in
ut
es
)
 
 
 
Figure 3.4. The effects of carboxyeosin on collagen and thrombin mediated platelet 
         aggregation 
Washed human platelets were pre-incubated with CE (10-50 μM) or DMSO (0.5%) 
prior to stimulation. Optical aggregometry was used to measure aggregation in response 
to thrombin (0.1 U/ml) or collagen (5 µg/ml) for 180 seconds with constant stirring 
(~1200 rpm). Figure (A) and (B) show typical aggregation traces representing inhibition 
in the presence of CE, (C) and (D) represent mean percentage aggregation ±S.E.M 
relative to DMSO. Where statistical comparisons were made a one-way ANOVA 
followed by a multiple comparison test was used to compare mean values *P<0.05, 
**P<0.01, ***P<0.001, n=4.  
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3.2.5. Validation of carboxyeosin as a selective PMCA inhibitor 
 
Previous reports have suggested that CE has an inhibitory effect at targets other than 
PMCA, notably the Na+/K+-ATPase (Ogan et al. 2007) and also inhibits transients 
during Ca2+ repletion (Zimlichman et al. 1987). Therefore, to investigate whether the 
inhibition of the Na+/K+ ATPase functionally affects platelets, a known inhibitor of 
this pump (ouabain) was investigated and the effects upon platelet aggregation 
measured. Washed platelets were pre-incubated with concentrations of ouabain 
previously shown to inhibit Na+/K+-ATPases (1-10 μM) (Ogan et al. 2007) and 
excess concentrations (200 μM). Platelets were then stimulated with either collagen 
(5 μg/ml) or thrombin (0.1 U/ml) and aggregation recorded. In the presence of 
ouabain (0.01-200 µM) the mean percentage of platelet aggregation displayed a non 
significant effect on both collagen and thrombin mediated aggregation (Fig. 3.5A 
and B). Therefore, although CE may exert effects via Na+/K+ ATPases, such actions 
are unlikely to explain the effects of CE on platelet function reported here, since 
inhibition of the Na+/K+ ATPase has no effect on collagen or thrombin induced 
platelet aggregation.  
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Figure 3.5. The Na+/K+ ATPase does not modulate platelet aggregation 
Washed human platelets were pre-incubated with ouabain (0.01 – 200 µM) or vehicle 
control (dH2O) prior to stimulation. Optical aggregometry was used to measure 
aggregation in response to (A) thrombin (0.1 U/ml) or (B) collagen 5 µg/ml.  Data 
represents mean percentage aggregation ±S.E.M relative to control responses. Where 
statistical comparisons were made a one-way ANOVA followed by a multiple 
comparison test was used to compare mean values. No significant changes were 
observed. P>0.05, n=4. 
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3.2.6. The effects of carboxyeosin on platelet adhesion 
 
To investigate another functional consequence of PMCA inhibition in platelets, 
platelet adhesion onto collagen (50µg/ml) and fibrinogen (50µg/ml) coated surfaces 
was measured spectrophotometrically using the colorimetric platelet phosphatase 
assay as described by Bellavite and colleagues (Bellavite et al. 1994) (Section 
2.2.4.2.) following pre-incubation of platelets with either CE (10-40 µM) or DMSO 
control (0.4%). Platelet adhesion onto fibrinogen coated surfaces was enhanced in a 
concentration-dependant manner in the presence of CE and was significant at 
concentrations of 30 and 40 µM compared to the DMSO control (normalised to 
100%): (30 µM) 148±4.4% (p<0.05) and (40 µM) 153±1.4% (p<0.05) (Fig. 3.6A). 
However, platelet adhesion to collagen showed a slight reduction (Fig. 3.6B) that 
was neither concentration dependent nor significant at any concentration tested. 
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Figure 3.6. Platelet adhesion to fibrinogen and collagen coated surfaces   
Platelet adhesion to collagen (50 µg/ml) and fibrinogen (50 µg/ml) coated surfaces was 
measured using an acid phosphatase static adhesion assay and absorbance’s for each 
well read at 405 nm. Absorbance values for CE treated cells (10-40 µM) or DMSO 
(0.4%) were normalised to percentage values obtained for non treated cells. Figure (A) 
Shows the normalised % adhesion of platelets onto fibrinogen coated plates. (B) Shows 
the normalised % adhesion onto collagen coated plates. Data represents mean ±S.E.M in 
relative units to control responses. Where statistical comparisons were made a one-way 
ANOVA followed by a multiple comparison test was used to compare mean values, 
**P<0.05, n=4. 
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3.2.7. The effects of carboxyeosin on clot retraction 
 
To investigate whether the inhibition of PMCA elicits an effect on the later stages of 
platelet activation, platelet clot retraction was measured. Human PRP was pre-
incubated with CE (10-40 µM) or DMSO control (0.4%) and clot retraction 
measured as described in section 2.2.4.3. Figure 3.7A displays a representative set of 
clots which have retracted over 2 hours and shows more retracted clots in the 
presence of CE (20 and 40 µM) compared to a DMSO control. The % clots weight 
was calculated based on the weight of serum subtracted from the serum weight of a 
non-stimulated sample. Data was expressed as the % clot weight of each sample as 
shown in Fig. 3.7B. Clots formed in the presence of CE (10-40 µM) expressed an 
enhancement i.e. a smaller clot weight compared to the control (normalised to 
100%) which was significant at 30 µM (71±3.1% (p<0.05)) and 40 µM (60±4.4% 
(p<0.01)) (Fig.3.7B). 
In contrast to platelet aggregation, which is suppressed following PMCA inhibition, 
clot retraction was enhanced suggesting that PMCA positively regulates platelet 
aggregation but negatively regulates clot retraction and platelet adhesion. 
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Figure 3.7. Inhibiting PMCA accelerates clot retraction  
The effect of PMCA inhibition by CE on clot retraction was measured. Human PRP was 
incubated with CE (10-40 µM) or DMSO control (0.4%). Figure (A) shows the clots 
formed and retracted in the presence of DMSO or CE (20 and 40 µM) at 2 hours. (B) 
shows mean data for the clot weights (normalised to control 100%) ±S.E.M weight in 
the presence of CE (10-40 µM) or DMSO control (0.4%). Where statistical comparisons 
were made a one-way ANOVA followed by a multiple comparison test was used to 
compare mean values, *P<0.05, **P<0.01, n=5. 
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3.2.8. Carboxyeosin inhibits aggregation of wild-type mouse platelets 
 
The functional observations in human platelets characterised the effects of PMCA in 
vitro. Before PMCA4 knock-out (-/-) mouse studies could be performed, we wanted 
to establish whether effects recorded in human platelets could be reproduced in 
wild-type (+/+) mice.  
Washed mouse platelets (Section 2.2.1.2) were incubated with CE (10-40 μM) or 
control DMSO (0.4%) and stimulated with either collagen (5 μg/ml) or thrombin 
(0.1 U/ml) which induced platelet aggregation shown as a fall in optical density (Fig. 
3.8A and B). Maximal aggregation was achieved at around three minutes.  In the 
presence of CE (10-40 µM), platelets exhibited a concentration dependent inhibition 
of aggregation upon stimulation. The mean percentage decrease in platelet 
aggregation was calculated for each concentration of CE stimulated firstly with 
thrombin (0.1 U/ml) (Fig. 3.8C) that was significant between 20 and 40 µM 
compared to the DMSO control (normalised to 100%): (10 µM) 39±1.3%, (20 µM) 
24±1.8% (p<0.05), (30 µM) 14±1.8% (p<0.01) and (40 µM) 7±1.6% (p<0.001) and 
collagen (5 µg/ml) which was significant at 40 µM only 38±3.8% (p<0.05) 
compared to the DMSO control (Fig. 3.8D). The effect CE has on mouse platelets is 
similar to that observed in human platelets, enabling progression to functional 
studies in PMCA4-/- mice. 
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Figure 3.8. The effect of carboxyeosin on collagen and thrombin mediated mouse 
         platelet aggregation  
Washed mouse platelets were pre-incubated with CE (10-40 μM) or DMSO (0.4%) 
prior to stimulation.  Optical aggregometry was used to measure aggregation in 
response to thrombin (0.1 U/ml) or collagen (5 µg/ml) for 180 seconds with constant 
siring (~1200rpm). Figure (A) and (B) show typical aggregation traces representing 
inhibition, (C) and (D) represent the mean percentage aggregation ±S.E.M relative to 
DMSO. Where statistical comparisons were made a one-way ANOVA followed by a 
multiple comparison test was used to compare mean values, *P<0.05, **P<0.01, 
***P<0.001, n=4. 
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3.2.9. Identification of PMCA in Mice 
 
Before identifying isomer specific roles of PMCA in mouse platelets, the expression 
of PMCA (isoform 4) platelets from (+/+) mice was investigated. Tissue samples 
were collected and snap-frozen into liquid nitrogen to prevent protein degradation. 
The aorta, kidney, heart, lung and platelets were homogenised/lysed (Section 
2.2.3.2.) and protein quantified (Section 2.2.3.1.). PMCA4 expression was finally 
identified using western blot methods (Section 2.2.3.2). Although PMCA4 is 
ubiquitously expressed in all major cell types (Carafoli 1991), experiments showed 
little expression in most tissue samples according to the kD band location (Fig. 3.9). 
A protein band was however identified for PMCA4 in the platelet samples. This was 
located at 145kD (indicated by the arrow). 
 
Figure 3.9. PMCA4 expression in the wild-type mouse tissue samples 
Protein lysates were separated and blotted using a PMCA 4 antibody (SWANT, 
Bellinzona, Switzerland) (1:1000), Immuno-blots were developed using an ECL 
detection system. (PMCA4 is ≈145 kD, as indicated by the arrow).  
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3.2.9.1. Ablation of mouse platelet PMCA4 inhibits agonist mediated 
  aggregation and adhesion 
 
It has been well documented that there are two PMCA isoforms present on the 
surface of human platelets PMCA1 and 4 (Martin et al. 2000). The availability of 
PMCA4 (-/-) mice allowed the determination of isoform specific roles of PMCA4 in 
regulating platelet function. Tail tips from heterozygous (+/-), (+/+) and (-/-) mice 
were digested and DNA amplified using PCR to identify zygosity (Section 2.2.2.1.). 
Bands corresponding to the PMCA insert showed at 344bp and neomycin at 245bp. 
Mice expressing heterozygous zygosity had bands appearing at 344bp, wild-type at 
both 344 and 245bp and knock-out expressing only 245bp (Fig. 3.9.1A). Once mice 
were genotyped, washed mouse platelets from (-/-) and (+/+) mice were stimulated 
with collagen (0.2 μg/ml) and aggregation recorded using optical aggregometry over 
a three minute period to establish maximal aggregation. Figure 3.9.1B shows a 
representative trace of platelets from (+/+) and (-/-) mouse aggregations and mean 
data calculated over four separate experiments is shown in Figure 3.9.1C. (-/-) 
mouse platelets exhibited a significant decrease in platelet response when stimulated 
with collagen (0.2 µg/ml) compared to the (+/+) control (normalised to 100%): (+/+) 
100±1.5%, (-/-) 82±7.2% (p<0.05). In addition, platelet adhesion to collagen (50 
µg/ml) was performed in platelets from (+/+) and (-/-) mice as previously described 
(Section 2.2.4.2.). Absorbance values for (+/+) mouse platelets were normalised to 
100% and absorbance values for (-/-) platelets defined as a percentage of this. 
Platelet adhesion of (-/-) mice exhibited a small but significant decrease in adhesion 
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compared to (+/+) controls: (-/-) 72±2.6% (p<0.05) (Fig. 3.9.1D) indicating reduced 
adhesive response to collagen when PMCA4 is ablated. 
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Figure 3.9.1. PMCA4 expression and inhibition of platelet function 
(A) PCR blot from tail tips genotyped from (+/-), (+/+) and PMCA4 (-/-) mice. (B) 
Shows a typical aggregation trace from platelets isolated from PMCA4 (-/-) mice and 
(+/+) controls stimulated with 0.2μg/ml collagen. (C) Graph represents mean percentage 
aggregation ±S.E.M relative to (+/+) control. Figure (D) Represents the mean 
percentage ±S.E.M adhesion to collagen (50 µg/ml) compared to (+/+) control. 
Aggregations n=4. Adhesion n=8.  Where statistical comparisons were made a T-test 
was performed,* P<0.05. 
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3.2.9.2. PMCA inhibition does not desensitise platelets 
 
Raised basal Ca2+ levels and impaired Ca2+ extrusion accompanied a decrease in 
platelet aggregation observed with CE (Fig.3.1 and 3.4). Therefore, to assess the 
mechanisms underlying these effects and to determine if these effects were as a 
result of platelet pre-activation, platelet dense granule secretion and light 
transmission were measured in resting platelet suspensions incubated with CE (10-
40 µM). In addition, and for comparison, granule secretion and light transmission 
were also determined in resting platelets incubated with the SERCA inhibitor 
thapsigargin (0.025-5 µM) which also leads to increased [Ca2+]i.  
Human platelets were loaded with [3H] 5-HT and dense granule secretion measured 
(Section 2.2.4.5.). Loaded platelets were pre-incubated with concentrations of 
thapsigargin (0.05-5 µM), CE (10-40 µM) or control DMSO (0.05 or 0.4%). 
Platelets pre-treated with thapsigargin (0.05-5 µM) displayed an increase in granule 
secretion that was significant at 5 µM: 32±4.5% (p<0.01) compared to the DMSO 
control (DMSO 3±1.3%) (Fig. 3.9.2A). However, platelets pre-treated with CE (10-
40µM) showed no increase in dense granule secretion at any concentration 
compared to the DMSO control (2.9±1.1%) (Fig. 3.9.2B). 
To further investigate platelet pre-activation, light transmission was measured in 
platelet suspensions in the absence of platelet agonists. Washed human platelets 
were incubated with either thapsigargin (0.025-1 µM), CE (10-40 µM), or DMSO 
(0.0025 or 0.4%) and light transmission measured by optical aggregometry. 
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Maximal aggregation was calculated as the largest fall in optical density from a 
baseline. A fall in optical density indicated pre-activation of platelets. Platelets were 
then stimulated with thrombin (0.1 U/ml) to assess desensitisation. 
Thapsigargin pre-treatment of platelets caused a concentration dependent increase in 
light transmission that was significant between 0.25-1µM: (0.25 µM) 20±4.2% 
(p<0.5), (0.5 µM) 41±2.1% (p<0.01) and (1 µM) 43±2.9% (p<0.01) compared to the 
DMSO control (normalised to 100%) (Fig. 3.9.2C). In contrast platelets pre-treated 
with CE (10-30 µM) exhibited no increase in light transmission with the exception 
of 40µM where there was a small but significant increase compared to the DMSO 
control (normalised to %) (40 µM) 7.9±1.5% (p<0.05) Fig. 3.9.2D. These results 
suggest that like dense granule secretion, there appeared to be no indication of pre-
activation of platelets pre-incubated with CE. When platelets were subsequently 
stimulated with thrombin, there was a concentration dependent reduction in 
aggregation in the presence of CE that was significant at 30 and 40 µM compared to 
the DMSO control (30 µM) 75± 0.02 (p<0.05), (40 µM) 58± 1.2 (p<0.01). 
Thapsigargin pre-treatment however, had no effect on subsequent thrombin induced 
aggregation. 
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Figure 3.9.2. Increased [Ca2+]i following PMCA inhibition does not desensitise 
  platelets 
Washed platelets were pre-incubated with either (A) thapsigargin (0.05-5µM) or (B) CE 
(10-40µM) or DMSO control (0.4%) and [3H] 5-HT release measured from un-
stimulated platelets. Light transmission of un-stimulated platelet suspensions in the 
presence of (C) thapsigargin (0.025-1µM) or (D) CE (10-40µM) or DMSO (0.4%) was 
measured using optical aggregometry and compared to stimulated (thrombin 0.1 U/ml) 
preparations. Data represents mean percentage ±S.E.M in relative units or percentage 
aggregation. Where statistical comparisons were made a one-way ANOVA followed by 
a multiple comparison test was used to compare mean values, *P<0.05, **P<0.01, n=4. 
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3.2.9.3. Carboxyeosin enhances VASP phosphorylation independently of 
  cGMP 
 
To address other possible mechanisms behind the inhibitory effects observed upon 
platelet aggregation with CE (Fig. 3.4), possible inhibitory pathways associated with 
PMCA were investigated. It has been documented that PMCA can regulate 
inhibitory signalling within cardiomyocytes (Oceandy, Cartwright et al. 2007) and 
vascular smooth muscle where PMCA associates with nNOS (Schuh et al. 2003).  
Therefore, it was hypothesised that CE could exert these inhibitory effects in 
platelets by raising Ca2+ locally to allow PMCA to activate inhibitory signalling 
molecules such as VASP. Aggregations were performed with washed platelets pre-
incubated with CE (10-40 µM) and stimulated with collagen (5 µg/ml), platelets 
were lysed and western blotting performed (Section 2.2.3.2.) to identify Ser239-
VASP phosphorylation and demonstrated a concentration dependent increase in 
Ser239-VASP phosphorylation in platelets incubated with CE that was significant at 
30 and 40µM compared to the DMSO control: (DMSO) 0.17±0.2, (30 µM) 0.75±1.2 
(p<0.001) and (40 µM) 0.89±1.4 (p<0.001) (Fig. 3.9.3A). Data was normalised to 
total VASP levels and arbitrary units were analysed using the ImageJ densitometry 
software (NIH, USA) (Fig. 3.9.3B) indicating that PMCA may act to prevent VASP 
phosphorylation. 
To further investigate these findings, platelet aggregation in the presence of the 
guanylate cyclise (SGC) inhibitor (ODQ) was investigated to determine the role of 
SGC in mediating the inhibitory effects of CE.  Washed platelets were pre-incubated 
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with NO donor sodium nitroprusside (SNP) (1 µM), and stimulated with collagen (5 
µg/ml) which almost completely inhibited platelet aggregation compared to control 
(normalised to 100%): (1 µM) 3±0.9% (p<0.001) (Fig. 3.9.3C). This inhibition was 
significantly reversed by ODQ (10 µM): 97.99±1.4% (p<0.001) indicating effective 
inhibition by ODQ. CE (40 µM) induced inhibition of aggregation that was 
significant compared to the control: (40 µM) 76±1.2% (p<0.01). However, the 
inhibitory effect of CE was not impaired by ODQ (10 µM) 1±0.9% (p>0.05) 
suggesting that the inhibition caused by CE, although mediated through VASP, was 
independent of cGMP. 
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Figure 3.9.3. PMCA enhances VASP phosphorylation independently of cGMP 
Platelet lysates from collagen (5 µg/ml) stimulated platelets pre-incubated with CE (10-
40 µM) were immunoblotted for phospho-VASP (Ser239) or total VASP (A) and 
phospho-VASP levels normalised and densitometry performed to calculate arbitrary 
units (B). Optical aggregometry was used to measure aggregation in response to 
collagen (5 µg/ml). Figure (C) shows the mean percentage aggregation of platelets pre-
incubated with carboxyeosin (CE, 20 µM) or (SNP, 1 µM) in the presence and absence 
of ODQ (10 µM) relative to a collagen control. Where statistical comparisons were 
made a one-way ANOVA followed by a multiple comparison test was used to compare 
mean values, **P<0.01 ***P<0.001, n=4. 
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3.2.9.4. The effects of carboxyeosin on platelet aggregation in vivo 
 
CE has been shown to inhibit platelet aggregation in vivo when applied to platelets 
prior to mouse infusion via the femoral vein (S. Jones, personal communication). 
Therefore, to determine whether systemic infusion of CE causes an anti-platelet 
effect in vivo, CE (30 µM) or control DMSO (0.3%) was infused systemically into 
anaesthetised mice prior to induction of in vivo platelet aggregation with collagen 
(50 µg/kg). Washed platelets were isolated via cardiac puncture from anaesthetised 
C57/SV-129 donor mice and radio-labelled as described in sections 2.2.1.2. and 
2.2.5.1. 
An initial dose of collagen (50 µg/kg) was administered via the femoral vein to 
ensure platelet responsiveness. An increase in counts was observed after 
administration followed by a return to baseline indicating platelet aggregation and 
dissolution (Fig. 3.9.4A blue line and B orange line). CE (30 µM) or DMSO (0.3%) 
was then administered and left to equilibrate for a further 10 minutes (Fig. 3.9.4A 
black line and B green line). Finally, collagen (5 µg/kg) was administered to 
determine whether the prior-administration of either CE (30 µM) or DMSO (0.3%) 
had an effect on platelet aggregation (Fig. 3.9.4A pink line and B grey line).  
Mean data from four separate experiments indicate that DMSO (0.3%) had a non 
significant effect on basal counts compared to CE alone: (CE) 1.45±0.2%, (DMSO) 
0.35±0.01% (p>0.05) (Fig. 3.9.4C) Platelet aggregation measured in the presence of 
CE (30 µM) exhibited a slight decrease (% maximum response) however, this was 
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not significant compared to the collagen control: (collagen) 18±3.4%, (CE+collagen) 
16±3.1% (p>0.05) (Fig. 3.9C). There appeared to be a slight delay in platelet counts 
returning to base-line in the presence of CE (Fig. 3.9.4B grey line), however mean 
data representing AUC demonstrated that this was also not significant compared to 
collagen: (collagen) 39±4.2, (CE+collagen) 52±5.6 (p>0.05) (Fig. 3.9.4D). Whilst 
these experiments were conducted to determine whether CE (30 µM) had any anti-
thrombotic effect when infused systemically into an in vivo model of platelet 
aggregation, results indicate that the presence of CE (30 µM) had no effect on the 
platelet aggregate formation but may indicate a trend towards a delay in aggregate 
dissolution. 
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Figure 3.9.4. Measurement of in vivo platelet aggregation responses in the mouse  
Washed mouse platelets were isolated form donor mice and radiolabelled with 
111Indium Oxine. Recipient mice were injected with either collagen (5 µg/kg), DMSO 
(0.3%) or CE (30 µM) and platelet counts recorded. Traces (A) and (B) represent the 
mean percentage change in radioactive counts against time. Graphs (C) represents the 
mean ±SEM maximal percentage increase in radioactive counts and (D) mean ± SEM 
area under curve (AUC) in counts. Where statistical comparisons were made a one-way 
ANOVA followed by a multiple comparison test was used to compare mean values. No 
significant observations were found, (P>0.05), n=4. 
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3.2.9.5. Carboxyeosin selectively inhibits PMCA4 in mice 
 
To determine the selectivity of CE on PMCA4, aggregations were performed in 
platelets isolated from PMCA4 (+/+) mice and PMCA4 (-/-) mice in the presence of 
CE. Washed mouse platelets were incubated with CE (40 μM) and stimulated with 
either collagen (5 μg/ml) or thrombin (0.1 U/ml) (Fig. 3.9.5.A and B) which induced 
maximal aggregation at around three minutes.  Platelets isolated from (-/-) mice 
aggregated normally upon stimulation despite the presence of CE in comparison to 
platelets from (+/+) mice, where the response was inhibited, demonstrating that CE 
selectively exerts its effects via PMCA4.  
 
(A)      (B) 
 
Figure 3.9.5. Carboxyeosin exerts its effects selectively at PMCA4  
Washed mouse platelets from PMCA4 +/+ and -/- mice were pre-incubated with CE (40 
μM) prior to stimulation.  Optical aggregometry was used to measure aggregation in 
response to thrombin (0.1U/ml) or collagen (5µg/ml) for 180 seconds with constant 
stirring (~1200rpm). Figure (A) and (B) show typical aggregation traces representing 
inhibition of aggregation in wild-type but not PMCA4-/- platelets. n=2.  
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3. 3. Discussion  
 
The aims of the research carried out in this chapter were to determine whether 
PMCA plays a role in regulating Ca2+ homeostasis and function in human and in 
mouse platelets. Further work was conducted using PMCA4 (-/-) mice to examine 
the specific roles of PMCA4 and the possible molecular signalling pathways 
associated with PMCA were also considered. The aims were addressed using a 
pharmacological inhibitor of PMCA, CE, to inhibit the activity of PMCA at the 
platelet membrane, using a variety of functional, molecular and in vivo techniques. 
 
Ca2+ regulation 
To identify whether PMCA could influence Ca2+ homeostasis, Ca2+ measurements 
were investigated in resting platelets and upon stimulation. Our initial hypothesis 
was that any inhibition of PMCA would impair Ca2+ extrusion and elevate [Ca2+]i 
levels, leading to platelet activation by sub-threshold concentrations of platelet 
agonists.  
Preliminary experiments demonstrated an elevation of basal Ca2+ levels in the 
presence of increasing concentrations of CE. Following this elevation, subsequent 
stimulation with thapsigargin produced a rise in [Ca2+]i (also demonstrated by 
Rosado and colleagues (Rosado & Sage 2000)) followed by a concentration 
dependent inhibition of Ca2+ extrusion in the presence of CE. The extrusion of Ca2+ 
under the experimental conditions employed in this thesis has been shown to occur 
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exclusively through PMCA, with a negligible contribution by other Ca2+ removal 
mechanisms (Rosado & Sage 2000). In addition, an inhibition of Ca2+ extrusion was 
also reported by S. Jones, who observed similar effects when platelets were 
stimulated with collagen and thrombin (personal communication, data not shown). 
These initial experiments determined concentrations of CE that could inhibit PMCA 
and indicates the role of PMCA in the maintenance of low resting Ca2+ in platelets 
as described by Hammes and colleagues in other cell types (Hammes et al. 1994). 
The data also suggests that PMCA acts to propagate the rise in [Ca2+]i following 
stimulation as CE is able to inhibit agonist induced intracellular Ca2+ release shown 
as a reduced peak response. The impaired Ca2+ extrusion through PMCA following 
stimulation with thapsigargin may have been due to differences in Ca2+ store release. 
However, there appeared to be no change in Ca2+ release (measured as peak minus 
basal) indicating normal store loading in the presence of CE and an equal amount of 
Ca2+ release into the cytosol upon stimulation. In conclusion, PMCA is a key 
modulator of Ca2+ homeostasis at rest and during platelet activation. In addition, CE 
at 10-40 µM, inhibits Ca2+ extrusion through PMCA. 
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Validation of carboxyeosin 
CE has been used to determine function in a variety of different cell types for 
example, the application of CE in mouse embryonic stem cells induces a large 
increase in [Ca2+]i (Yanagida et al. 2004). Furthermore, in rat ventricular myocytes, 
CE had been used to demonstrate the role of PMCA in controlling resting 
intracellular Ca2+ (Choi & Eisner 1999). The question as to whether the elevation of 
basal Ca2+ levels was due to PMCA inhibition by CE and not a consequence of Fura-
2 fluorescence interference in prepared platelet suspensions, was addressed by 
performing experiments to see if eosin (the cleaved form of carboxyeosin) or CE 
itself could concentration dependently increase Fura-2 emission independently of 
Ca2+. These results clarified that there was no significant difference between 
fluorescence readings using a wide range of concentrations of CE or eosin 
supporting the initial Ca2+ experiments where CE elevated Ca2+ levels in resting 
platelets, concluding that PMCA regulates basal [Ca2+]i. Further validation of CE as 
a selective inhibitor of PMCA was confirmed with the use of LaCl3, where similar 
increases in basal Ca2+ levels also occurred following inhibition of Ca2+ extrusion at 
the plasma membrane confirming that CE exerted its inhibitory effects at the plasma 
membrane. These experiments do not exclude the possibility that CE could exert its 
effects at other sites located on the plasma membrane for example at the NCX or 
NKA, and so, further validation studies were conducted. We found no evidence of a 
role for the Na+/K+ ATPase in modulating platelet aggregation. Therefore, although 
CE exerts inhibitory effects at Na+/K+ ATPases (Ogan et al. 2007), the effects of CE 
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on platelet aggregation is unlikely to be mediated through inhibition of Na+/K+ 
ATPase since inhibition of this pump at excessive concentrations of ouabain had no 
effect on platelet aggregation. 
 
Platelet function 
Platelet function was assessed using a range of standard platelet functional assays 
with collagen or thrombin as the two potent agonists chosen. In human washed 
platelet aggregation assays, CE was found to inhibit platelet aggregation in a 
concentration dependant manner indicating a positive regulatory role of PMCA 
during platelet activation. This was surprising, as one would expect platelets to 
activate as a result of elevated [Ca2+]i. One possible mechanism, by which PMCA 
inhibition could impair aggregation, could include partial activation and subsequent 
desensitisation of platelets. This would be in line with elevations of [Ca2+]i and will 
be discussed later.  The formation of a platelet plug has been described as a 
spatiotemporal process (Brini 2009), from initial adhesion to clot retraction. 
Contrary to the inhibitory effect of CE on platelet aggregation, platelet adhesion to 
fibrinogen was enhanced. Adhesion, which is one of the initial steps in clot 
formation, occurs when receptor integrins (notably αIIbβIII) express themselves in 
response to elevated [Ca2+]i. These receptors have a high affinity towards the 
fibrinogen receptor located on the sub-endothelial matrix of exposed/damaged 
tissue. The elevated basal Ca2+ levels seen in initial experiments suggest that in the 
early stages of platelet activation PMCA acts to suppress both Ca2+ and activation.  
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This appears to be consistent with the Ca2+ dependence of the fibrinogen receptor 
αIIbβIII. Exposed collagen, which is also present during the early stages of 
adhesion, appeared to show a decreased trend in platelet adhesion compared with 
fibrinogen. This could suggest that PMCA negatively regulates adhesion to 
fibrinogen however, in the case of collagen, which activates the platelet through 
additional and different pathways, the negative effect on adhesion is cancelled out 
by a positive effect on collagen induced aggregation i.e. there is an aggregation 
component to the adhesion assay when collagen is used but with fibrinogen only 
adhesion of platelets occurs resulting in different functional effects.  
Platelets provide an excellent model with which to address the issue of matrix 
retraction, since platelets develop contractile activity, fibrin clots and retraction is 
easy to assess.  It is also a good functional assay to observe integrin αIIbβ3 activity. 
The first evidence for a role of αIIbβ3 in retraction has been deduced from studies of 
a human hereditary hemorrhagic condition termed Glanzmann thrombasthenia, 
which is characterised by a quantitative or a qualitative defect in αIIbβ3 (Nurden 
2005).  
Following platelet activation through inside-out signalling, the fibrinogen receptor 
(integrin αIIbβ3) undergoes a conformational change in which it facilitates 
fibrinogen binding. Downstream of this, PKCβ activation assists interactions with 
cytoskeletal actin (Buensuceso et al. 2005)  leading to the generation of contractile 
forces from the platelet actin cytoskeleton. These forces are exerted on the fibrin 
matrix which induces contractions of the fibrin fibres and creates a ‘pulling in’ effect 
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in which the clot shrinks and becomes more compact and stable (Osdoit & Rosa 
2001).  Therefore, the analysis of clot retraction is a commonly used measure of 
outside-in signalling through integrin αIIbβ3 and any alterations involved in this 
pathway may be investigated. 
Upon investigation, an enhanced clot retraction was observed when PMCA was 
inhibited using CE.  This could be as a result of prolonged elevations of [Ca2+]i 
driving Ca2+ dependent myosin activity which is essential for the clot retraction 
process. These findings are consistent with results published by Dean and colleagues 
who observed that PMCA association with the cytoskeleton during platelet 
activation results in translocation of PMCA to filopodia and affects later stages of 
platelet activation measured as clot retraction (Dean & Whiteheart 2004). This 
suggests that PMCA acts to slow the rate of clot retraction towards the later stages of 
platelet activation, presumably to ensure effective healing of underlying damaged 
tissue so that PMCA may possess an important role in blood vessel integrity and 
disease for example in atherosclerosis. In conclusion, PMCA differentially regulates 
the various stages of platelet activation. It positively drives platelet aggregation 
since inhibition with CE leads to reduced aggregation but negatively regulates the 
earlier and later stages of activation measured as enhanced adhesion to fibrinogen 
and clot retraction respectively.  
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PMCA4 studies 
To determine whether the inhibitory effects observed previously in human platelets 
were specific to PMCA4, studies were carried out firstly in mouse platelets to 
investigate whether the effects observed in human platelets could be reproduced in 
mice and subsequently determine the isomer specific roles of PMCA4 using 
PMCA4 (-/-) mice. Experiments were initially conducted in platelets of wild-type 
(+/+) mice to determine whether the inhibition of PMCA with CE affected mouse 
platelet aggregation. In (+/+) mice, platelets were incubated with varying 
concentrations of CE and upon stimulation with either collagen or thrombin 
exhibited the same inhibitory effects as in isolated human platelets suggesting that 
PMCA regulates platelet function in both human and mouse platelets.  
As male mice are infertile (Schuh et al. 2004), knock-out mice were bred through a 
heterozygous breeding programme. Once litters were old enough, mice were 
genotyped to identify the knock-out populations, and once identified, platelets were 
isolated from (-/-) mice and used to perform functional studies. In addition, PMCA 
expression was also investigated in mouse platelets and other tissues using western 
blotting methods. Platelets isolated from (-/-) mice demonstrated an impaired 
aggregatory response when stimulated with collagen in comparison to wild-type 
(+/+) mice and also an impairment to platelet adhesion onto fibrinogen was 
apparent. The effects of PMCA4 ablation on platelet aggregation was mild 
compared to that observed with CE. This may reflect compensatory changes in 
PMCA4 -/- mice. Alternatively, their may be a role of PMCA1 that is apparent 
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following application of CE which does not have isoform specificity. In addition, it 
is possible that CE exerts non-specific effects at other ATPases that have yet to be 
identified in PMCA4-/- mice. 
Further aggregation studies were carried out in platelets isolated from (-/-) and (+/+) 
mice incubated with CE and stimulated with thrombin. Preliminary data showed that  
CE inhibited aggregation in (+/+) mice but not PMCA4 (-/-) mice suggesting that 
although CE inhibits all isoforms of PMCA, its effects in platelets are at least partly 
mediated via inhibition of PMCA4 and that the PMCA4 isoform is a key modulator 
of platelet function. The possibility that other isoforms of PMCA (particularly 
PMCA1), may have important functional roles in platelets cannot be ruled out. 
Whilst mouse platelets possess both PMCA 1 and 4, genetically modified ablation of 
a particular isoform (in this case PMCA4) could present questions as to whether the 
effects of CE in platelet function are mediated exclusively through this isoform. One 
way to distinguish between isomer specific roles would be to perform functional and 
in vivo studies using isomer selective antagonists or knock-out mice. In the case of 
PMCA1, which is crucial for embryonic development (Tempel & Shilling 2007), 
and is also ubiquitously expressed, the use of platelets from a PMCA1 (-/-) mouse 
would allow comparison of the role of PMCA1 with PMCA4 by contrasting data 
from PMCA4 (-/-) mice.  Unfortunately, PMCA1 (-/-) strains are embryonically 
lethal making these experiments impossible to perform at this stage. It would also be 
necessary to investigate whether there are changes in the expression of other 
isoforms of PMCA for example, PMCA1 and 3 in PMCA4 (-/-) mice that partially 
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explain the observed platelet phenotype. Therefore, at present, it is only possible to 
conclude that PMCA4 has an important role in platelet function. 
 
In vivo studies 
To identify whether the use of CE exhibited any anti-thrombotic properties, further 
investigations to look at the effect of systemic infusion of CE on platelet function in 
vivo were performed.  
Our group has established a real time in vivo mouse model of pulmonary embolism 
(Section 2.2.5.) and upon systemic infusion of CE at concentrations known to 
produce inhibitory effects in human platelets, there appeared to be no change in the 
maximum response (calculated as percentage count) of clot formation in the lungs 
when compared to a DMSO control. There was also no change in the area under the 
curve over 10 minutes (i.e dissolution of the clot) when platelets were stimulated 
with collagen. Therefore, although inhibition of the platelet response was observed 
in vitro, the effects of CE upon platelets when infused systemically could not be 
detected. One could suggest that the ability of CE to interact with platelet PMCA 
could have been compromised. CE may have been taken up by the RBC, which is 
another main source of PMCA therefore limiting the availability of CE to act 
directly on the platelets themselves and produce an inhibitory response. Further 
investigation and experiments are warranted to establish whether CE has uses as an 
anti thrombotic agent. These would include experiments with higher concentrations 
of CE and in vivo experiments in PMCA4 (-/-) mice. The described mouse 
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experiments provide strong evidence that the observed impairment of platelet 
function i.e. aggregation, occurs because of loss of PMCA4 activity. This is the first 
demonstration of a functional role of the PMCA4 isoform in platelets. 
 
Platelet desensitisation 
Partial mechanisms by which PMCA inhibition could have reduced platelet 
aggregation include partial activation and subsequent desensitisation of platelet 
function. This may well have been as a result of elevated [Ca2+]i levels observed in 
preliminary experiments. Another theory is that PMCA could be coupling to a 
negative regulator that affects platelet function which is Ca2+ dependent, such as 
NO. The former hypothesis was explored first.  It has been reported that a mutation 
of stromal interaction molecule (STIM1), a Ca2+ sensor situated in the ER, leads to 
elevation of [Ca2+]i in platelets, resulting in a pre-activation state and reduced 
response to collagen (Grosse et al. 2007). Therefore the pre-activation states of 
isolated human platelets in the presence of thapsigargin, which has been shown to 
elevate basal [Ca2+]i and CE were investigated. From these results, evidence of pre-
activation was not identified, this was measured by observing dense granule 5-HT 
secretion when platelets were incubated with CE and thapsigargin for comparison, 
and also by assessing changes in light transmission during pre-incubation with CE. 
Elevations of [Ca2+]i through SERCA inhibition (i.e. with thapsigargin), despite 
stimulating dense granule secretion and partial aggregation, did not desensitise 
platelets to collagen whereas CE caused no detectable pre-activation using either 
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assay. Therefore, a background elevation of [Ca2+]i did not per se contribute towards 
the subsequent inhibition of agonist induced aggregation. To further these studies, 
molecular analysis was conducted to identify the alternative hypothesis stated 
previously that PMCA acts to regulate negative signalling events such as VASP 
phosphorylation.  
 
Molecular studies 
It has been demonstrated that following thrombin mediated platelet activation, 
PMCA is phosphorylated on tyrosine residue 1176 , resulting in a 40% reduction in 
ATPase activity compared to resting platelets (Redondo et al. 2005; Dean et al. 
1997; Wan et al. 2003; Bozulic et al. 2007), however unlike most calmodulin 
regulated enzymes, PMCA’s are constitutively active with  substantial un-stimulated 
basal activity. 
In addition, very little PMCA is associated with the cytoskeleton under resting 
conditions, upon stimulation however approximately 80% of the total PMCA is 
redistributed to the cytoskeleton, where it retains Ca2+ ATPase activity (Zabe & 
Dean 2001), this potentially enables Ca2+ and signalling events to be regulated 
locally. It is possible therefore, that differential regulation of PMCA occurs with 
phosphorylation and inhibition of a localised subset of the PMCA population.  
This PMCA subset may be both isoform specific and/or spatially determined. 
During platelet activation, phosphorylated PMCA is inhibited to allow activated 
platelets to raise the global [Ca2+]i, however one can suggest that a distinct subset of 
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these ATPases, associate with the cytoskeleton and maintain function allowing them 
to act as signalling molecules by maintaining  microenvironments with low Ca2+ 
concentration. Thus, the application of CE in these experiments inhibits platelet 
aggregation by inhibiting PMCA’s and raising Ca2+ in these microenvironments. 
To assess whether PMCA4 can modulate inhibitory signalling events in activated 
platelets VASP-Ser239 phosphorylation was assessed.  VASP-Ser239 phosphorylation 
was clearly increased in stimulated platelets in the presence of CE, indicating that 
PMCA may aid platelet activation by preventing the phosphorylation of VASP. One 
of the major mechanisms of Ser-239 VASP phosphorylation in platelets is increased 
cGMP production by NO. NO is an important negative regulator of platelet function 
(Section 1.4.1), which can inhibit platelet secretion, aggregation and intracellular 
Ca2+ mobilisation through the stimulation of SGC and the production of cGMP.  
Platelets come into contact with NO produced in endothelial cells by eNOS, it is 
also believed that platelets contain eNOS and can produce NO, however this is now 
highly controversial and although there is large body of data to support platelet 
derived NO production (Randriamboavonjy & Fleming 2005), difficulties in 
detecting eNOS in human platelets have lead to suggestions that it is not present 
(Gambaryan et al. 2008; Tymvios et al. 2009; for review see Naseem 2008). 
In this study, the inhibition of platelet aggregation by CE was not reversed by the 
SGC inhibitor ODQ (10 μM) suggesting that CE inhibits platelet function 
independently of cGMP. Although Ser239 is considered the preferred 
phosphorylation site for cGMP/PKG and Ser157 is thought to be the preferred 
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phosphorylation site for cAMP/PKA, the sites are not exclusive and PKA has been 
demonstrated to phosphorylate VASP-Ser239 (Sudo et al. 2003) indicating that 
PMCA inhibition may potentially facilitate the cAMP/PKA pathway in platelets. 
Conversely, PMCA may regulate the signalling of an as yet unidentified calcium 
dependent inhibitory pathway in platelets.   As research continues into the role of 
PMCA4 as a signalling molecule, more proteins capable of interacting with PMCA 
via PDZ domains have emerged. PMCA associates  with Ras-associated factor 1 
(RASSF1), which in turn inhibits activation of the Erk pathway (Armesilla et al. 
2004) as well as the Ca2+/calmodulin dependent phosphatase calcinuerin (Buch et al. 
2005; Holton et al. 2007) . In platelets, PMCA associates with CLP36, which 
associates with α-actinin (Bozulic et al. 2007). It has been reported that CLP36 is 
important for the assembly of focal adhesions in BeWo cells (Tamura et al. 2007), 
raising the question of what other proteins form complexes with PMCA/CLP36 in 
platelets. Further research is required to fully elucidate the mechanisms by which CE 
inhibits platelet aggregation and to assess whether there are distinct subpopulations 
of PMCA in platelets with unique functional roles.  
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Overall conclusions 
In conclusion, the data presented in this chapter demonstrate that PMCA is involved 
in the regulation of intracellular calcium in both resting and activated platelets. 
PMCA regulates platelet function with temporal dependence. The effects on platelet 
function correspond with changes in both global intracellular calcium levels and 
changes in inhibitory signalling pathways. Further study is required to elucidate 
fully the mechanisms by which PMCA regulates calcium signalling spatially and 
temporally although PMCA is clearly a critical regulator of platelet calcium 
homeostasis, signalling and function and is therefore likely to be a key regulator of 
haemostasis and thrombosis. 
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4.1. INTRODUCTION 
 
In non-excitable cells, many agonists increase [Ca2+]i by inducing inositol 1,4,5-
trisphosphate (IP3)-mediated Ca2+ release from the intracellular stores while Ca2+ 
influx from the extracellular medium may then sustain the Ca2+ signal. Following 
this, [Ca2+]i recovers to its resting level as a consequence of Ca2+ removing 
mechanisms, i.e. plasma membrane Ca2+-ATPase (PMCA), Na+/Ca2+ exchanger 
(NCX) and sarco-endoplasmic reticulum Ca2+-ATPase (SERCA). 
Previous experiments have shown that an inhibition of PMCA in platelets results in 
differences in Ca2+ homeostasis and function at various stages of platelet activation. 
To determine whether these functional observations are specific to PMCA, 
experiments were conducted by inhibiting two major Ca2+ transporters in platelets, 
SERCA and the NCX. 
In this chapter, two pharmacological inhibitors of the NCX and SERCA, Bepridil 
and BHQ, were examined to compare the consequences of inhibiting these two 
transporters upon Ca2+ homeostasis and at the various stages of platelet activation.  
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4.1.1. Aims of the study 
 
• To investigate the roles of NCX and SERCA in regulating Ca2+ homeostasis 
in platelets. 
• To examine the functional consequence of NCX and SERCA inhibition using 
various functional assays.  
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4.2. RESULTS 
 
4.2.1. The role of SERCA and the NCX in regulating [Ca2+]i in resting platelets 
 
To determine whether the NCX or SERCA are able to regulate Ca2+ homeostasis, 
two known inhibitors of these pumps were used to measure [Ca2+]i in either resting 
or stimulated platelets. 
Washed human platelets were loaded firstly with the Ca2+ sensitive loading dye 
Fura-2 (5 µM) for 40 minutes in the dark (Section 2.2.4.4.) and later with 
concentrations of either the SERCA inhibitor, BHQ (0.01-100 µM), the NCX 
inhibitor, Bepridil (1-100 µM) or controls; mTHB, or DMSO (1%) for 30 minutes. 
Basal Ca2+ responses were recorded in the presence of EGTA (100 µM) for 30 
seconds as previously described in section 2.2.4.4.  
The mean percentage of basal [Ca2+]i was calculated for both BHQ and Bepridil 
(Fig. 4.1A and B) and resulted in a non significant effect at these concentrations 
(p>0.05). However, higher concentrations of Bepridil (i.e. 100 µM) displayed a 
slight increase in basal Ca2+ levels, however, this was not significant compared to 
the control (normalised to 100%): 183±3.5% (p>0.05) (Fig. 4.1B).  
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Figure 4.1. The effects of BHQ and Bepridil on basal Ca2+ levels in resting platelets 
Washed human platelets were loaded with Fura-2 incubated with BHQ (0.01-100 µM), 
Bepridil (1-100 µM) or controls: mTHB or DMSO (1%). Fura-2AM ratio emission at 
340/380 nm was measured for 30 seconds and basal [Ca2+]i levels recorded. Graphs 
show the mean percentage of basal [Ca2+]i in resting platelets for both (A) BHQ and (B) 
Bepridil relative to controls. Where statistical comparisons were made a one-way 
ANOVA followed by a multiple comparison test was used to compare mean values. No 
significant values were observed, (P>0.05), n=4. 
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4.2.2.  SERCA and the NCX in regulating [Ca2+]i extrusion in stimulated 
 platelets 
 
To investigate whether the NCX or SERCA elicit an effect in regulating Ca2+ 
homeostasis upon stimulation,  Ca2+ measurements were recorded in platelets 
stimulated with thapsigargin plus ionomycin.  Washed human platelets were loaded 
with Fura-2 (5 µM) as described in section 2.2.4.4. and later with concentrations of 
BHQ (0.01-100 μM), Bepridil (1-100 µM) or controls mTHB or DMSO (1%). Ca2+ 
responses were recorded in the presence of EGTA (100 µM) and stimulated using 
thapsigargin (1 µM) plus ionomycin (50 nM) which was sufficient to induce a rapid 
and transient increase in [Ca2+]i following release from stores.  The mean percentage 
in [Ca2+]i remaining 3 minutes after stimulation was calculated for each 
concentration of BHQ and Bepridil. The results indicate a non-significant effect of 
either  BHQ or  Bepridil in regulating Ca2+ extrusion at these concentrations 
compared to their controls (normalised to 100%): BHQ: (0.01 µM) 100±0.1%, (0.1 
µM) 101±1.0%, (1 µM) 92±0.3%, (10 µM) 97±1.1% and (100 µM) 101±0.1% 
(p>0.05) (Fig. 4.2A). Bepridil: (1 µM) 87±0.99%, (10 µM) 102±0.05%, (50 µM) 
93±0.5% and (100 µM) 125±1.8% (p>0.05) (Fig. 4.2B). There was also no evidence 
of an effect of either BHQ or Bepridil on Ca2+store release since [Ca2+]i, (measured 
as peak minus basal (Fig. 4.2.C and D) was unaffected by this treatment (normalised 
to 100%): BHQ (0.01µM) 95±0.2%, (0.1µM) 86±0.7%, (1 µM) 92±0.4%, (10 µM) 
90±0.5% and (100 µM) 95±0.2% (p>0.05). Bepridil: (1 µM) 88±1.7%, (10 µM) 
81±2.7%, (50 µM) 82±2.7% and (100 µM) 92±1.0% (p>0.05). These results indicate 
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indicated that neither SERCA nor the NCX play a role in [Ca2+]i extrusion following 
stimulation. 
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Figure 4.2. The effects of BHQ and Bepridil on thapsigargin plus ionomycin 
induced [Ca2+]i release 
Washed human platelets were loaded with Fura-2 and incubated with BHQ (0.01-100 
µM), Bepridil (1-100 µM) or controls, mTHB or DMSO control (1%). Fura-2AM 
emission ratio at 340/380nm was measured in response to thapsigargin (1 µM) and 
ionomycin (50 nM) in the presence of EGTA (100 µM). Figures (A and B) show the % 
of [Ca2+]i remaining at 3 minutes post stimulation for both BHQ and Bepridil. Figures 
(C and D) show the % peak [Ca2+]i minus the basal [Ca2+]i post stimulation. Data 
represents mean percentage ±S.E.M relative to either control. Where statistical 
comparisons were made a one-way ANOVA followed by a multiple comparison test 
was used to compare mean values. No statistical significance were observed, (P>0.05), 
n=4. 
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4.2.3. SERCA and the NCX in regulating human platelet aggregation  
 
To investigate whether BHQ or Bepridil elicit a functional effect on washed 
platelets, cells were pre-incubated with concentrations of BHQ or Bepridil 
previously used to measure Ca2+ extrusion through their associated pumps 
(Trepakova et al. 1999; Shiraga et al. 1998). Washed human platelets were incubated 
with BHQ (0.01-100 µM), Bepridil (1-100 µM), or controls, mTHB or DMSO (1%) 
and stimulated with either collagen (5 μg/ml) or thrombin (0.1 U/ml). Maximal 
aggregation was achieved at around 3 minutes.  In the presence of BHQ, platelets 
exhibited a concentration dependent inhibition of aggregation upon stimulation. The 
mean percentage decrease in platelet aggregation was calculated for each 
concentration of BHQ stimulated firstly with collagen (5 µg/ml) which was 
significant between 1-100 µM compared to the control (normalised to 100%): (1 
µM) 42±4.0% (p<0.01), (10 µM) 31±4.8% and (100 µM) 17±5% (p<0.001) (Fig. 
4.3A), and thrombin (0.1 U/ml) between 1-100 µM compared to the control 
(normalised to 100%): (1 µM) 52±3.4% (p<0.05), (10 µM) 34±4% (p<0.01) and 
(100 µM) 15±6% (p<0.001) (Fig. 4.3.B).  
With Bepridil, a concentration dependent inhibition of aggregation was observed at 
100 µM that was significant when stimulated with collagen (5 µg/ml) compared to 
the control (normalised to 100%): (100 µM) 17±8% (p<0.01) (Fig. 4.3.C) and 
thrombin (0.1U/ml) which was significant at 70 µM and 100 µM compared to the 
control (normalised to 100%): (70 µM) 40±1.2% and (100 µM) 28±1.5% (p<0.01) 
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(Fig. 4.3D). The effects BHQ and Bepridil have on isolated human washed platelets 
demonstrate the functional consequences of the inhibition of Ca2+ extrusion through 
SERCA and the NCX respectively. 
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Figure 4.3. The effects of BHQ and Bepridil on collagen and thrombin mediated 
          aggregation 
Washed human platelets were pre-incubated with BHQ (0.01-100 µM), Bepridil (1-100 
µM) mTHB or DMSO (1%) prior to stimulation. Optical aggregometry was used to 
measure aggregation in response to thrombin (0.1 U/ml) or collagen (5 µg/ml) for 180 
seconds with constant stirring (~1200 rpm). Figures (A and B) show the mean 
percentage aggregation ±S.E.M of BHQ relative to DMSO, and (C and D) for Bepridil 
relative to mTHB. Where statistical comparisons were made a one-way ANOVA 
followed by a multiple comparison test was used to compare mean values, *P<0.05, 
**P<0.01, ***P<0.001, n=5. 
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4.2.4. The effects of BHQ and Bepridil on platelet adhesion 
 
To investigate another functional consequence of SERCA and NCX inhibition in 
platelets, platelet adhesion onto fibrinogen (50 µg/ml) coated surfaces was measured 
spectrophotometrically using the colorimetric platelet phosphatase assay as 
described by Bellavite and colleagues (Bellavite et al. 1994) (Section 2.2.4.2.) 
following pre-incubation of platelets with either BHQ (0.01-100 µM), Bepridil (1-
100 µM) or controls, mTHB and DMSO (1%). 
Platelet adhesion in the presence of BHQ was enhanced in a concentration 
dependent manner onto fibrinogen coated surfaces (Fig.4.4A) and was significant at 
all concentrations of BHQ compared to the DMSO control (normalised to 100%): 
(0.01 µM) 132±0.04%, (0.1 µM) 205±0.3%, (1 µM) 237±0.01%, (10 µM) 
311±0.005%, (50 µM) 345±0.001% and (100 µM) 417±0.03% (p<0.001). However, 
platelet adhesion in the presence of Bepridil (Fig.4.4B) was found to be reduced in a 
concentration dependent manner which was significant at all concentrations 
compared to the control (normalised to 100%): (1 µM) 95±0.2%, (10 µM) 90±0.9%, 
(50 µM) 66±0.1% and (100 µM) 47±0.8% (p<0.001). 
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Figure 4.4. Platelet adhesion to fibrinogen coated surfaces 
Platelet adhesion onto a fibrinogen (50 µg/ml) coated surface was measured using an 
acid phosphatase static adhesion assay and absorbance for each well read at 405 nm. 
Absorbance values for BHQ (0.01-100 µM) and Bepridil (1-100 µM) were normalised 
to percentage values obtained for non treated cells. Figure (A) Shows the normalised % 
adhesion of platelets onto fibrinogen coated plates in the presence of BHQ and (B) 
Bepridil. Data represents mean ±S.E.M in relative units to control responses. Where 
statistical comparisons were made a one-way ANOVA followed by a multiple 
comparison test was used to compare mean values, ***P<0.001, n=4. 
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4.2.5. The effects of SERCA and the NCX on clot retraction 
 
To investigate whether the inhibition of SERCA or the NCX affected the later stages 
of platelet function, platelet clot retraction was measured. Human PRP was pre-
incubated with BHQ (0.01-10 µM), Bepridil (1-100 µM) or controls, mTHB or 
DMSO (1%) and clot retraction measured as described in section 2.2.4.3. Data was 
presented as the % clot weight of each sample as shown in Figures (4.5A and B). 
PRP treated with DMSO (1%) formed a retracted clot within a two hour time frame. 
Basing each control sample as 100% clot formation, subsequent clots formed in the 
presence of either BHQ or Bepridil expressed an enhancement i.e. a tighter clot form 
which was significant for BHQ between 0.1- 10 µM compared to the control 
(normalised to 100%): (0.1 µM) 61±4% (p<0.01), (1 µM) 39±6.2% and (10 µM) 
19±8% (p<0.001) (Fig. 4.5.A) and Bepridil 10-100 µM compared to the control 
(normalised to 100%): (10 µM) 64±4% (p<0.05), (50 µM) 47±5% and (100 µM) 
32±2% (p<0.001). In contrast to platelet aggregation, which is suppressed following 
SERCA and NCX inhibition the enhanced clot retraction demonstrated here suggests 
that although these pumps positively regulate platelet aggregation they negatively 
modulate clot retraction. 
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Figure 4.5. Inhibiting SERCA and the NCX accelerates clot retraction  
The effect of SERCA and NCX inhibition by BHQ and Bepridil on clot retraction was 
measured. Human PRP was incubated with BHQ (0.01-10 µM), Bepridil (1-100 µM) or 
controls, mTHB or DMSO (1%). Figures (A and C) shows the mean data for the clot 
weights (normalised to control 100%) ±S.E.M weight in the presence of (0.01-10 µM), 
Bepridil (1-100 µM) or controls, mTHB or DMSO (1%) and (B and D) are 
representative clots formed and retracted in the presence of BHQ (0.01-10 µM), 
Bepridil (1-100 µM) or controls, mTHB or DMSO (1%) at 2 hours. Where statistical 
comparisons were made a one-way ANOVA followed by a multiple comparison test 
was used to compare mean values, *P<0.05, **P<0.01, ***P<0.001, n=5. 
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4.3. Discussion  
 
The aims of the research carried out in this chapter were to determine the effects of 
SERCA and NCX inhibition upon Ca2+ homeostasis and platelet function. As 
discussed in chapter three, PMCA plays an important role in Ca2+ homeostasis and 
platelet function which appears to be time dependant. However, to address whether 
these effects were specific to PMCA, other possible Ca2+ pumps that could 
potentially influence Ca2+ regulation and function in platelet were investigated. This 
was addressed using known inhibitors of SERCA and the NCX, BHQ and Bepridil, 
to inhibit the activity of these pumps at their respective sites in platelets using a 
variety of functional assays. 
 
Ca2+ regulation 
In the resting state, concentrations of Ca2+ ions in the cell and its compartments have 
to be maintained. All ion channels are closed, there being only (uncontrolled) 
leakage from intracellular stores. These passive ion fluxes have to be countered 
actively by the fluxes generated by corresponding mechanisms. 
The passive flux of Ca2+ via the plasma membrane is thought to be counteracted by 
the activities of PMCA and NCX. The NCX in particular, can operate in either 
direction as described by Juška, 2010 by removing Ca2+ ions from cytosol (Juska 
2010). The leakage via the plasma membrane and the activities of NCX and PMCA, 
presumably, determine the resting (or background) Ca2+ concentration in the cytosol 
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whereas leakage from the stores is counteracted by the activity of SERCA’s, whose 
fluxes determine Ca2+ concentrations within the stores and the leakage from 
mitochondria is balanced by the activity of NCX and that of uniporters located in the 
mitochondrial membranes. To maintain the equilibrium of Ca2+ fluxes in platelets, 
the above systems have to operate permanently.  
The purpose of these experiments was to determine whether any inhibition of 
SERCA or the NCX critically affected the regulation of Ca2+ homeostasis in 
comparison to PMCA. 
Thapsigargin and BHQ are described as sesquiterpene lactone tumour promoters and 
have proved useful in the study of Ca2+ homoeostasis in a number of different cell 
types (Thastrup et al. 1990) including platelets (Vostal et al. 1991). Both compounds 
are membrane permeable and thus block ER Ca2+ pumps in intact cells (Thastrup et 
al. 1990). These compounds have been shown to exert their inhibitory effects by 
stabilising the E2 conformational state of the ATPase (see section 1.6.3.) and 
potentially affect PLA2 activation due to the elevations in [Ca2+]i (Wictome et al. 
1992). 
Both compounds are known to elevate cytosolic Ca2+ levels via the release of Ca2+ 
from intracellular stores, followed by influx from the extracellular medium. This is 
achieved by inhibiting Ca2+ uptake into inositol 1,4,5-trisphosphate releasable pools 
by inhibiting SERCA without affecting plasma membrane Ca2+ transport. Therefore, 
the increase in [Ca2+]i in intact cells is due to the release of  Ca2+  from stores 
resulting from prevention of reuptake (Brüne & Ullrich 1991).  
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The results presented here indicate that whilst SERCA is responsible for the 
elevations in [Ca2+]i upon activation via the release of Ca2+ from stores, it does not 
play a critical role in the maintenance of basal Ca2+ levels in resting platelets. This 
could partly be due to passive Ca2+ leakage from stores into areas such as the DTS to 
maintain Ca2+ in a steady state and regulate [Ca2+]i. As previous data indicated a role 
for PMCA in maintaining basal Ca2+ levels, the actions of both SERCA and PMCA 
in a resting state may prevent inappropriate activation.   
Upon stimulation with thapsigargin which has been shown to deplete Ca2+ from 
stores (also demonstrated by Rosado and colleagues (Rosado & Sage 2000)), there 
appeared to be no change in Ca2+ release into the cytosol when SERCA was 
inhibited. It has also been reported that both thapsigargin and BHQ exert their 
effects at different isoforms of SERCA within platelets, one sensitive to BHQ 
(SERCA3) and the other to thapsigargin (SERCA2b) (Cavallini et al. 1995; 
Redondo et al. 2008).  This might suggest that whilst BHQ may inhibit SERCA3, 
the sequestration of Ca2+ by SERCA2a might compensate and still function to 
sequester some but maybe not all cytosolic Ca2+ back into stores.    
The capability of SERCA to lower Ca2+ concentration in the cytosol, presumably, is 
rather limited (if any) unless the stores are empty or depleted considerably by 
thapsigargin. This was evident as Ca2+ extrusion through PMCA was unaffected 
post-stimulation since the Ca2+ transient returned to baseline levels normally. 
There is increasing evidence the NCX is able to regulate basal Ca2+  in platelets 
(Bose et al. 2002)  and can easily reverse its direction and bring Ca2+ into the cell  if 
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the Na+ concentration gradient decreases and/or the membrane potential becomes 
less negative (Harper & Sage 2007). However, studies to determine whether the 
NCX plays a role in the maintenance of resting Ca2+ have yet to be investigated. The 
results reported in this chapter demonstrate that whilst the NCX is present within 
platelets to functionally regulate Na+ gradients across the membrane, it appeared to 
play a negligible role in the maintenance of Ca2+ in resting platelets, and did not 
affect Ca2+ release from stores or extrusion under the experimental conditions here. 
This is consistent with studies performed by Rosado and colleagues who 
demonstrated that in platelets suspended in medium where all Na+ had been replaced 
by N-methyl-D-glucamine, [Ca2+]i was elevated to similar levels as control and then 
fell back to basal levels after stimulation with thapsigargin (Rosado & Sage 2000). 
Whilst PMCA and the NCX are the only transporters capable of extruding Ca2+ from 
the cell, the results here indicate that the NCX has a negligible, if any effect on the 
restoration of [Ca2+]i to low resting levels when a rise in [Ca2+]i is induced by 
depletion of the intracellular Ca2+ stores using thapsigargin and a low concentration 
of ionomycin. There was a slight increase in basal Ca2+ levels in the presence of high 
concentrations of Bepridil (100 µM), however, this was not significant and could 
possibly be attributed to a non-specific effect. This demonstrates a comparative 
difference of the NCX in its responsibility for the maintenance of low resting [Ca2+]i  
and active Ca2+ release in these cells compared to PMCA. 
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Aggregation 
To determine whether the inhibition of SERCA or the NCX elicit a role in platelet 
function, platelet aggregation was investigated.  
Thapsigargin has been shown to induce aggregation and secretion (Harper et al. 
2009; Marumo & Wakabayashi 2010), and responses have been shown to be 
inhibited by cyclo-oxygenase inhibitors (Murthy et al. 1995). BHQ however, 
appears not to promote aggregation or secretion, but has been shown to inhibit the 
formation of thromboxane B2 (Brune & Ullrich 1987).  
Our initial hypothesis after preliminary Ca2+ experiments were performed was that 
any impairment of SERCA function would not affect platelet aggregation as 
extrusion of cytosolic Ca2+ remained intact i.e. PMCA is still functional. However, 
early experiments indicated a concentration dependant inhibition of aggregation in 
response to collagen and thrombin stimulation. One possible mechanism by which 
SERCA inhibition could impair aggregation would be its association of local 
negative regulators upon activation. Studies in myocytes have suggested that cGMP 
signalling affects function through phosphorylation of phospholamban which 
regulates SERCA activity by increasing its affinity to Ca2+ (Zhang et al. 2005). 
Another study by Redondo and colleagues demonstrated that the inhibition of 
SERCA by BHQ accelerated Ca2+ store discharge and subsequently enhanced the 
extent of SOCE stimulated by thrombin in human platelets indicating a negative role 
for SERCA’s in the regulation of Ca2+ entry (Redondo et al. 2008). One would 
expect an increases in [Ca2+]i following agonist stimulation and subsequent depletion 
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of stores to promote this event. It could be suggested that prior to stimulation, 
platelet desensitisation occurs during the incubation process, as studies previously 
showed an increase in dense granule secretion in platelet pre-treated with 
thapsigargin (Fig. 3.9.2A). The reasons as to why aggregation is impaired following 
SERCA inhibition in the presence of BHQ requires further investigation and the role 
it plays in the regulation of platelet function in this instance, cannot be fully 
elucidated without investigating the underlying mechanisms associated with this 
pump. The purpose of these experiments was to directly compare the functional 
consequence of SERCA inhibition to that of PMCA. 
Our initial hypothesis suggested that any impairment of the NCX would not affect 
cytosolic Ca2+ release, as the presence of PMCA would not perturb Ca2+ extrusion 
via PMCA. Early experiments confirmed this, as Ca2+ extrusion was unaffected by 
the treatment of NCX inhibitor Bepridil. This would support studies performed by 
Shiraga and colleagues who demonstrated that Bepridil concentration dependently 
inhibited platelet aggregation induced by ADP or thrombin. They attributed this to a 
possible elevation in [Ca2+]i and subsequent calpain activation which  is known to be 
a potential negative regulator of signalling processes associated with the NCX 
(Shiraga et al. 1998). 
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Adhesion and clot retraction 
Platelet adhesion and clot retraction were investigated to identify whether the 
inhibition of SERCA or the NCX play a role in regulating these processes. As 
observed previously, platelet adhesion and clot retraction were elevated in the 
presence of the PMCA inhibitor CE due to elevated [Ca2+]i  which is consistent with 
the activity of both fibrinogen and downstream outside in signalling. Therefore, as 
initial experiments indicated no change in basal Ca2+ levels in resting platelets when 
SERCA was inhibited, it was surprising to see an elevation of adhesion to fibrinogen 
along with enhanced clot retraction as both integrin expression and the activation of 
myosin requires raised Ca2+ as a prerequisite. One explanation could be that there 
are different types of Ca2+ sensitive pools located in platelets as described by 
Cavallini and colleagues, and that expression of different isoforms of SERCA could 
be more or less sensitive to BHQ inhibition (Cavallini et al. 1995). It could be 
suggested that in the presence of BHQ, which has a higher affinity for SERCA 
isoform 3, other isoforms of SERCA, for example SERCA2 may still be functional 
and deplete stores, raise cytosolic Ca2+ levels and potentially activate inside-out 
signalling to facilitate fibrinogen binding and downstream PLCβ activation required 
for  cytoskeletal actin contraction.  
To determine whether or not the NCX plays a role during platelet adhesion or clot 
retraction, platelet NCX was inhibited using Bepridil. As previous experiments 
showed no change in resting Ca2+ levels along with Ca2+ extrusion operating 
normally through PMCA, there appeared to be a decrease in adhesion to fibrinogen.  
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One explanation could be that passive leakage of Ca2+ from stores is not enough to 
elicit a change in cytosolic Ca2+ levels required for integrin expression. This 
supports our findings that PMCA acts to regulate Ca2+ levels upon activation during 
the early and later stages of Ca2+ release. Another explanation could be that the 
inhibition of the NCX causes a rise in intracellular Na+ concentration, which may be 
linked to increase refilling of stores to regulate the cytosolic Na+/Ca2+ balance within 
the cell. As there is increasing evidence that the NCX operating in reverse mode 
may be directly involved in inside-out signalling that activates alpha αIIbβIII, it is 
possible that the NCX has more of a functional role in platelets than is currently 
understood (Shiraga et al. 1998). Despite there being an inhibition of adhesion 
during NCX inhibition, clot retraction was enhanced, presumably due to passive 
leakage of Ca2+ from stores and raising cytosolic Ca2+ levels over time during the 
course of these experiments.  
The interpretation of data in this chapter relies on the specificity of the inhibitors 
used. Concentrations were selected on the basis of published data which showed 
selective inhibition of the NCX and SERCA at these concentrations. The possibility 
remains, however, that some of the effects presented could have been due to non-
selective effects. Further studies are required to confirm this selectivity. These could 
involve the use of alternative inhibitors and knock-out mice as well as validatory 
studies such as those reported in Chapter 3 for CE. 
Previous experiments in this thesis outlined the various roles of PMCA in platelets 
and in contrast, the functional properties of other platelet Ca2+ pumps were 
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investigated. Although the mechanistic profiles of SERCA and the NCX were not 
explored, the purpose of these experiments were to identify whether the functional 
changes observed during PMCA inhibition, were specific, in comparison to the 
inhibition of other Ca2+ pumps present, i.e. the inhibition of SERCA and the NCX 
using BHQ and Bepridil respectively. These results, taken with previous finding for 
PMCA indicate that all three pumps play a pivotal but contrasting role in regulating 
platelet Ca2+ homeostasis and platelet function (See Table 4.3.).  
Table 4.3.  Comparative functional differences for inhibition of PMCA,  
  SERCA and the NCX 
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Introduction 
The role of platelet function in the development of thrombotic events has been 
studied extensively for many years as platelet and coagulation factor-dependent 
thrombus formation is critical to limit posttraumatic blood loss at sites of vascular 
injury. Under pathological conditions like rupture of an atherosclerotic plaque, 
thrombus formation may lead to vessel occlusion causing myocardial infarction or 
stroke. Therefore, antithrombotic treatment is the prime therapeutic option in the 
prophylaxis and treatment of ischaemic cardio- and cerebrovascular diseases 
The use of existing antithrombotic agents is, however, limited by their inherent 
effect on primary haemostasis. In recent years, major advances have been made in 
understanding the mechanisms of thrombus formation in haemostasis and 
thrombosis and some studies raised the interesting possibility that thrombus 
formation and haemostasis may involve partially different mechanisms (Hagedorn et 
al. 2010). 
 
Objectives of this thesis 
The main objective of this study was to investigate the role of PMCA in platelet 
function and Ca2+ homeostasis. This was achieved using a pharmacological inhibitor 
of PMCA, carboxyeosin. Following this, isomer specific roles were investigated 
using PMCA4 knock-out mice and by investigating the consequence of inhibition in 
comparison to other Ca2+ regulators in platelets, SERCA and the NCX.  
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Lastly, the molecular signalling pathways of PMCA were also explored. The results 
presented in this thesis indicate that PMCA is involved in the regulation of 
intracellular Ca2+ in both resting and activated platelets and differentially regulates 
the various stages of platelet activation with both stimulatory and inhibitory roles.  
The effects on platelet function correspond with changes in both [Ca2+]i and 
inhibitory signalling pathways. These roles were specific to PMCA when compared 
to other Ca2+ pumps located within platelets suggesting that all three Ca2+ pumps 
play pivotal but contrasting roles in regulating platelet function and Ca2+ 
homeostasis. 
 
Ca2+ regulation 
Ca2+ signalling modulates some of the most important processes, including cell 
origin at fertilisation, stimulus–contraction and stimulus–secretion coupling, 
intracellular communication, gene transcription, cell growth and apoptotic cell 
death. The correct functioning of these processes demands that the concentration of 
Ca2+ in the cytoplasm and in the different intracellular compartments must be tightly 
controlled. Alterations in this control may lead to various cell dysfunctions and 
diseases. 
The first indication that the plasma membrane of eukaryotic cells contains a Ca2+-
dependent ATPase was provided almost 50 years ago by Dunham & Glynn 
(Dunham & Glynn 1961). Five years later Schatzmann showed that the ATPase 
actually transported Ca2+ out of erythrocytes (Schatzmann 1966), but it took a 
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number of years before it became clear that the pump was, in fact, present in the 
plasma membranes of all eukaryotic cells. In 1988, the complete amino acid 
sequence of the pump was deduced by Shull & Greeb from complementary DNA 
isolated from rat brain (Shull & Greeb 1988) and by Verma and colleagues from 
human teratoma (Verma et al. 1988) but it wasn’t until the mid 1990’s when 
Bokkala and colleagues investigated PMCA in highly purified human platelet 
membranes using a monoclonal antibody, 5F10, raised to the red-cell membrane 
Ca2+ATPase (Bokkala et al. 1995).   
To date, role of PMCA and its importance in platelet function has yet to be 
characterised. 
 
PMCA’s importance in the cardiovascular system 
Platelets do not only have a profound impact within the cardiovascular system but 
may also be involved in the pathogenesis of other conditions such as diabetes 
(Chaabane et al. 2007; Jardín et al. 2006; Tempel & Shilling 2007). Work by 
Blankenship and colleagues has shown that PMCA function/expression in platelets 
of hypertensive individuals is impaired, resulting in increased platelet intracellular 
Ca2+ and hyperactive platelets which could lead to increased risk of heart attack and 
stroke (Blankenship et al. 2000) providing a justification for the  investigation of 
PMCA in platelets as a potential therapeutic target in this condition. In addition, 
work carried out by Jardin and colleagues have demonstrated PMCA as a potential 
target for the development of therapeutic strategies to palliate cardiovascular 
CHAPTER FIVE – General Discussion 
 
187 
 
disorders in non-insulin-dependent diabetes mellitus (Jardín et al. 2006) which also 
demonstrates PMCA’s importance as a therapeutic target. 
 
Inhibitors 
In recent years, considerable progress has been made in understanding the 
mechanisms of thrombus formation and studies in mice provided the first 
experimental evidence that pathological thrombus formation and primary 
haemostasis may be two mechanistically distinct processes (Hagedorn et al. 2010).  
There have been many studies which focus on platelet Ca2+ regulation, (Kouvelas et 
al. 2009) (Kouvelas et al. 2009)(Kouvelas et al. 2009)in which PMCA has been 
investigated alongside other Ca2+ pumps such as SERCA, SOCE and the NCX. 
However, there have been no studies to fully clarify the functional role of PMCA in 
platelets.   
In terms of targeting platelets in the treatment of thrombosis, the COX inhibitor, 
aspirin, is the most widely used over-the-counter drugs available. It has low (but 
useful) therapeutic activity, but is stigmatised by severe adverse side effects such 
prolonged inhibition of blood coagulation (Brune et al. 2009).   
Due to its effects at other ATPases, CE is unlikely to have value as a therapeutic 
target in platelets. Nevertheless, it is still an important tool to investigate the role of 
PMCA in other cell types as already demonstrated in various cell types, for example 
in endothelial cells (Moccia et al. 2002) and mesenchymal stem cells (Kawano et al. 
2003). In this thesis, CE has been applied to investigate platelet Ca2+ homeostasis 
and more importantly platelet functional responses.  
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The application of CE in the in vivo model of pulmonary embolism could be 
extended to include haemodynamic analysis in mouse models as described by 
Tymvios et al. (Tymvios et al. 2008). This would look at the direct relation CE has 
on the heart and its effects in blood pressure. 
 Recently, the identification and use of a more specific extracellular inhibitor of 
PMCA has emerged. The use of Caloxins to inhibit PMCA was first demonstrated 
by Chaudhary and colleagues in 2001, who screened a random peptide phage display 
library to select for peptides binding to the second extracellular domain sequence of 
PMCA which links transmembrane domains 3 and 4, which is shown to be 
inhibitory (Guerini et al. 1996). This discovery was the first of its kind to identify a 
specific extracellular inhibitor of PMCA (Chaudhary et al. 2001).  
Future experiments with these novel compounds may be useful in platelet functional 
studies both in vitro and in vivo.  
 
Other models 
Here we demonstrated the use of CE as a specific PMCA4 inhibitor by applying it 
not only to human platelets in vitro, but carrying it forward in models of in vivo 
thromboembolism.  Other applications would be to examine platelet inhibition in 
models of vascular disease, for example in vascular flow models already used in 
areas of endothelial research. By observing platelets in such settings, one could gain 
a better understanding of the mechanisms by which hemodynamics influences 
platelets within susceptible regions of the vasculature.  
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This could be further extended by introducing models of flow in conjunction with 
microscopic image sequence analysis as described by Macchin and colleagues who 
have developed a unique way of quantifying adhesion properties of platelets under 
flow conditions, over time (Machin et al. 2005). Other experimental approaches 
would be to look at vascular injury models such as endothelial laser injury as 
described by Atkinson and colleagues, who monitored Ca2+ mobilisation to assess 
activation of the laser-targeted cells (Atkinson et al. 2010; Hechler et al. 2010), or 
Hechler and colleagues who looked at transient thrombus formation in a model of 
laser-induced thrombosis in mesenteric arterioles (Hechler et al. 2010).  
Other vascular injury models such as ferric chloride induced thrombosis, endothelial 
denudation and the use of rose bengal in photochemical induced thrombosis may 
also be of interest by observing the effects of platelet inhibition using CE these 
settings.  
Signalling 
Studies to identify PMCA inhibition in human platelets using a variety of in vitro 
assays demonstrated that the inhibition of PMCA with CE displayed an impairment 
of intracellular Ca2+ extrusion coupled with a diminished response in platelet 
aggregation upon stimulation. Furthermore, an increase in basal Ca2+ levels was 
apparent. Although many of the observations are in fitting with PMCA’s role as a 
Ca2+ extruder, its role in positively driving platelet aggregation was somewhat an 
unanticipated response as one would expect platelets to activate giving the rise in 
cytosolic [Ca2+]i. Additional studies demonstrated that in the presence of CE, 
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platelets were not desensitised prior to stimulation owing to the background 
elevation of  [Ca2+]i. Therefore, to further characterise the profile of PMCA in 
platelets and address other possible mechanisms behind the inhibitory effects 
observed upon platelet aggregation with CE, inhibitory molecular signalling 
pathways associated with PMCA were investigated. 
A major negative regulator of platelets is the phosphorylation of VASP. Therefore, 
molecular signalling studies were conducted to identify VASP phosphorylation in 
platelets pre-treated with CE. From these studies, an increase in VASP-Ser239 
phosphorylation was apparent suggesting that PMCA may be negatively regulating 
signalling events in platelets. Similar studies have identified an association of 
PMCA with negative signalling molecules in other cell types. For example, PMCA 
has been shown to regulate inhibitory signalling within cardiomyocytes (Oceandy, 
Cartwright et al. 2007) and vascular smooth muscle where it associates with nNOS 
(Schuh et al. 2003) and eNOS in endothelial cells (Moccia et al. 2002). Therefore, it 
was suggested that perhaps the inhibitory effects observed with CE on platelet 
aggregation could be mediated by the association of PMCA with eNOS and 
subsequently phosphorylate VASP-Ser239 downstream of the NO-cGMP pathway. 
One of the major mechanisms of VASP-Ser239 phosphorylation in platelets is 
increased cGMP production by NO (Gambaryan et al. 2008). However, the question 
as to whether platelets contain NOS enzymes that directly activate the NO-cGMP 
pathway is somewhat controversial as there is still much debate as to whether NOS 
enzymes, in particular eNOS, are present in platelets (Naseem & Riba 2008). 
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Despite this controversy surrounding the expression of NOS enzymes in platelets, 
further investigations as to whether PMCA could regulate pathways downstream of 
NO were carried forward to look at the link between NO and SGC which is a 
downstream effector of this pathway. 
In studies carried out here, the inhibition of platelet aggregation by CE occurred 
independently of cGMP. Therefore, it left the question open as to what could be 
phosphorylating VASP. Although Ser239 is considered to be the preferred 
phosphorylation site for cGMP/protein kinase G (PKG), the site has also been 
shown to be both PKG-sensitive and PKA-sensitive (Li et al. 2003; Riba et al. 2006) 
indicating that PMCA inhibition may stimulate alternative Ca2+-dependent inhibitory 
pathways in platelets.  
These regulatory sites are not exclusive, and as the inhibition of platelet aggregation 
appeared to be independent of the cGMP/PKG pathway, it could be suggested that 
PMCA inhibition may potentially facilitate the cAMP/PKA pathway as PKA has 
also been shown to phosphorylate VASP-Ser239 (Sudo et al. 2003) It would also 
interesting to investigate the phosphorylation of VASP at Ser157 by protein kinase C 
(PKC) which correlates with reduced activation of integrin aIIbβ3 and an inhibition 
of platelet aggregation (Horstrup et al. 1994). To characterise a signalling pathway 
that is unique to one particular protein would require an immense amount of 
research. Nevertheless, to further investigate potential protein kinase pathways aside 
from the cGMP/PKG which are all Ca2+ dependent that may be involved in the 
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phosphorylation of VASP, experiments using commercially available inhibitors 
which are selective for PKC and PKA perhaps, would be of interest.  
Conversely, PMCA may also be involved in the regulation of signalling molecules 
of an as yet unidentified Ca2+ dependent inhibitory pathway in platelets such as 
those by acidic phospholipids (Carafoli 1994). It may also be interesting to 
investigate interaction partners of PMCA as demonstrated by various groups who 
have showed PMCA’s association with syntrophin (Williams et al. 2006), 
calcineurin (Buch et al. 2005; Holton et al. 2007) and Ras association domain-
containing protein 1 (RASSF1) (Armesilla et al. 2004) all of which regulate a 
number of processes in the cardiovascular system. The recently identified PDZ-
binding domain present within PMCA as described by Schuh and colleagues (Schuh 
et al. 2001) may also be of great interest to determine further interaction molecules 
that may regulate PMCA in platelets.  
Another approach would be to investigate the signalling interactions of another 
important isoform of PMCA, PMCA1 as this isoform, is essential as a housekeeping 
regulator of intracellular Ca2+ in cells and also for embryonic development (M. Brini 
2009). 
As research continues into the role of PMCA, novel interactions between PMCA 
and signalling molecules continually emerge, and this may ultimately clarify the role 
of PMCA in regulating signalling events in platelets. 
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Association of other Ca2+ pumps 
As well as PMCA, the inhibition of other Ca2+ pumps located in platelets was 
investigated. It was originally hypothesised that, perhaps, other Ca2+ pumps, notably 
SERCA and the NCX may be involved in the regulation of Ca2+. However, it was 
identified that neither of the two play a role in the maintenance of resting Ca2+ levels 
nor do they contribute towards a difference in the extrusion of Ca2+ upon 
stimulation. This was surprising, in the case of the NCX which has been shown to 
regulate basal Ca2+ levels in platelets (Bose et al. 2002). One would expect the NCX 
to contribute towards Ca2+ extrusion should intracellular concentrations become 
elevated. However, this was not the case as inhibition of PMCA but not the NCX 
resulted in an inhibition of the decay of Ca2+ transients. The observation of an 
impairment of aggregation was observed was also unexpected. It could be suggested 
that both pumps associate with local inhibitory signalling molecules that are 
involved in platelet activation but are independent from changes in cytosolic Ca2+ 
concentration. Alternatively, Ca2+ store release may have been distributed to areas 
within the platelet such as the DTS as a protective means to prevent inappropriate 
activation. It could also be suggested that the inhibition of SERCA and the NCX 
using the inhibitors employed may have desensitised platelets during the 
experimental incubation processes leading to a subsequent reduction in aggregation 
prior to stimulation.  It would be interesting to investigate whether there are any 
changes in Ca2+ homeostasis and function in platelets in the presence of two or more 
inhibitors in combination.  
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Knock-out mice 
A major breakthrough in studies of PMCA was the affinity purification of the 
enzyme 25 years ago by Niggli and colleagues (Niggli et al. 1979). Since then, four 
PMCA isoforms 1-4, and several dozen splice variants have been identified in 
mammalian tissues (Strehler & Zacharias 2001). PMCA1 and PMCA4 are expressed 
in all tissues, suggesting that they are necessary for housekeeping functions (Greeb 
& Shull 1989; Stauffer et al. 1994), although they undoubtedly serve tissue-specific 
functions as well. 
Ideally experiments in which Ca2+ homeostasis and platelet function in vitro and in 
vivo are observed in PMCA1 knock-out mice and compared to PMCA4 knock-out 
mice would determine the specific role of PMCA4 and identify its characteristics 
further. However, as PMCA1 is essential during embryogenesis, reflecting a major 
housekeeping function, knock-out mice are not available. PMCA’s role as a major 
housekeeping role is further demonstrated by the observation that loss of one copy 
of the PMCA1 gene in a PMCA4 null background can lead to apoptosis of vascular 
smooth muscle cells (Okunade et al. 2004), presumably due to Ca2+ overload.  
As an alternative approach, knock-down studies could be performed where by the 
PMCA1 gene is reduced, either through genetic modification of the DNA of one 
chromosome or by treatment with a reagent such as a short DNA or RNA 
oligonucleotide with a sequence complementary to either an mRNA transcript or a 
gene. However, it would take several years to establish such a technique and other 
factors such cell viability would need to be considered.  
CHAPTER FIVE – General Discussion 
 
195 
 
These experiments would however, provide further insight into the distinct role of 
PMCA 1 and 4.  In addition, it would be interesting to investigate the functional 
consequence of any compensatory expression of PMCA1 in PMCA4-/- mice.  
Diabetes, hypertension and type 2B von Willebrand disease have all been associated 
with altered expression of PMCA and all of these conditions are associated with 
platelet dysfunction through mechanisms that are incompletely understood.  
In characterising the integrative role of PMCA in regulating platelet function, this 
thesis has provided potential mechanisms by which PMCA may modulate platelet 
function and hence the development and progression of these diseases.  
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5.1  Conclusions 
In conclusion, PMCA is involved in the regulation of [Ca2+]i in both resting and 
activated platelets. PMCA differentially regulates the various stages of platelet 
activation with both stimulatory and inhibitory roles which contrast with other Ca2+ 
pumps such as SERCA and the NCX. The effects on platelet function correspond 
with changes in both [Ca2+]i and inhibitory signalling pathways.  
 
 
The data presented in this thesis demonstrates that PMCA is clearly a critical 
regulator of platelet Ca2+ homeostasis, signalling and function, is a key 
regulator of haemostasis and thrombosis, and may be a therapeutic target in 
the treatment of platelet driven disorders such as myocardial infarction. 
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Summary. Background: The plasma membrane calcium AT-
Pase (PMCA) regulates localized signaling events in a variety of
cell types, although its functional role in platelets remains
undeﬁned. Objectives: To investigate the role of PMCA in
determining platelet intracellular calcium concentration
([Ca2+]i) at rest and following agonist stimulation, and to
deﬁne the corresponding eﬀects upon diﬀerent stages of platelet
activation. Methods: [Ca2+]i was continuously measured in
Fura-2-loaded platelets and in vitro and in vivo functional
analyses performed in the presence of the PMCA inhibitor
carboxyeosin (CE). Results: Concentrations of CE that selec-
tively inhibited Ca2+ extrusion through PMCA were estab-
lished in human platelets. [Ca2+]i was elevated by CE in resting
platelets, although collagen-stimulated Ca2+ release was
reduced. ImpairedCa2+mobilization upon agonist stimulation
was accompanied by reduced dense granule secretion and
impaired platelet aggregation. Platelet aggregation responses
were also reduced in PMCA4)/) mice and in an in vivo mouse
model of platelet thromboembolism. Conversely, inhibition of
PMCA promoted the early and later stages of platelet
activation, observed as enhanced adhesion to ﬁbrinogen, and
accelerated clot retraction. Investigations into the signaling
mechanisms underlying CE-mediated inhibition of platelet
aggregation implicated cGMP-independent vasodilator-stimu-
lated phosphoprotein phosphorylation. Conclusions: Disrup-
tion of PMCA activity perturbs platelet Ca2+ homeostasis and
function in a time-dependent manner, demonstrating that
PMCA diﬀerentially regulates Ca2+-dependent signaling
events, and hence function, throughout the platelet activation
process.
Keywords: calcium, pharmacology, platelet, signaling, throm-
bosis.
Introduction
An increase in intracellular calcium concentration ([Ca2+]i) and
subsequent stimulation of localized Ca2+-dependent signaling
processes is central to platelet activation. Platelet Ca2+
homeostasis is therefore tightly regulated to maintain low
resting Ca2+ levels, which rise with spatiotemporal speciﬁcity
upon activation [1].
The plasma membrane calcium ATPase (PMCA) has
been described as the predominant route of Ca2+ extrusion
across the platelet plasma membrane [2], although there is
increasing evidence of a functional role of the Na+/Ca2+
exchanger. Na+/Ca2+ exchange has been shown to regulate
basal [Ca2+]i [3] and, in reverse mode, can increase [Ca
2+]i
and promote platelet aggregation [4,5] by inﬂuencing
cytoskeletal function [5] and dense granule secretion [6].
Thus, the distinct role of Ca2+ extrusion through PMCA in
regulating Ca2+ homeostasis and function in platelets
remains unclear.
PMCAs are encoded by four independent genes. Alternative
splicing of the primary constructs of these genes results in
approximately 30 PMCA isoforms [7]. Platelets express
PMCA4b and, to a lesser extent, PMCA1b [8]. Traditionally,
PMCA has been thought to play a housekeeping role in
controlling basal Ca2+ levels [9], but more recently has been
shown to act as a versatile signaling molecule [10], for example
by undergoing interactions with PDZ-domain-containing
proteins such as neuronal nitric oxide (NO) synthase (nNOS)
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to produce functionally important effects, including changes in
contractile function in the heart [11].
In platelets, PMCA interacts with the actin cytoskeleton
and localizes to the ﬁlopodal region during activation [12],
suggesting roles that are temporally and spatially dependent.
The roles of PMCA in regulating [Ca2+]i and function
during the various stages of platelet activation are not
known. In the present study, the role of PMCA in regulating
platelet [Ca2+]i and function was investigated with the
PMCA inhibitor carboxyeosin (CE). We established concen-
trations of CE that inhibited Ca2+ extrusion through PMCA
in platelets, and conﬁrmed that CE acted selectively at
PMCA. The consequences of PMCA inhibition for Ca2+
homeostasis and platelet function were then determined, and
the validity of our functional observations was conﬁrmed
with parallel experiments in PMCA4 knockout (PMCA4)/))
mice. Mechanistic studies were initiated as a ﬁrst step in
elucidating the pathways linking PMCA activity with func-
tion in platelets.
Materials and methods
Materials
Materials used were as follows: [3H]5-hydroxytryptamine (5-
HT) and indium-111 oxine (GE Healthcare, Amersham, UK);
collagen (Nycomed,Munich, Germany); CE and p-nitrophenyl
phosphate (Invitrogen, Paisley, UK); anti-vasodilator-stimu-
lated phosphoprotein (VASP) and anti-phospho-VASP
(Ser239) (New England Biolabs, Hitchin, UK). All other
materials were purchased from Sigma-Aldrich (Poole, UK).
Tyrodes–Hepes buffer contained 134 mM NaCl, 2.9 mM KCl,
12 mM NaHCO3, 0.34 mM Na2HPO4, 20 mM Hepes, 5 mM
glucose and 1 mM MgCl2 (pH 7.3).
Platelet preparation
Blood was taken from aspirin-free human volunteers or
terminally anesthetized mice, and washed platelets were
prepared by differential centrifugation as previously described
[13,14]. Informed consent from all blood donors was obtained,
and procedures were approved by the National Research
Ethics Service.
[Ca2+]i measurements
Human platelets were loaded with Fura-2 by incubation with
5 lM Fura-2/AM, and washed in modiﬁed Tyrodes–Hepes
buffer before resuspension to a density of approximately
4 · 108 cells mL)1. Platelets were incubated with CE for
30 min, and [Ca2+]i measurements were made with an LS50B
ﬂuorescence spectrometer (Perkin Elmer, Cambridge, UK) in
platelets stimulated with collagen (5 lg mL)1) or thapsigargin
(1 lM) plus ionomycin (50 nM) or in resting platelets. Unless
otherwise stated, Ca2+ analyses were conducted in Ca2+-free
buffer in the presence of 100 lM EGTA.
Platelet aggregation
Platelets were incubated for 30 min with CE (10–40 lM) or
dimethylsulfoxide (DMSO) (0.4%) prior to stimulation with
collagen (5 lg mL)1) or thrombin (0.1 U mL)1), and aggre-
gation was measured at 37 C under stirring conditions in an
optical aggregometer (Chrono-log Corporation, Havertown,
PA, USA). When sodium nitroprusside (SNP) and 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were used,
platelets were incubated with these compounds for 60 s prior
to stimulation. Mouse studies were conducted as above by
isolating platelets from pooled groups of wild-type and
PMCA4)/) mice. Unless otherwise indicated, all aggregation
studies were conducted in modiﬁed Tyrodes–Hepes buffer
containing 1 mM CaCl2.
Dense granule secretion
Washed platelets preloaded with [3H]5-HT (0.5 lCi mL)1)
were incubated for 30 min with CE (10–40 lM) or DMSO
(0.4%) prior to stimulationwith collagen (5 lg mL)1) for 180 s
under stirring conditions. [3H]5-HT release was measured in
supernatants by scintillation counting.
Platelet adhesion
Ninety-six-well plates were coated with 100 lg mL)1 ﬁbrino-
gen for 1 h at room temperature and blocked with 1% bovine
serum albumin (BSA) for 1 h. Washed platelets treated with
CE (10–40 lM) were incubated in wells for 1 h at 37 C, and
wells were washed three times with Tyrodes–Hepes buffer prior
to incubation with acid phosphatase buffer for 1 h at 37 C.
Then, 2 mMNaOHwas added to the wells and absorbance was
measured at 405 nm.
Clot retraction
Platelet-rich plasma (200 lL) was incubated with DMSO
(0.4%) or CE (20 or 40 lM) for 30 min before being
transferred to a glass test tube containing Tyrodes–Hepes
buffer (750 lL). Erythrocytes were added to enhance the color
for photographic purposes before thrombin (2.5 U mL)1) was
added and a glass rod was inserted to initiate clot formation.
After 2 h at room temperature, the clots were photographed
and weighed.
Immunoblotting
Proteins were separated by SDS-PAGE and transferred to
poly(vinylidene diﬂuoride) membranes. Membranes were
blocked with 5% (w/v) milk and incubated with anti-
phospho-VASP (Ser239) or anti-VASP (1 : 1000 in TBST,
2%BSA) overnight at 4 C. Blots were washed, and incubated
with horseradish peroxidase-conjugated secondary antibody
(1 : 5000 in TBST, 2% BSA) prior to detection with an
enhanced chemiluminescence detection system.
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Mice
Male Balb/c mice (20–30 g) were purchased from Harlan
(Bicester, UK). PMCA4)/) mice were bred under a hetero-
zygous breeding program and genotyped according to
published protocols [15]. All protocols involving the use of
animals were licensed by the UK Home Ofﬁce, approved by
the Ethical Review Panel at Imperial College London, and
reﬁned in association with the National Centre for Replace-
ment, Reﬁnement and Reduction of Animals in Research
(NC3Rs) [16].
In vivo platelet thromboembolism
Amouse model of platelet thromboembolism developed in our
laboratory was employed [16]. Blood was collected from
terminally anesthetized donor mice by cardiac puncture, and
platelets were isolated and incubatedwith 1.8 MBq indium-111
oxine for 10 min. Platelets were then resuspended in modiﬁed
Tyrodes–Hepes buffer in the presence of CE (20 or 40 lM) or
DMSO (0.4%). Anesthetized mice were infused with radiola-
beled platelets prior to administration of intravenous collagen
(25–75 lg kg)1). Platelet thromboembolic responses were
measured in the pulmonary region as changes in platelet-
associated counts, using a single point extended area ratio
detector (eV Products, Saxonburg, PA, USA), and recorded
with the use of custom software (Mumed systems, London,
UK), as previously described [16].
Data analysis and statistics
All data are expressed as mean ± standard error of the mean.
Where statistical comparisons were made, a Students t-test or
one-way analysis of variance followed by a multiple compar-
ison test was used to compare mean values, and a P-value
< 0.05 was considered to denote statistical signiﬁcance.
Results
PMCA regulates [Ca2+]i in resting and stimulated platelets
In control platelets loaded with Fura-2 and monitored in
Ca2+-free media in the presence of EGTA to assess release of
stored Ca2+, thapsigargin plus ionomycin (Tg + Iono)
induced a transient increase in [Ca2+]i that decayed towards
baseline because of Ca2+ release from internal stores and
extrusion through PMCA, as previously reported [2] (Fig. 1A).
Pretreatment of platelets with 10–40 lM CE dose-dependently
inhibited Ca2+ extrusion through PMCA, shown as impaired
Ca2+ decay following Tg + Iono treatment (Fig. 1A). There
was no evidence of an effect of CE on store loading, as Ca2+
release (measured as peak minus basal) was unaffected by this
treatment (Fig. 1A and Fig. S1).
CE also dose-dependently increased [Ca2+]i in resting
platelets (Fig. 1B), indicating a role for PMCA in maintaining
basal Ca2+ levels.
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Fig. 1. Carboxyeosin (CE) inhibits Ca2+ extrusion through plasma
membrane calcium ATPase (PMCA) in platelets and modiﬁes Ca2+
homeostasis. Washed platelets loaded with Fura-2 were incubated for
30 min with the PMCA inhibitor CE (10–40 lM) or dimethylsulfoxide
(DMSO) (0.4%, control), and the intracellular Ca2+ concentration
[Ca2+]i was measured as the 340/380-nm emission ratio (F 340/380). (A)
Platelets were stimulated with thapsigargin (Tg, 1 lM) supplemented with
ionomycin (Iono, 50 nM) to induce Ca2+ release followed by extrusion
through PMCA. CE pretreatment impaired Ca2+ extrusion, shown as an
impaired return to baseline. Ca2+ release from stores is indicated by ar-
rows for the control and 40 lM CE treatments, and shows that Ca2+
release is not aﬀected by CE. Typical smoothed traces of n = 5 are shown.
(B)Mean [Ca2+]i in resting platelets. (C)Meanmaximal [Ca
2+]i following
stimulation with collagen (5 lg mL)1) for 180 s. (D) Time course of the
340/380-nm emission ratio in platelets stimulated with collagen for 30 min,
showing a typical trace of n = 5. Data represent mean ± standard error
of the mean, n = 4, *P < 0.05, **P < 0.01.
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The peak [Ca2+]i following collagen stimulationwas reduced
in CE-pretreated platelets, indicating reduced collagen-medi-
ated Ca2+ release (Fig. 1C). Time-course experiments revealed
that [Ca2+]i in control platelets had returned to basal levels
180 s after stimulation, whereas in platelets incubated with CE,
[Ca2+]i remained elevated beyond this time (Fig. 1D). Thus,
CE reduces the amplitude of the initial Ca2+ transient
following collagen stimulation, but leads to an elevated
response at later time points.
Validation of CE as a PMCA inhibitor
As the pharmacologically active, free acid form of CE is eosin,
which is ﬂuorescently active, we conducted a series of
experiments to determine whether eosin could dose-depen-
dently increase Fura-2 emission independently of [Ca2+] and
thus invalidate the data presented in Fig. 1. A broad range of
eosin concentrations (0.1–50 lM) caused an apparent suppres-
sion of 340/380-nm emission that was neither signiﬁcant nor
dose-dependent (Fig. S2A). Although excess CE was removed
from platelets prior to analysis, we could not guarantee its
absence from our preparations, and so we additionally
demonstrated that CE (0.1–50 lM) did not affect Fura-2 340/
380-nm emission (Fig. S2B). Thus, we conclude that although
the observed increases in Fura-2 emission in resting platelets
containing eosin may have been suppressed (i.e. underesti-
mated) and quantitative studies could not be performed, our
ﬁnding of a dose-dependent increase in Fura-2 emission with
CE and our conclusion that PMCA regulates basal [Ca2+]i are
valid.
We were also able to observe a similar increase in basal
[Ca2+]i to that observed with CE by incubating platelets with
the non-selective cation channel antagonist lanthanum (1 mM)
(Fig. S3), conﬁrming a comparable increase in Ca2+ following
inhibition of Ca2+ extrusion through an independent mecha-
nism and in the absence of potentially confounding ﬂuores-
cence issues. In addition, the effect of CE on Ca2+ homeostasis
did not occur in platelets pretreated with lanthanum, indicating
that the effect of CE on Ca2+ homeostasis was exerted at the
plasma membrane rather than at a location independent of
PMCA (Fig. S3).
As CE has been shown to inhibit Na+/K+-ATPase pumps
[17] as well as PMCA, we investigated the effects of the Na+/
K+-ATPase inhibitor ouabain on platelet aggregation. Con-
centrations of ouabain previously shown to inhibit Na+/K+-
ATPases in platelets (1–10 lM [18,19]) and excess concentra-
tions (200 lM) had no effect on collagen-induced or thrombin-
induced platelet aggregation (Fig. S4A,B).
PMCA positively regulates platelet aggregation and secretion
CE dose-dependently inhibited collagen-mediated (Fig. 2A)
and thrombin-mediated (Fig. S5A) human platelet aggrega-
tion, indicating a positive regulatory role of PMCA in these
processes. CE also inhibited collagen-evoked 5-HT secretion
(Fig. 2B) and inhibited collagen-evoked aggregation of mouse
platelets (Fig. S5B). Collagen-induced platelet aggregation
responses were also signiﬁcantly reduced in platelets from
PMCA4)/) mice as compared with those from wild-type
controls (Fig. 2C,D). Finally, the inhibitory effect of CE
observed in platelets from wild-type mice did not occur in
platelets from PMCA4)/) mice, which aggregated normally in
the presence of CE (Fig. 2E,F), demonstrating that CE exerted
its effects via inhibition of PMCA4.
PMCA regulates platelet function in vivo
CE dose-dependently impaired platelet aggregatory responses
to collagen in vivo (Fig. 3A). The maximal percentage increase
in platelet-associated counts in response to collagen was
signiﬁcantly reduced by CE (Fig. 3B), indicating reduced
platelet responsiveness in vivo following PMCA inhibition.
PMCA negatively regulates early and late stages of platelet
activation
Although agonist-induced Ca2+ release was suppressed by CE
(Fig. 1C), [Ca2+]i was elevated in resting platelets (Fig. 1B) and
in the later stages of activation (Fig. 1D). To establish whether
these temporal differences in [Ca2+]i impacted on platelet
function, we determined the consequences of PMCA inhibition
for platelet adhesion and clot retraction to assess the early and
later stages of platelet activation, respectively.
In contrast to platelet aggregation and secretion, which were
suppressed following PMCA inhibition (Fig. 2), CE signiﬁ-
cantly enhanced platelet adhesion to ﬁbrinogen (Fig. 4A) and
dose-dependently reduced clot weight (Fig. 4B–C), indicating
enhanced clot retraction. Thus, PMCA positively regulates
platelet aggregation but negatively regulates platelet adhesion
and clot retraction.
PMCA inhibition does not desensitize platelets
To assess whether prestimulation resulting from raised basal
[Ca2+]i [20] was the mechanism underlying the inhibition of
platelet aggregation observed with CE, platelet secretion and
aggregation were measured in resting platelets incubated with
CE. For contrast, secretion and aggregation were additionally
determined in resting platelets incubated with the SERCA
inhibitor thapsigargin,whichalso leads to increased [Ca2+]i [21].
Thapsigargin dose-dependently increased dense granule
secretion (Fig. S6A) and light transmission (Fig. S6B) in
unstimulated platelets, indicating prestimulation. When thapsi-
gargin-pretreated platelets were subsequently stimulated with
collagen (Fig. S6B), there was no difference in platelet
aggregation from that seen in DMSO controls.
In contrast, there was no signiﬁcant increase in dense granule
secretion during incubation with CE at concentrations shown
to inhibit aggregation responses (Fig. S6C). Similarly, light
transmission in unstimulated platelets was not signiﬁcantly
increased by CE, with the exception of 40 lM, where there was
a small but signiﬁcant increase of 5.3% ± 1.6% (Fig. S6D).
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CE enhances VASP phosphorylation independently of cGMP
Western blots clearly demonstrated a dose-dependent increase
in VASP (Ser239) phosphorylation in platelets incubated with
CE (Fig. 5A), which was normalized to total VASP levels (Fig.
5B).
The NO donor SNP (1 lM) almost completely inhibited
collagen-mediated aggregation, and this inhibition was
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reversed by the guanylyl cyclase inhibitor ODQ (10 lM),
indicating effective inhibition by ODQ (Fig. 5C). CE-induced
inhibition of aggregation, however, was not impaired by ODQ,
suggesting that the inhibition caused byCE, althoughmediated
through VASP phosphorylation, was independent of cGMP.
Discussion
The ability of PMCA to regulate Ca2+-dependent signaling
events and hence function in a variety of cell types [10] led us to
investigate its role in platelet Ca2+ homeostasis and relate this
to the various stages of platelet activation. This is an essential
step in elucidating the signaling and functional events regulated
by PMCA in the platelet.
We initially determined concentrations of CE that effectively
inhibited Ca2+ extrusion through PMCAby showing impaired
extrusion under experimental conditions in which PMCA
activity predominates [2]. We then used these effective concen-
trations of CE to ascertain the role of PMCA in regulating
Ca2+ homeostasis and function in human platelets.
We had originally hypothesized that inhibition of PMCA
would impair Ca2+ extrusion and elevate [Ca2+]i, leading to
platelet activation by subthreshold concentrations of platelet
agonists. Early experiments, however, demonstrated that
whereas CE elevated basal [Ca2+]i, demonstrating its role in
the maintenance of low resting [Ca2+]i, it inhibited agonist-
induced intracellular Ca2+ release, indicating that PMCA
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somehow propagates the rise in [Ca2+]i following agonist
stimulation. Further investigation revealed that reduced Ca2+
mobilization following PMCA inhibition was accompanied by
impaired dense granule secretion and aggregation, consistent
with PMCA being a positive driving force behind these
processes. Moreover, inhibition of PMCA resulted in platelets
being unable to function normally in vivo, conﬁrming the
relevance of our observations to physiologic and pathologic
processes.
The validity of our data obtained with CE relies on its
speciﬁcity as an inhibitor of PMCA. CE crosses the plasma
membrane and is then cleaved by intracellular esterases to yield
eosin. Eosin interacts with amine groups in proteins and
inhibits PMCA independently of the ATPase site [22,23]. In
terms of speciﬁcity, CE inhibits PMCA at the concentrations
employed here without inhibiting SERCA or Na+/Ca2+
exchange [22–24], and in line with this we were able to
demonstrate normal store loading in the presence of CE, as
there was no change in Tg + Iono-induced Ca2+ release
calculated from data shown in Fig. 1A as peak response minus
stable prestimulation values (Fig. S1). CE has been used to
determine the function of PMCA in cardiomyocytes [24],
sperm [15], embryonic stem cells [25] and vascular endothelial
cells [26]. Critical to our argument, the validity of these
functional observations has been conﬁrmed by studies in
PMCA4–/–and transgenic lines [11,15,27,28], suggesting a
predominant action of CE at PMCA in a range of cell types.
CE does, however, inhibit Na+/K+-ATPase activity at
micromolar concentrations [17], and effects on transients
during Ca2+ repletion [19] and procoagulant effects [29] have
been reported. We could ﬁnd no published evidence for a role
of this pump in modulating platelet aggregation, and demon-
strated here that the Na+/K+-ATPase inhibitor ouabain had
no effect on platelet aggregation under our experimental
conditions. Thus, the effect of CE on platelet aggregation is
unlikely to be mediated through inhibition of Na+/K+-
ATPase activity. As the complete inhibitory proﬁle of CE is
unknown, we also conducted experiments in PMCA4)/) mice
to determine whether a similar inhibition of platelet aggrega-
tion could be observed in the absence of confounding non-
speciﬁc pharmacologic effects. Platelet aggregation was signif-
icantly reduced in PMCA4)/)mice. The occurrence of the same
functional observation following both pharmacologic inhibi-
tion of PMCAand genetic ablation of PMCA4 provides strong
evidence that the observed impairment of platelet aggregation
in both situations occurs as a result of loss of PMCA activity.
This was further shown by our data indicating that CE
inhibited aggregation in wild-type but not PMCA4)/) mice
(Fig. 2E–F). These data also suggest that although CE inhibits
all isoforms of PMCA, its effects in platelets are mediated via
inhibition of PMCA4, and that the PMCA4 isoform is a key
modulator of platelet function.
In contrast to the inhibitory effect of CE on platelet
aggregation, platelet adhesion and clot retraction were
enhanced. Increased platelet adhesion to ﬁbrinogen and
elevated basal Ca2+ prior to this response suggest that, in the
early stages of platelet activation, PMCA acts to suppress both
[Ca2+]i and activation, consistent with the Ca
2+ dependence of
the ﬁbrinogen receptor integrin aIIbb3, which mediates adhe-
sion. Similarly, enhanced clot retraction occurred against a
background of prolonged elevations of [Ca2+]i (Fig. 1D).
These elevations are consistent with the Ca2+ dependence of
myosin activity, which is essential for the clot retraction
process. Thus, PMCA acts to slow the rate at which clots
retract, presumably to ensure effective healing of underlying
damaged tissue. Our clot retraction data are consistent with
results published by Dean et al. [12] demonstrating that
preventing translocation of PMCA to the ﬁlopodia of activated
platelets enhanced clot retraction. Together, these two sets of
data demonstrate the importance of both the locality and
function of PMCA in regulating the clot retraction process.
Possible mechanisms by which PMCA inhibition could
reduce platelet aggregation include partial activation and
subsequent desensitization of platelets by elevated [Ca2+]i or
coupling of PMCA with a Ca2+-dependent negative regulator
of platelet function. The former hypothesis was explored ﬁrst.
It has recently been reported that a mutation of stromal
interaction molecule 1, a Ca2+ sensor situated in the endo-
plasmic reticulum, leads to elevated [Ca2+]i in platelets,
resulting in a preactivation state and reduced responses to
collagen [20]. We could not, however, ﬁnd evidence of
preactivation in our experiments, as we were unable to detect
secretion or aggregation during preincubation with CE.
Furthermore, elevation of [Ca2+]i through SERCA inhibition,
despite stimulating dense granule secretion and partial aggre-
gation, did not desensitize platelets to collagen. Thus, we
conﬁrmed that our methodologies for detecting platelet
preactivation against a background of elevated [Ca2+]i were
effective, and that elevating [Ca2+]i in platelets did not per se
lead to inhibition of subsequent agonist-induced aggregation.
Very little PMCA is associated with the platelet cytoskeleton
under resting conditions, but upon stimulation approximately
80% of the total PMCA is redistributed by the cytoskeleton
and retains ATPase activity [30]. This redistribution potentially
enables Ca2+ and signaling molecules, potentially inhibitory
signaling pathways, to be regulated locally. Such a role of
PMCA in regulating inhibitory signaling pathways has already
been demonstrated in cardiomyocytes [11] and vascular smooth
muscle cells [27], where PMCA exerts its functional effects by
regulating nNOS activity. Thus, the application of CE in our
study could inhibit platelet aggregation by raising Ca2+ in the
vicinity of localized inhibitory signaling molecules, such as
those regulating VASP activity. VASP (Ser239) phosphoryla-
tion was shown to be increased by CE, indicating that PMCA
prevents the phosphorylation of VASP.
One of the major mechanisms of VASP (Ser239) phosphor-
ylation in platelets is increased cGMP production by NO and
other mediators such as von Willebrand factor [31]. In our
study, the inhibition of platelet aggregation by CE occurred
independently of cGMP. Although Ser239 is considered to be
the preferred phosphorylation site for cGMP/protein kinase G
(PKG), the site has also been shown to be both PKG-sensitive
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and protein kinase A-sensitive [32,33], indicating that PMCA
inhibition may stimulate alternative Ca2+-dependent inhibi-
tory pathways in platelets. As research continues into the role
of PMCA, novel interactions between PMCA and signaling
molecules continually emerge [34–36], and may ultimately
clarify the role of PMCA in regulating signaling events in
platelets.
Altered expression of PMCA has been reported in patients
with diabetes [37], hypertension [38] and type 2B von Wille-
brand disease [39]. All of these conditions are associated with
platelet dysfunction through mechanisms that are incompletely
understood. In deﬁning the role of PMCA in regulating platelet
function, we provide potential mechanisms by which PMCA
may modulate platelet function and hence the development
and progression of these diseases.
In conclusion, PMCA is involved in the regulation of [Ca2+]i
in both resting and activated platelets. PMCA differentially
regulates the various stages of platelet activation with both
stimulatory and inhibitory roles. The effects on platelet
function correspond with changes in both [Ca2+]i and inhib-
itory signaling pathways. PMCA is clearly a critical regulator
of platelet Ca2+ homeostasis, signaling and function, and is
therefore a key regulator of hemostasis and thrombosis, and
may be a therapeutic target in platelet driven diseases.
Acknowledgements
We thank F. Baudoin for excellent technical assistance. This
work was funded by a Research Grant from the Wellcome
Trust (085132/Z/08/Z) to M. Emerson. L. Neyses is supported
by anMRC ProgrammeGrant and by the NIHR (Manchester
Biomedical Research Centre). A. Solomon is supported by a
National Heart and Lung Institute Foundation Studentship.
Disclosure of Conflict of Interests
The authors state that they have no conﬂict of interest.
Supporting Information
Additional Supporting Informationmay be found in the online
version of this article:
Fig. S1. Carboxyeosin does not affect stored Ca2+ release.
Fig. S2. Effect of eosin and carboxyeosin on Fura-2 emission
spectra.
Fig. S3. Effect of blockade of Ca2+ extrusion on platelet Ca2+
homeostasis.
Fig. S4. Na+/K+-ATPase does not modulate platelet aggre-
gation.
Fig. S5. Carboxyeosin inhibits aggregation of human and
mouse platelets.
Fig. S6. Increased [Ca2+]i following plasmamembrane calcium
ATPase (PMCA) inhibition does not desensitize platelets.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
References
1 Bobe R, Bredoux R, Corvazier E, Lacabaratz-Porret C, Martin V,
Kovacs T, Enouf J. Howmany Ca(2)+ATPase isoforms are expressed
in a cell type? A growing family of membrane proteins illustrated by
studies in platelets. Platelets 2005; 16: 133–50.
2 Rosado JA, Sage SO. Regulation of plasmamembrane Ca2+-ATPase
by small GTPases and phosphoinositides in human platelets. J Biol
Chem 2000; 275: 19529–35.
3 Bose R, Li Y, Roberts D. Na+/Ca2+ exchange in activated and
nonactivated human platelets. Ann NY Acad Sci 2002; 976: 350–3.
4 Roberts DE,McNicol A, Bose R.Mechanism of collagen activation in
human platelets. J Biol Chem 2004; 279: 19421–30.
5 Harper AG, Sage SO. A key role for reverse Na+/Ca2+ exchange
inﬂuenced by the actin cytoskeleton in store-operated Ca2+ entry in
human platelets: evidence against the de novo conformational coupling
hypothesis. Cell Calcium 2007; 42: 606–17.
6 Harper AG, Mason MJ, Sage SO. A key role for dense granule
secretion in potentiation of the Ca2+ signal arising from store-oper-
ated calcium entry in human platelets. Cell Calcium 2009; 45: 413–20.
7 Carafoli E. The calcium pumping ATPase of the plasma membrane.
Annu Rev Physiol 1991; 53: 531–47.
8 Martin V, Bredoux R, Corvazier E, Papp B, Enouf J. Platelet
Ca(2+)ATPases : a plural, species-speciﬁc, and multiple hypertension-
regulated expression system. Hypertension 2000; 35: 91–102.
9 Hammes A, Oberdorf S, Strehler EE, Stauﬀer T, Carafoli E, Vetter H,
Neyses L. Diﬀerentiation-speciﬁc isoform mRNA expression of the
calmodulin-dependent plasma membrane Ca(2+)-ATPase. FASEB J
1994; 8: 428–35.
10 Brini M. Plasma membrane Ca(2+)-ATPase: from a housekeeping
function to a versatile signaling role. Pﬂugers Arch 2009; 457: 657–
64.
11 OceandyD, Cartwright EJ, EmersonM, Prehar S, Baudoin FM, ZiM,
Alatwi N, Schuh K, Williams JC, Armesilla AL, Neyses L. Neuronal
nitric oxide synthase signaling in the heart is regulated by the sarco-
lemmal calcium pump 4b. Circulation 2007; 115: 483–92.
12 Dean WL, Whiteheart SW. Plasma membrane Ca(2+)-ATPase
(PMCA) translocates to ﬁlopodia during platelet activation. Thromb
Haemost 2004; 91: 325–33.
13 Tymvios C,Moore C, Jones S, SolomonA, Sanz-RosaD, EmersonM.
Platelet aggregation responses are critically regulated in vivo by
endogenous nitric oxide but not by endothelial nitric oxide synthase.Br
J Pharmacol 2009; 158: 1735–42.
14 Moore C, Tymvios C, Emerson M. Functional regulation of vascular
and platelet activity during thrombosis by nitric oxide and endothelial
nitric oxide synthase. Thromb Haemost 2010; 104: 342–9.
15 Schuh K, Cartwright EJ, Jankevics E, Bundschu K, Liebermann J,
Williams JC, Armesilla AL, Emerson M, Oceandy D, Knobeloch KP,
Neyses L. Plasma membrane Ca2+ ATPase 4 is required for sperm
motility and male fertility. J Biol Chem 2004; 279: 28220–6.
16 Tymvios C, Jones S, Moore C, Pitchford SC, Page CP, Emerson M.
Real-time measurement of non-lethal platelet thromboembolic re-
sponses in the anaesthetized mouse. Thromb Haemost 2008; 99: 435–
40.
17 Ogan JT, Reifenberger MS, Milanick MA, Gatto C. Kinetic charac-
terization of Na,K-ATPase inhibition by Eosin. Blood Cells Mol Dis
2007; 38: 229–37.
18 Lees AD, Wilson J, Orchard CH, Orchard MA. Ouabain enhances
basal and stimulus-induced cytoplasmic calcium concentrations in
platelets. Thromb Haemost 1989; 62: 1000–5.
19 Zimlichman R, Goldstein DS, Zimlichman S, Keister HR. Eﬀects of
ouabain on cytosolic calcium in lymphocytes, platelets and adreno-
medullary cells. J Hypertens 1987; 5: 605–9.
PMCA and platelet function 2773
 2010 International Society on Thrombosis and Haemostasis
20 Grosse J, Braun A, Varga-Szabo D, Beyersdorf N, Schneider B,
Zeitlmann L, Hanke P, Schropp P, Mu¨hlstedt S, Zorn C, Huber M,
Schmittwolf C, Jagla W, Yu P, Kerkau T, Schulze H, Nehls M,
Nieswandt B. An EF hand mutation in Stim1 causes premature
platelet activation and bleeding in mice. J Clin Invest 2007; 117: 3540–
50.
21 Redondo PC, Salido GM, Pariente JA, Sage SO, Rosado JA. SER-
CA2b and 3 play a regulatory role in store-operated calcium entry in
human platelets. Cell Signal 2008; 20: 337–46.
22 Gatto C, Milanick MA. Inhibition of the red blood cell calcium pump
by eosin and other ﬂuorescein analogues. Am J Physiol 1993; 264:
C1577–86.
23 Gatto C, Hale CC, Xu W, Milanick MA. Eosin, a potent inhibitor of
the plasma membrane Ca pump, does not inhibit the cardiac Na–Ca
exchanger. Biochemistry 1995; 34: 965–72.
24 Choi HS, Eisner DA. The role of sarcolemmal Ca2+-ATPase in the
regulation of resting calcium concentration in rat ventricularmyocytes.
J Physiol 1999; 1: 109–18.
25 Yanagida E, Shoji S, HirayamaY, Yoshikawa F, OtsuK, UematsuH,
Hiraoka M, Furuichi T, Kawano S. Functional expression of Ca2+
signaling pathways in mouse embryonic stem cells. Cell Calcium 2004;
36: 135–46.
26 Sedova M, Blatter LA. Dynamic regulation of [Ca2+]i by plasma
membrane Ca(2+)-ATPase and Na+/Ca2+ exchange during capa-
citative Ca2+ entry in bovine vascular endothelial cells. Cell Calcium
1999; 25: 333–43.
27 Schuh K, Quaschning T, Knauer S, Hu K, Kocak S, Roethlein N,
Neyses L. Regulation of vascular tone in animals overexpressing the
sarcolemmal calcium pump. J Biol Chem 2003; 278: 41246–52.
28 Cartwright EJ, Schuh K, Neyses L. Calcium transport in cardiovas-
cular health and disease – the sarcolemmal calcium pump enters the
stage. J Mol Cell Cardiol 2005; 39: 403–6.
29 TomasiakM, Stelmach H, Rusak T, Ciborowski M, Radziwon P. The
involvement of Na+/K(+)-ATPase in the development of platelet
procoagulant response. Acta Biochim Pol 2007; 54: 625–39.
30 Zabe M, Dean WL. Plasma membrane Ca(2+)-ATPase associates
with the cytoskeleton in activated platelets through a PDZ-binding
domain. J Biol Chem 2001; 276: 14704–9.
31 Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt
PJ, Muller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-
independent regulation of human and murine platelet soluble guanylyl
cyclase activity. J Thromb Haemost 2008; 6: 1376–84.
32 Li Z, Ajdic J, Eigenthaler M, Du X. A predominant role for cAMP-
dependent protein kinase in the cGMP-induced phosphorylation of
vasodilator-stimulated phosphoprotein and platelet inhibition in
humans. Blood 2003; 101: 4423–9.
33 Riba R, Oberprieler NG, Roberts W, Naseem KM. von Willebrand
factor activates endothelial nitric oxide synthase in blood platelets by a
glycoprotein Ib-dependent mechanism. J Thromb Haemost 2006; 4:
2636–44.
34 Armesilla AL, Williams JC, Buch MH, Pickard A, Emerson M,
Cartwright EJ, Oceandy D, Vos MD, Gillies S, Clark GJ, Neyses L.
Novel functional interaction between the plasma membrane Ca2+
pump 4b and the proapoptotic tumor suppressor Ras-associated factor
1 (RASSF1). J Biol Chem 2004; 279: 31318–28.
35 BuchMH, PickardA, Rodriguez A,Gillies S,Maass AH, EmersonM,
Cartwright EJ, Williams JC, Oceandy D, Redondo JM, Neyses L,
Armesilla AL. The sarcolemmal calcium pump inhibits the calcineurin/
nuclear factor of activated T-cell pathway via interaction with the
calcineurin A catalytic subunit. J Biol Chem 2005; 280: 29479–87.
36 Holton M, Yang D, Wang W, Mohamed TM, Neyses L, Armesilla
AL. The interaction between endogenous calcineurin and the plasma
membrane calcium-dependent ATPase is isoform speciﬁc in breast
cancer cells. FEBS Lett 2007; 581: 4115–19.
37 Chaabane C, Dally S, Corvazier E, Bredoux R, Bobe R, Ftouhi B,
Raies A, Enouf J. Platelet PMCA- and SERCA-type Ca2+-ATPase
expression in diabetes: a novel signature of abnormal megakaryocy-
topoiesis. J Thromb Haemost 2007; 5: 2127–35.
38 Dally S, Chaabane C, Corvazier E, Bredoux R, Bobe R, Ftouhi B,
Slimane H, Raies A, Enouf J. Increased expression of plasma mem-
brane Ca(2+)ATPase 4b in platelets from hypertensives: a new sign of
abnormal thrombopoiesis? Platelets 2007; 18: 543–9.
39 Nurden P, Debili N, Vainchenker W, Bobe R, Bredoux R, Corvazier
E, CombrieR, FressinaudE,MeyerD,NurdenAT, Enouf J. Impaired
megakaryocytopoiesis in type 2B von Willebrand disease with severe
thrombocytopenia. Blood 2006; 108: 2587–95.
2774 S. Jones et al
 2010 International Society on Thrombosis and Haemostasis
